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Abstract
The present thesis describes our latest results in the chemistry of morphine alkaloids.
An enantiodivergent synthesis of codeine utilizing a cis-cyclohexadiene diol derived
from microbial whole cell oxidation of ~-bromoethylbenzene,as starting material is
discussed. The total synthesis of (+)-codeine in 14 steps featuring a Mitsunobu
inversion and two intramolecular Heck cyclizations is presented. Investigation of a
regioselective nucleophilic opening of a homochiral vinyl oxirane, which led to a
total synthesis of the natural isomer of codeine, is detailed.
Furthermore, described herein are novel methodologies designed for the
transformation of naturally occurring opiates into medicinally relevant derivatives.
Two studies on the conversion of thebaine into the commercially available analgesic
hydrocodone, two novel ·transition metal catalyzed N-demethylation procedures for
opioids, and the development of a catalytic protocol for N-demethylation and N-
acylation of morphine and tropane alkaloids are presented.
In addition, reactions of a menthol-based version of the Burgess reagent with
epoxides are discussed. The synthetic utility of this novel chiral derivative of the
Burgess reagent was demonstrated by an enantiodivergent formal total synthesis of
balanol.
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1. Introduction
Morphine alkaloids have been fascinating mankind since the days of antiquity. They
are extensively used as medicines for the treatment of pain and are equally abused as
illicit narcotics. In 2007 the estimated total amount of raw opium produced
worldwide was 8200 tons, 1 with the major portion of it being used for illicit drug
manufacturing. Raw opium contains varying amounts of morphine (1), codeine (2),
narcotine, papaverin (3), and thebaine (4) (Figure 1).2 Morphine, the most famous
among the opiates, was first isolated in pure form by Friedrich Wilhelm Sertuerner in
1805,3 its empirical formula was elucidated by Laurent in 1832,4 and the structure
was proposed by Robinson and Gulland in 1925.5 Since the first reported total
synthesis of morphine by Gates in 1952,6 the alkaloid still remains a challenging
target for synthetic organic chemists. Almost thirty total or formal syntheses of
morphine alkaloids have been reported, of which none can be considered as a
genuinely practical synthetic route, capable of competing with the natural supply. A
practical synthesis would allow for the production of sufficient amounts of morphine
to satisfy the world's demand for this valuable drug. It would therefore eliminate the
uncertainty associated with the production of natural morphine in countries with
MeoM~I~
a = Mea":.'.~NMe
HO"'V
morphine
1
codeine
2
papaverine
3
thebaine
4
Figure 1. Morphine alkaloids.
1
certain political instability such as Afghanistan, the country with the highest opium
production in the world.
Over the last 20 years a major goal of the Hudlicky group has been the development
of a practical synthesis of morphine alkaloids. The current thesis will discuss an
enantiodivergent chemoenzymatic synthesis of codeine, combining strategies from
Parker's,? as well as Trost's synthesis.8 The approach to (+)-codeine (2) is envisioned
by connecting allylic alcohol 6 with an aromatic fragment by a Mitsunobu reaction to
yield a suitable precursor for subsequent intramolecular Heck cyclizations. The key
step in the approach to (-)-codeine is based upon on a regioselective nucleophilic
opening of vinyl oxirane 7. This maneuver should allow for the formation of
compound 9, which is envisioned to be converted to (-)-codeine (2) by intramolecular
Pd-catalyzed cyclizations similar to the (+)-codeine approach (Figure 2).
6
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Figure 2. Design for the enantiodivergent synthesis of codeine (2).
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Hudlicky's enantiodivergent synthetic strategy of morphine alkaloids presents a
unique approach since chirality for both enantiomers is introduced by an enzymatic
reaction, known to be enantiospecific.
Our interest in morphine alkaloids is not limited to their syntheses. Semi-synthetic
drugs derived from opiates have affected society for more than 100 years.
Diacetylmorphine, better known as heroin (10), was first synthesized by the English
chemist Charles Robert Albert Wright9 and was marketed by Bayer in 1898 as a non-
addictive morphine substitute and cough suppressant. The even more addictive
properties of heroin compared to those of morphine were realized years later and
Bayer was forced to take heroin off the market in 1910.
ACOM~·I~
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Figure 3. Semi-synthetic opioids.
Two semi-synthetic opioids, oxycodone (11) and hydrocodone (12) (Figure 3), were
discovered shortly after the mass production of heroin was stopped. IO Both
derivatives posses less addictive and euphoric properties than morphine and are still
marketed as analgesics throughout the world. Naltrexone (13) is another semi-
synthetic drug derived from thebaine (4) and is used for the treatment of alcohol and
opioid dependence. The manufacturing of semi-synthetic opioids represents a
prospering market. In cooperation with Noramco Inc., a subsidiary of Johnson &
3
Johnson, we became interested in the conversion of naturally occurring morphine
alkaloids into more valuable derivatives utilizing economic and environmentally
benign transformations. Thebaine (4), a minor constituent in the latex of Papaver
somniferum, is an ideal starting material for the preparation of semi-synthetic
analgesics. Tasmanian Alkaloids, in partnership with Noramco Inc., developed a
genetically engineered poppy plant, the latex of which contains up to 30% thebaine
(4).11 Of special interest would be the conversion of thebaine (4) into neopinone ketal
14, an alternative intermediate for the synthesis of 14-hydroxylated opiates.
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Figure 4. Functionalization of thebaine (4).
The potential advantage in the use of neopinone ketal 14 as starting material for 14-
hydroxylated morphinans lies in the avoidance of a,~-unsaturated ketone
intermediates, which frequently occur in the currently used commercial syntheses.
This is of great importance since the ICH (International Conference on
Harmonisation) have suggested strict limits in the amount of a,~-unsaturatedcarbonyl
containing compounds in pharmaceutical preparations. 12
Novel hydrogenation procedures for the conversion of thebaine (4) into the
commercially available analgesic hydrocodone (12) will be investigated to provide
for a catalytic and environmentally friendly procedure compared to the current
4
hazardous diimide reduction process. Further work, which will be presented in this
thesis, will include investigations of an alternative approach to oxycodone (11) via
the selective functionalization of the C-14 carbon of hydrocodone (12). A wide range
of oxidative conditions, previously reported in the literature to effect the
hydroxylation of tertiary carbons, will be tested.
o
R = alkyl, O-alkyl
15 12
NMe
16
NH
Figure 5. Functionalization of hydrocodone (12).
N-demethylation or N-demethylation / acylation reactions of morphine alkaloids
represent key transformations in the synthesis of semi-synthetic opioids such as
naltrexone (13). Our latest investigations in this field will be presented in Chapter
3.2.5 and 3.2.6.
In addition to the work related to morphine alkaloids, new reactive options of methyl
N-(triethylammoniumsulfonyl)carbamate inner salt, more commonly known as the
Burgess reagent 18, with epoxides will be explored. Originally, the Burgess reagent
was designed as a mild dehydrating agent for secondary and tertiary alcohols. 13 It
found further application as the reagent of choice for the synthesis of urethanes from
primary alcohols,14 and dehydration of amides to nitriles. 15
5
17
+
Et3NS02NC02Me
18
o
O::::S..--~C02Me
c6 ~R~Lrl.\\RR'~R'
19 20
Figure 6. Proposed mechanism for the dehydration of alcohols.
Its polymer linked version was also employed in the synthesis of oxazolidines.16 The
Burgess reagent has been used in the preparation of a- and ~-glycosylamines from
carbohydrates, 17 sulfamidates from 1,2-diols,18 sulfamidates from 2,3-
epoxyalcohols,19 and sulfamides from aminoalcohols.2o In 2003, the Hudlicky group
reported the reaction of epoxides with the Burgess reagent to yield 5- and 7-
membered sulfamidates,21 despite the fact that epoxides were thought to be inert to
this reagent. 13b Further investigations of the reaction of the Burgess reagent with
epoxides and a p~ssible mechanism of this transformation merit investigation.
QJl- + o~/o o~od *M02C8 *M02C~;' '9+ + 0: 0 NS02NEt3~
21 22 23a 23b
Figure 7. Chiral version of the Burgess reagent and its reaction with epoxides.
We envisioned that the reaction of a chiral version of the Burgess reagent, such as
menthol-based reagent 21, with epoxides might allow for the synthesis of both
homochiral cis- and trans-amino alcohols, which are frequently used in the
pharmaceutical sector.22 Application of this novel methodology would also lead to an
enantiodivergent approach to balanol, a fungal metabolite with significant inhibitory
activities against protein kinase C isozymes.23
6
This thesis describes our results attained in the projects described above. A historical
overview of all relevant areas is provided.
2. Historical
The following historical chapter is divided into two parts, and addresses the topic of
the Burgess reagent as well as the chemistry of morphine alkaloids.
The Burgess reagent is a mild and selective dehydrating reagent for secondary and
tertiary alcohols. The scope of the reagent has been broadened and its latest
applications as well as a historical perspective is presented.
The isolation, structure determination, biosynthesis and pharmacology of the most
relevant opiates is discussed, along with a review of selected total syntheses of
morphine alkaloids.
2.1 Burgess Reagent
2.1.1 Dehydration of Alcohols
The first preparation of an alkyl N-(triethylammoniumsulfonyl)carbamate inner salt,
the ethyl derivative 24, was reported by George M. Atkins and Edward M. Burgess in
1968.24 It was initially designed as an electrophilic N-sulfonylamine derivative and its
reactions with amines, alcohols, allenes, and olefins were studied. The reaction of
inner salt 24 with aniline gave N-carbethoxy-N'-phenylsulfamide (25) in nearly
7
quantitative yield, while the reaction with isopropanol afforded isopropyl carbethoxy
sulfamate (26) in significant lower yield. Electrophilic addition of 24 to N-
vinylpyrollidone was observed and N-(2-carbethoxyamidesulfonylvinyl) pyrrilidone
(27) was isolated in 50% yield as shown in Figure 8. The application of the methyl
derivative, methyl N- (triethylammoniumsulfonyl)carbamate inner salt, known as the
Burgess reagent (18), 13 as a dehydrating reagent was first reported in 1970.25 Burgess
demonstrated that the reaction of compound 18 with secondary and tertiary alcohols
yielded the corresponding olefins.
a a \/'-..)l II +)
./ ~o N-S-N~
- 8 / \
24
OH
A
C>=o
N
~ /'oJlN_~fNb
H 8
27
Figure 8. Reactions of ethyl N- (triethylammoniumsulfonyl)carbamate inner salt
(24).
The same group conducted a kinetic study of the dehydration of erythro- and threo-2-
deuterio-1,2-diphenyl ethanols. The results were consistent with rate limiting
formation of an ion pair, followed by fast syn-~-proton transfer. Geometrical
constraints require that the abstracted hydrogen is syn with respect to the leaving
group. The mechanism is similar to the Chugaev elimination of dithiocarbonate
(xanthate) esters and follows Saytzeff's rule.
8
Jl Q,,9
MeO . N.... S'NEt3 a ~ ,C02Me o ~ ,C02Me+HO H 18 ~S-N- + slow ~S-N- fast H Ph
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Pti D Pti D
28 29 30 +NHEt3 31
~ 18 ~
32 33
Figure 9. Proposed mechanism for the dehydration of alcohols with the Burgess
reagent (18).
Based on this observation, the generality of the cis elimination was suggested.
However, double bond formation can be less predictable, such as the case when a
carbocation intermediate is highly stabilized. Reaction of tertiary alcohol 32 with the
Burgess reagent (18) gives olefin 33 via a Wagner Meerwein rearrangement.
In contrast to the dehydration reaction of secondary and tertiary alcohols, primary
alcohols react with the Burgess reagent to give carbamates. During the decomposition
of the intermediate primary alkyl N-methoxycarbonylsulfamate salt, a SN2 pathway is
energetically more favourable than an elimination reaction and carbamates are
isolated in high yield. Subsequent hydrolysis gives the primary amines and therefore
this sequence represents an efficient two step synthesis of primary amines from
alcohols.
Allylic alcohols can undergo either elimination or an SN1 reaction and the outcome of
the reaction can be tuned by the reaction conditions applied. Solvent free treatment of
allylic alcohol 37 with the Burgess reagent provides carbamate 38 in nearly
9
quantitative yield, while the reaction in triglyme gives hexadiene 39 as the major
product, as shown in Figure 10.
18
34
o
-)l
( ~~ OMe
V\9)to
35
-803
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39
OH
~
37
18
neat, 80°C
NHCOMe
~
38
Figure 10. Formation of carbamates from primary alcohols.
2.1.2 Application of the Burgess Reagent as Dehydrating Reagent in Organic
Synthesis
The Burgess reagent can effect the dehydration of secondary and tertiary alcohols to
the respective olefins under mild conditions. Many alternative dehydration methods
are acid-mediated and require elevated temperatures. This can result in
rearrangements or alterations to acid and/or heat sensitive functionalities. In addition,
the compatibility of the Burgess reagent with many functional groups makes it an
attractive technique for the introduction of carbon-carbon double bonds into highly
~~functionalized molecules.
The first application of the Burgess reagent in organic synthesis was reported by
Crabbe and Leon only a few months after its initial discovery. Various steroidal
secondary and tertiary alcohols such as 3a-hydroxy-5a-androstan-17-one (40) were
10
subjected to dehydration, with the corresponding olefins being isolated in
satisfactorily yields.26 In 1974 Caspi and coworkers reported one of the rare cases
where the Burgess mediated dehydration reaction proceeded in an anti fashion, as
shown in Figure 11. The unlikely possibility that cis elimination occurred first and
was followed by a subsequent isomerisation was not ruled OUt.27
40
42
18
18
H
41
43
Figure 11. Application of the Burgess reagent in steroid chemistry.
/
The preparation of 3-keto-1,4-dienes provides for a useful entry to annulated
cyclopentenones via the Nazarov cyclization. Burgess mediated dehydration of a'-
hydroxy vinyl ketones, such as 44, followed by acid treatment yielded the desired
annulated cylopentenones in moderate to high yields as shown by Jacobson and
Lahm.28
The Burgess reagent found further application in Stork's general approach to the.
tetracyclic II-ketosteroid nucleus of several cortical hormones. Regioselective
dehydration of 47 led to trienone 48, which represented the precursor for an
intramolecular Diels-Alder reaction. Stork employed this sequence for the concise
syntheses of cortisone, adrenosterone (49), 11-ketoprogesterone, and 11-
ketotestosterone.29
11
During Weyerstahl's total synthesis of the sesquiterpene isocanambrin, 51 and 52
were obtained with Burgess reagent in 90% yield, whereas attempted dehydration of
this seven-membered ring with acidic reagents led mainly to ring contraction via
cationic rearrangement.30
HO 0
cJ\
44
18
o
cY\
45
acid
46
18
o
49
Figure 12. Preparation of Nazarov cyclization precursors with the Burgess reagent.
The synthetic value of the Burgess reagent as a dehydrating reagent is further
underlined by its application in Rigby's syntheses of cedrene31 and pancratistatin
(55),32 Paquette's synthesis of ikarugamycin,33 Nicolaou's syntheses of
efrontomycin34 and thiostrepton,35 Daniewski's synthesis of pravastatin (58),36
Wovkulich's synthesis ofmevinolin,37 and Holton's syntheses of the C and D rings of
paclitaxel.38
12
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Figure 13. Application of the Burgess reagent in natural product syntheses.
2.1.3 Alternative Applications of the Burgess Reagent in Organic Synthesis
Formation of nitriles, isocyanides, carbodiimides, and nitro alkanes
The Burgess reagent can be effectively used for the dehydration of primary amides to
nitriles at room temperature and was shown to be superior to other methods which are
often incompatible with many functional groups. 15
13
°0,,/)
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Figure 14. Formation of nitriles, isocyanides, carbodiimides, and nitro alkanes.
Prathapan and coworkers showed that cis-aldoximes are converted to nitriles by the
Burgess reagent.39 In a similar fashion, the Burgess reagent transforms formamides to
isocyanides,4o ureas to carbodiimides,41 and primary nitro alkanes to nitrile oxides,42
as shown in Figure 15.
Formation of heterocycles via cyclodehydration
The utility of the Burgess reagent was expanded by Wipf and coworkers, who applied
inner salt 18 to the formation of oxazolines as well as thiazolines. In 1992, Wipf and
Miller reported that the Burgess reagent promotes the formation of 4,5-
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dihydrooxazole 72 from ~-hydroxy-a-amino acid 71 (Figure 15).43 As expected,
cyclodehydration takes place with inversion of the configuration at the ~-position.
Common side products such as aziridines, dehydroamino acid side products, and ~­
lactams often obtained with other methods were not detected in the reaction mixture.
Thioamides are converted to the corresponding thiazolines in a similar fashion.44 This
novel cyclodehydration method was found to be extremely useful for highly
functionalized or sensitive substrates with epimerizable centers. A direct conversion
of oxazolines to thiazolines can be achieved by thiolysis of oxazolines with hydrogen
sulphide followed by cyclodehydration of the resulting thioamide with the Burgess
reagent to yield the corresponding thiazolines.45
The scope of this novel cyclodehydration method was shown for example in Wipf's
total syntheses of westiellamide46, thiangazole,47 and (+)-curacin A,48 in Meyers's
synthesis of (-)-bistatramide C,49 and in Pattenden's synthesis of lissoclinamide.5o
Cyclodehydration promoted by the Burgess reagent is not limited to the synthesis of
oxazolines and thiazolines. The formation of various other heterocyclic systems such
as oxazoles from 2-acylamino carbonyl compounds,5! 1,3,4-oxadiazoles from 1,2-
diacylhydrazines,52 1,3-oxazines from y-hydroxyamides,53 1,3-thiazines from y-
hydroxythiamides,53 thiazepines from b-hydroxythiamides,53 as well as the syntheses
of N~bridged 5,6-bicyclic pyridines from 2-substituted pyridines bearing a carbonyl
group in the 3-position54 have been reported.
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Figure 15. Formation of oxazolines and thiazolines.
Preparation of sulfamidates, sulfamides, and glycosylamines
Besides the application of the Burgess reagent as a mild and selective dehydrating
reagent in total synthesis,34,35 the Nicolaou group developed a novel regio- and
stereoselective synthesis of sulfamidates from 1,2-diols. Treatment of such
sulfamidates with aqueous acid led to the formation of p-amino alcohols. Therefore
this sequence represents a two step conversion of diols to amino alcohols. 18 A
mechanism for the formation of sulfamidates from 1,2-diols was proposed and is
shown in Figure 16.
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Figure 16. Proposed mechanism or the formation of sulfamidates from 1,2-diols.
Reaction of the diol with two equivalents of Burgess reagent (18) leads to the
formation of bis-carbonylsulfamoyl intermediate 78, which upon SN2 displacement of
the more activated leaving group, gives cyclic sulfamidates of the general structure
79. Styrene derived diols were chosen as model substrates, because of their ease of
preparation as single enantiomers via Sharpless asymmetric dihydroxylation.55
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Figure 17. Formation of sulfamidates from 1,2-diols.
Burgess mediated sulfamidate synthesis followed the expected pattern for inductive
influence in nucleophilic displacement at the benzylic position: electron-donating
groups displayed excellent regioselectivity, whereas a poor selectivity was observed
with electron-withdrawing groups as shown in Figure 17. It was later shown by the
Hudlicky group that compounds 82a and 85a, assigned as regioisomers by the
17
Nicoleaou group are indeed 7-membered sulfamidates as shown ~ in Figure 17 (see
page 21 for more details).21
An application of this novel methodology can be found in the synthesis of (S)-u-
trifluoromethylisoserine by Pergrina and coworkers.56 Hydroxysulfamidates were
reported to be prepared in a similar fashion by the reaction of the Burgess reagent
with epoxyalcohols. 19
Using the concept of s!Ilfamidate formation from diols, the Nicolaou group applied
the same strategy to the synthesis of sulfamides from amino alcohols.2o The desired
cyclic sulfamides were reported to be obtained in high yield, regardless of the nature
of the group attached to the nitrogen. The Burgess reagent was shown to react with ~­
as well as y-amino alcohols to yield 5- and 6-membered nonsymmetrical
monoprotected sulfamides, respectively. Deprotection of the carbamate group is
achieved under basic conditions, giving access to a wide range of sulfamides after
substitution with appropriate electrophiles as demonstrated by Nicolaou and
" coworkers. Besides the formation of cyclic sulfamides, the syntheses of several linear
sulfamides were presented in the same publication.2o Further non-dehydrative utility
of the Burgess reagent was discovered in the synthesis of both u- and ~­
glycosylamines from a wide range of carbohydrate scaffolds as shown in Figure 18.
The reaction protocol was found to be tolerant to numerous protecting groups as well
as applicable for scale-up. 17
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Figure 18. Synthesis of a- and ~-glycosylamines.
Burgess-type reagents
The commercially available Burgess reagent is sensitive to oxidative conditions,
moisture, and heat. It must be stored at low temperature and has a limited shelf life.
Yields are therefore highest with freshly prepared reagent. Various groups have tried
to improve the properties, the stability as well as the reactivity of the Burgess reagent
(18). Wipf and Venkatramen reported the synthesis of polyethylene glycol (PEG)
supported Burgess type reagents 91, with molecular weight ranges from 750 to
2000. 16a This PEG-supported reagent gave various oxazolines and thiazolines in 10-
20% higher yields compared to the yields obtained from reactions with the regular
reagent. In addition, the PEG supported Burgess reagent showed improved stability
under wet and oxidative conditions and was readily separated from the reaction
mixture, as highlighted in Wipf's publication. 16a
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Figure 19. Burgess-type reagents.
The first Burgess type reagent, which had both the amine as well as the alcohol
portion varied, was introduced by Montero and coworkers. tert-Butyl ester in in place
of methyl and DMAP instead of triethylamine were the changes in this Burgess type
reagent 92. It allowed sulfamoylation of various amines under mild conditions to give
sulfamide derivatives in good yields.57
The formation of carbamates from primary alcohols, rather than the dehydration
product, was mentioned earlier in this chapter. This transformation has seen limited
use due to the harsh conditions required for the removal of the methoxycarbamate
protecting group. Modification of the methyl ester to a benzyl ester allowed for the
preparation of benzyl Burgess reagent 93.58 Application of the benzyl Burgess
reagent led to the smooth conversion of several primary alcohols to the corresponding
CBz protected amines in good yields. In addition to the use of the Burgess reagent as
a versatile reagent for the synthesis of sulfamidates and sulfamides, the Nicolaou
group prepared four different Burgess type reagents 93, 94, 95, and 96, representing
an orthogonal set of amine protecting groups (based on deprotection by
hydrogenation,photolysis, exposure to palladium based catalysts, or treatment with
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zinc).18 They demonstrated that the reaction of the new reagents with several diols,
amino alcohols and carbohydrates resulted in the formation of the desired products in
comparable efficiency and selectivity as observed with the original Burgess reagent
18. 17,18,19,20
The group of Masui disclosed a one pot synthesis of N-acyl substituted sulfamides
starting from chlorosulfonylisocyanate and isopropanol followed by addition of
pyridine to the N-chlorosulfonylcarbamate intermediate to give Burgess type reagent
97, which can be further reacted with aqueous or anhydrous amines to yield the
desired substituted sulfamides in excellent yield.59
Miscellaneous Uses
The use of the Burgess reagent leads occasionally to unexpected products. Ring
contraction of the neutral oleandrose sugar in the 14-membered macrolide antibiotic
oleandomycin was observed, instead of the desired dehydration, by Nagel and
coworkers.6o The facile formation of organotin reagents like vinyltributyltin and
tributyl isocyanate was reported by the application of the Burgess reagent.61 Makara
and coworkers published that carboxylic acids are converted to novel mixed
sulfcarboxyanhydrides upon treatment with the Burgess reagent. Subsequent
treatment of such mixed anhydrides with amines at elevated temperatures yields acyl
ureas and amides.62 Baylis-Hilmann adducts can be converted into carbamates of
unsaturated ~-amino acids in a one-pot reaction when treated with the Burgess
reagent.63 In addition, the oxidation of heterocyclic benzoin type compounds to the
21
corresponding benzil derivatives64 as well as the preparation of sulfilimines from the
corresponding sulfoxides have been achieved with the Burgess reagent.65
Formation of Sulfamidates from Epoxides
In 2003, the Hudlicky group published the first report on the reactivity of the Burgess
reagent with epoxides.21 Aliphatic epoxides yielded 5-membered sulfamidates upon
treatment with 2.3 equivalents of Burgess reagent (18) whereas benzylic epoxides
gave a separable mixture of 5- and 7-membered sulfamidates, as shown in Figure 20.
This aspect of the Burgess reactivity is especially noteworthy because epoxides were
believed to be inert to the action of the Burgess reagent as reported by Lamberth in
2000. 13b
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Figure 20. Formation of sulfamidates from epoxides.
Sulfamidates, derived from aliphatic epoxides, were further converted to their
corresponding cis-~-amino alcohol derivatives. It was further suggested that treatment
of the same sulfamidate intermediate under reductive conditions would lead to the
corresponding trans amino alcohols. Comparison of the spectral data of the products
derived from the reaction of styrene oxide (100) with the Burgess reagent (18), to
22
spectral data of the products derived from styrene diol, revealed that the minor
products, reported by Nicolaou as regioisomers (see 82a and 85a, page 16), were
actually 7-membered sulfamidates. 18 X-ray crystal structure analysis confirmed the
structure of compound 102. Hudlicky and coworkers proposed a mechanism to
account for the formation of 7-membered sulfamidates from either epoxides or 1,2-
diols and suggested that the latter compounds yield in some cases 7-mernbered
sulfamidates, as shown in Figure 21.
103a 103b
~OH
U
104
1
100
18a
1
/C02Me
o 0 -N
\\ij \ ~o
~ Ii
106
O~~O
101 107
Figure 21. Proposed mechanism for the formation of7-membered sulfamidates.
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Interestingly, the hybrid resonance form of the Burgess reagent 18a only plays a role
in the reaction of benzylic epoxides and no 7-membered sulfamidates were detected
in the reaction with aliphatic epoxides.
Further applications of the Burgess reagent and new reactive options are presented in
the Discussion, Section 3.1.
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2.2 Morphine Alkaloids
2.2.1 History of Morphine Alkaloids
Opium has been used to produce euphoria, analgesia, sleep, and relief from cough
and diarrhoea for thousands of years. 66 The word "opium" has been postulated to be
of Greek origin, deriving from "opos" Guice) and "opion" (poppy juice). The recorded
history of opiates dates back to the times of the Sumerians 3400 years BC. It seems
likely that the Summerians were aware of the mood elevating properties of the dried
sap obtained from the unripe seed pod of the poppy flower, Papaver Somniferum.67 In
pre-Christian centuries opium was primarily used for its constipation effect and for its
sleep-inducing properties, as noted by writers such as Homer, Hippocrates, Virgil,
and Ovid.66 In China and other oriental countries, where alcohol was prohibited
because of religious beliefs, opium was commonly used as an intoxicant. The nearly
bankrupt East Indian Company stabilized its financial situation with opium exports to
China, which led to India becoming the main producer of opium. Chinese efforts to
suppress the sale and use of opium failed because the British forced the Chinese to
permit opium trade and consumption.68 The invention of laudanum, an alcoholic
herbal preparation of opium, by the Swiss physician Paracelsus established opium as
a premium painkiller in Europe. One major drawback of opium was that the
administration was difficult since the content of the active ingredients of the raw
material was unknown to the physician.
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The isolation of morphine (1) from opium was a seminal event in the development of
the fields of chemistry and pharmacology. In 1805, Friedrich Wilhelm Sertlimer, a
young german pharmacist in Paderborn, isolated morphine (1) in its pure form from
raw opium. He named the compound after Morpheus, the Greek God of Dreams.3 The
applied protocol for the isolation of the pure substance was rather simple and
involved trituration of Indian opium with hot water until the filtrate became colorless.
The filtrates were then concentrated, and saturated with ammonia. The semi
crystalline material was then washed with water and triturated with ethanol. Serttirner
identified morphine (1) as a potent active component of opium and recognized
morphine (1) to be a base, marking the birth of alkaloid chemistry. Besides morphine
(1), which accounts for 10-16% of weight, raw opium contains varying amounts of
codeine (2) 1-3%, papaverine (3) 0.8-1 %, thebaine (4) 0.5-2%, traces of oripavine
(108), and narcotine (109) 1-7% as shown in Figure 22.
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Figure 22. Natural occurring morphine alkaloids.
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Structural elucidation began soon after the isolation of morphine (1) and early studies
by Liebig were followed by those of Laurent, who correctly deduced the empirical
formula for morphine as C17H19N03 in 1847.4 Within a few years of its isolation,
Heinrich Emmanuel Merck of Darmstadt began selling morphine as a painkiller,
resulting in the development of an eponymous company. In 1853, the use of
morphine proliferated with the invention of the hypodermic syringe, which provided
a superior method of administration. The initial application of morphine for the
treatment of alcohol and opium addiction was soon revised and research efforts were
focused on the development of a less addictive derivative. Diacetylmorphine,- known
as heroin, was first synthesized by the English chemist Charles Robert Albert Wright
and marketed by Bayer in 1898 as a non-addictive morphine substitute and cough
suppressant.9 Although heroin is metabolised to morphine in the human body and
therefore has the same pharmacology as morphine, the semi-synthetic opioid has the
ability to cross the blood brain barrier faster, which creates an euphoric rush. This
property made the substance even more addictive and led to an immense illicit
demand, which continues to this day. Besides the first synthesis of heroin, Wright
also contributed to the elucidation of the oxygenation pattern in morphine.69
Numerous degradive experiments by Hofmann, Pschorr, and von Gerichten on
morphine and codeine confirmed the presence of an oxygenated phenanthrene
skeleton.7o In 1925, Robinson and Gulland were able to propose the correct structure
of morphine based on their own degradative studies as well as on the findings by
Pschorr, Hofmann, Freund, and many others.5 This proposal was ultimately
confirmed by the first total synthesis by Gates in 1952.6 The relative stereochemistry
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of morphine was further confirmed by X-ray diffraction analysis by MacKay and
Hodgkin in 1955.71 The absolute stereochemistry was established by Jeger and
coworkers by the chemical degradation of hydrocodone.72 The structural elucidation
of morphine represents one of the largest scientific efforts ever undertaken, spanning
just over 150 years and was reviewed in an excellent publication by Butora and
Hudlicky.73
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2.2.2 Biosynthesis of Morphine Alkaloids
Morphine and codeine belong to a large group of secondary plant metabolites, more
precisely to the group of benzylisoquinoline alkaloids. The biosynthetic pathway that
produces all benzylisoquinoline alkaloids begins with the conv~rsion of the amino
acid tyrosine (110) into both dopamine (111) and 4-hydroxyphenylacetaldehyde (112)
by four enzymes that catalyze hydroxylation, decarboxylation, as well as
transamination reactions.74
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Figure 23. Biosynthesis of (7S)-salutaridinol (118).
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The first step of the pathway towards morphine alkaloids involves the enzyme
norcoclaurine synthase, which catalyzes the condensation of dopamine (111) and 4-
hydroxyphenylacetaldehyde (112) in an asymmetric Pictet-Spengler reaction to form
(S)-norcoclaurine (113), the central precursor to all benzylisoquinoline alkaloids in
plants.75 More recently the gene responsible for this transformation has been
overexpressed in Escherichia coli and the protein has been purified.76 Subsequent
methylation catalyzed by a N-methyltransferase77 and P-450 mediated hydroxylation
give (S)-3~-hydroxy-N-methylcoclaurine (114),78 which is further converted to (S)-
reticuline (115), the precursor of more than 2500 benzylisoquinoline alkaloids.
Interestingly, this substrate is not transformed into (+)-morphine, but is first
converted into its enantiomer (R)-reticuline (116). Epimerization occurs via
stereospecific reduction of its Schiff base catalyzed by the NADPH requiring enzyme
1,2-dehydroreticuline reductase.79 Probably the most remarkable transformation of
the morphine biosynthesis is the regioselective oxidative phenolic coupling catalyzed
by the NADPH dependent cytochrome P450, salutaridine synthase.8o Unlike most of
the P-450 mediated reactions in alkaloid biosyntheses, salutaridine synthase
represents an oxidase rather than a monooxygenase; this means no molecular oxygen
is incorporated into the substrate. The ketone functionality of salutaridine (117) is
reduced to (7S)-salutaridinol (118),81 and the latter is then acylated by (7S)-
salutaridinol-7-0-acetyltransferase.82 The resulting allylic acetate 119 undergoes a
non-enzymatic syn SN2' displacement by the phenolic hydroxy group to yield
thebaine (4).
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Figure 24. Biosynthesis of morphine.
Demethylation of the C-6 enol ether functionality by an as yet uncharacterized
enzyme results in the formation of neopinone (120), which exists in equilibrium with
its fully conjugated isomer, codeinone (121). Reduction of the C-6 keto group by
codeinone reductase83 and final demethylation of the phenolic ether yields morphine
(1), as shown in Figure 24. Interestingly, an alternative pathway which leads to the
formation of morphine (1) has been postulated and is shown in Figure 25.84
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Figure 25. Alternative biosynthesis of morphine (1).
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Experiments with radio-labelled morphine precursors revealed that oripavine (108) is
formed from thebaine (4) by 3-0-demethylation. Subsequent enol-ether cleavage
produces morphinone, which is further reduced by codeine reductase to yield
morphine (1). This alternative biosynthetic pathway was further proven by the
preparation of a poppy mutant known as top] (for 'thebaine oripavine poppy 1,).11
Commercial poppy cultivar were treated with a mutagen and then screened for
progeny plants. The mutant top] was found to accumulate thebaine (4) and oripavine
(108) but not morphine (1) and codeine (2). Feeding experiments with radioactive
intermediates confirmed that there was a block in both arms of the bifurcated pathway
at thebaine and oripavine. The authors suspected·that a defect in the enzyme thebaine
demethylase, which is responsible for the 6-0-demethylation of both thebaine and
oripavine, caused the variation in the morphine biosynthesis.
The development, of the top] mutant not only contributed to the understanding of the
biosynthetic pathway of morphine alkaloids, but also provides for an agriculturally
viable supply of thebaine (4) and oripavine (108), which are employed in the
manufacturing of the vast majority of semi-synthetic opioids.
The current picture of the morphine biosynthesis in plants, involving 19 steps, is
nearly complete.85 However, recent studies have also provided evidence for the
presence of morphine alkaloids in animals. Trace amounts have been detected in
various tissues of mammals and lower animals.86 The origin of the endogenous
morphine has been a matter of controversy since morphine was also found in hay,
lettuce, human milk, and cow milk as well as commercial rat and rabbit feed. 87 The
group of Zenk could unambiguously demonstrate that human neuroblastoma cells are
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capable of synthesizing morphine. On the basis of radiolabelled precursor feeding
experiments, they provided a detailed picture of the biosynthesis of morphine in
human cells starting from the amino acid tyrosine (110).86,88
The two main sources of morphine (1) for commercial applications are either opium
or poppy straw. Both sources are obtained from processing the capsules of Papaver
somniferum. Opium is the sun-dried sap obtained from incised capsules.
Approximately 80 days after planting, the green capsule is incised and the released
sap is collected and dried. Severallancings are combined and dried in special open air
tanks until the moisture content is reduced to approximately 15%. The second
commercial source for morphine alkaloids is poppy straw. Poppy straw consists of
dried capsules which were freed from their seeds and milled. Although the alkaloid
content of green, undried capsules would be considerably higher, the valuable seeds
would be lost. Only the additional profit derived from the sale of the seeds makes the
business of growing poppies lucrative, since the commercial value of the seeds is
equal to the value of the alkaloids.89
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2.2.3 Overview of Selected Morphine Synthesis
Since the first reported total synthesis of morphine by Gates and Tschudi in 1952,
morphine has remained a challenging target for the synthetic community.9o There are
a number of unique structural features which contribute to its complexity as a
synthetic target: the C-13 quarternary center, the C-4, C-5 ether linkage, five vincinal
stereocenters, the pentacyclic framework and especially the dissonantly assembled 17
carbons of morphine, as shown in Figure 26. (The concept of consonance/dissonance
was first introduced by Evans and was discussed in detail by Hudlicky and Reed. 91)
The following section summarizes a selection of synthetic efforts towards the total
synthesis of morphine alkaloids which employ Diels-Alder, Grewe cyclization,
radical cyclization, or palladium cyclizations as key strategies.
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Figure 26. Dissonant relationships in morphine (1) connectivity.
Gates (1952, full disclosure 1956)6,92
The first total synthesis of morphine was published by Gates and Tschudi in 1952
requiring 24 steps to construct morphine (1) from 2,6-dihydroxynaphthalene (122) in
an overall yield of 0.01 %.
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The symmetry of the starting material allowed Gates to synthesize intermediate 125
in an iterative fashion by employing a nitrosation/reduction/oxidation sequence. This
sequence allowed for the installation of the two different 1,2-dioxygenation
functionalities on both rings in a very efficient way. A Michael-type reaction of
compound 125 and ethyl cyanoacetate, followed by re-oxidation and base-catalyzed
decarboxylation provided the precursor for the subsequent Diels-Alder reaction.
Earlier model studies had shown that the C-13 quaternary center of morphine could
be constructed via cycloaddition of compound 126 and butadiene. 93
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Reagents and Conditions: a) BzCI, py, dioxane (72%); b) NaN02, AcOH (88%); c) Pd/C, H2, AcOH,
then FeCl3 (85%); d) S02, MeOH (91 %); e) K2C03, dimethyl sulfite (82-86%); f) KOH, MeOH (80%);
g) ethyl cyanoacetate, NEt3, then K3Fe(CN)6 (84%); h) KOH, MeOH, H20 (97%); i) butadiene, AcOH
(66%).
Scheme 1. Gates synthesis of Diels-Alder product 127.
Diels-Alder adduct 127 underwent reductive cyclization through what the authors
described as relatively "mild conditions" (130 °C, 27 atm of H2) to give keto lactam
128. This unusual cyclization was discovered by Gates and Woodward in an earlier
series of model studies, two years before the first total synthesis of morphine was
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reported.94 The course of this reductive cyclization "was far from clear" as stated by
Gates in his 1956 publication. Nevertheless, it produced the tetracyclic carbon-
nitrogen skeleton stereoisomeric of that of morphine (1) very efficiently.
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NH NMe
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MeO
NMe
HO
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HO h HO f,g
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Reagents and Conditions: a) Cu-Cr, H2 (50%); b) KOH, N2H4 (90%); c) NaH, Mel; d) LAH (54%);
e) dilute H2S04 (28%); f) KOH, ethylene glycol (54%); g) tert-BuOK, Ph2CO (89%); h) Br2, AcOH,
2,4-DNP (41%).
Scheme 2. Gate's synthesis of intermediate 132.
The keto functionality was reduced using a modified Wolff-Kishner protocol,
followed by methylation and lithium aluminium hydride reduction to give d-fJ-LJ6-
dihydrodesoxycodeine (129), which represents the entire carbon skeleton of
morphine. The infrared spectrum of compound 129 was identical to that of natural d-
fJ-LJ6-dihydrodesoxycodeine methyl ether, which was obtained by degradation of fJ-
dihydrothebainone. In addition, the resolution of morphinan 129 into its enantiomers
was easily effected by crystallization with dibenzoyltartaric acid and provided the
natural enantiomer in this series, but epimeric at C-14. The stereochemical
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assignment of compound 129 is based on comparison with products obtained from
degradation of naturally occurring morphine alkaloids. Acid mediated hydration of C-
6 followed by selective cleavage of the proximal anisole methyl ether furnished
compound 131. The remaining challenge in Gates' synthesis, the epimerization of the
C-14 center, was solved in an elegant manner. Ketone 131 was treated with two
equivalents of bromine followed by hydrazone formation with 2,4-
dinitrophenylhydrazine as shown in Figure 27.
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Figure 27. C-14 epimerization via hydrazone formation.
The introduction of the a,~-unsaturation in compound 134 allowed for the
equilibration of the C-14 hydrogen, because of the formation of the more stable cis
fused ring system of compound 136. It has to be mentioned that Gates' sequence is
still the method of choice for the equilibration of C-14 center in morphine alkaloid
synthesis.
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Reagents and Conditions: a) H2, Pt02; b) Br2, AcOH, 2,4-DNP (26%); c) HCI, acetone (27%); d)
LAH (quant); e) H2, Pd/C; f) Py·HCI (34%).
Scheme 3. Gate's final transformation to (-)-morphine (1).
Acid mediated hydrolysis of the hydrazone, followed by hydrogenation gave the
precursor for the C-4, C-5 dihydrobenzofuran closure 137. The construction of the
complete morphine pentacyclic core was achieved by applying the same remarkable
conditions which addressed the problem of the C-14 epimerization. Treatment of
ketone 137 with bromine in the presence of 2,4-2,4-dinitrophenylhydrazine effected
the C-4, C-5 ether closure as well as introduced the 117-8 unsaturation unit. Cleavage
of the phenylhydrazone unit with hydrochloride acid followed by treatment with
lithium aluminium hydride furnished codeine (2) in 27% over two steps. Repetition
of the conditions reported by Rapoport and coworkers for the demethylation of
codeine completed the first synthesis of morphine (1).95
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Rice (1980)96
Rice's work in opiate total synthesis was initiated by two events, the world-wide
opium shortage of 1973-1975, as well as the discovery of morphine receptors and the
resulting need of unnatural enantiomers for affinity studies.
Figure 28. Cyclization of benzylhexahydroisoquinoline 140.
Rice's strategy was presumably inspired by previous reports that described a Grewe-
type electrophilic cyclization of rac-1-benzylhexahydroisoquinoline (140), which
gave dihydrothebainone (141) in 3% yield with isomeric 142 as the predominant
cyclization product (Figure 28).97 Those studies were followed by the work of
Beyerman and coworkers who utilized a blocking group (a methyl group at the C-1)
of the benzoyl moiety in order to direct cyclization to the desired oxygenation
pattem.98
Rice's synthesis starts with the preparation of amine 145 by condensation of amine
143 and acid 144, followed by Bischler-Napieralski cyclization. Birch reduction of
the more electron deficient aromatic ring gave amide 146 after formylation.
Ketalisation and regioselective bromination of 146 was carried out consecutively in a
one pot reaction.
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NH3, THF, tert-BuOH (90%); e) PhOCHO, EtOH (94%); f) ethylene glycol, MeS03H, THF; g) NBA
(88%); h) HC02H-H20 (90%); i) NH4eHF, CF3S03H (60%); j) MeOH, HCl (92%); k) H2, Pd/C,
AcOH, HCHO; 1) Br2, AcOH ; m) NaOH, CHCI3; n) H2, AcOH, HCHO (79% over 4 steps).
Scheme 4. Rice's synthesis of hydrocodone 12.
Careful hydrolysis of compound 147, followed by hydrogen fluoride mediated Grewe
cyclization furnished dihydrothebainone derivative 148 in a remarkable 60% yield.
The pentacyclic framework of morphine alkaloids was completed by mild hydrolysis
of amide 148 followed by a-bromination to the ketone and base induced ring closure.
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Removal of the aryl bromide and methylation of the secondary amine were achieved
by hydrogenation over palladium in a mixture of acetic acid and formalin. Rice's
synthesis of racemic hydrocodone 12 involves the isolation of only six intermediates,
which required no chromatographic purification and proceeded in 29% overall yield.
In addition Rice reported the resolution of compound 145 and therefore allowed
access to both the natural as well as the unnatural series of morphine alkaloids. Rice's
biomimetic route represents the most practical synthesis of morphine alkaloids to date
and would be amenable to commercial production of a wide variety of opiates.
Despite the efficiency of Rice's synthesis, the isolation of opiates from natural
sources remains more cost effective and therefore the need for an even more practical
synthesis still exists.
Overman (1993)99
The first genuinely asymmetric synthesis of morphine was reported by Overman in
1993. All of the previously published syntheses were either racemic or involved a
classic resolution strategy. Inspired by the previous synthesis of Grewe and Rice, 96,
97a Overman employed an iminium ion-allylsilane cycliczation as well as an
intramolecular Heck reaction of an enantioenriched octahydroisoquinoline derivative
to construct the morphine skeleton. Chirality was incorporated in the first step of the
synthesis via enantioselctive reduction of 2-allylcyclohexenone derivative 150 with
catecholborane in the presence of (R)-oxazaborolidine catalyst 154 to give the
corresponding alcohol in 96% ee. 100 Condensation of this intermediate with
phenylisocyanate, followed by selective dihydroxylation of the terminal double bond
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and protection resulted in the formation of compound 151. A copper mediated
suprafacial SN2' displacement of the allylic carbamate with lithium dimethyl silane
was achieved with minimal stereochemical erosion.
0 gCONHPh SiMe2Ph SiMe2Ph
~ a, b, C • CJ1{ d ~I- e, f mHDBS
150 151 152 153
H PhffiPh
N'B"O
I
Me
154
Reagents and Conditions: a) 154, catechol borane (93%); b) PhNCO (93%); c) OS04, acetone, HCI
(78%); d) n-BuLi, CuI(Ph3P)2, PhMe2SiLi (81 %); e) p-TsOH, MeOH, NaI04; f) DBS-NH2, NaCNBH3
(88%).
Scheme 5. Overman's preparation of chiral intermediate 153.
Deprotection of the acetonide group, followed by sodium periodate cleavage of the
diol unit gave the corresponding aldehyde which yielded compound 153, upon
condensation with dibenzosuberylamine (DBS-NH2) as shown in Scheme 5.
The second component of the iminium ion-allylsilane cyclization was prepared from
isovanillin derivative 155 as shown in Scheme 6. Lithiation of compound 155
(available in two steps from isovanillin), followed by treatment with.elemental iodine
and subsequent cleavage of the acetal group provided aldehyde 156. Reaction of this
intermediate with dimethylsulfonium methylide followed by Lewis acid catalyzed
rearrangement of the resulting epoxide gave compound 157 in excellent yield.
Condensation of amine 153 and aldehyde 157 in the presence of ZnI2, followed by
42
iminium ion-allylsilane cyclization yielded the desired octahydroisoquinoline 159 in
high diasteroselectivity.
Q:Mel2 CHO 6°¢\I SiMe2Pha,b,c . I ~ OBn d,e ~I + mHDBSI~ OMOM -6- OBn
OMe OMe OMe
155 156 157 153
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MeO -.?"
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SBD/N H [PhM~Ar ]I ":::NDBS MeO ~ f DBS
OBn
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Reagents and Conditions: a) n-BuLi, 12(80%); b) 6N HCl; c) BnBr, K2C03 (97%); d) CH2SMe2
(91 %); e) BF3·0Et2, THF (92%); f) Zn12' EtOH, 60°C (82%).
Scheme 6. Overman's synthesis of Heck cyclization precursor 159.
The crucial C-13 quaternary center of the morphine skeleton was forged by
intramolecular Heck cyclization of 159 catalyzed by 10 mol% Pd(TFA)2(Ph3P)2 in
the presence of four equivalents of 1,2,2,6,6-pentamethylpiperidine. After cleavage of
the benzyl ether, the final ring of the opioid skeleton was formed by reaction of the
camphersulfonate salt of the free phenol with three equivalents of 3,5-dinitrobenzoic
acid. Oxidation of 161, followed by hydrogenolysis of the DBS group in the presence
of formaldehyde provided hydrocodone (12), which was further converted to
morphine (1) as described by Rice. IOI
43
:::X(\
I~NDBS
159
a
MeO
BnO
NDBS
160
Me0)lA"'"I~
o -:~'.~NMe
HO)J
b,c
Rice
Meo~
,Mo -:'\~NDBS
HO~
161
Meo~
/L~
q..)<:Ao~ NMe
12
Reagents and Conditions: a) Pd(TFA)2(Ph3P)2, 1,2,2,6,6-pentamethylpiperidine, toluene (60%); b)
BF3·OEt2, EtSH (79%); c) CSA, 3,5-dinitroperoxybenzoic acid (60%); d) TPAP, NMO (86%); e) H2,
Pd(OH)2, HCHO (80%).
Scheme 7. Overman's final transformation to hydrocodone (12).
It is noteworthy that application of the (8) enantiomer of the oxazaborolidine reagent
gives the opposite enantiomer of allylic alcohol 151 in comparable
enantioselectivity.l00 In identical fashion as described for the synthesis of (-)-
morphine, Overman was able to prepare (+)-hydrocodone, as well as (+)-morphine.
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Parker (1992, 2006)7
Parker's approach to the morp,hine ring system was based on a tandem cyclization of
an ortho allyloxy radical. In 1992 Parker and Fokas reported the racemic synthesis of
dihydroisocodeine in 11 steps, which constitutes a formal synthesis of morphine.
Fourteen years later the original synthesis was modified resulting in an asymmetric
synthesis of (-)-hydrocodone (12).
The key intermediate in Parker's synthesis represents an aryl cyclohexenyl ether,
which was prepared by a Mitsunobu reaction. The synthesis of the cyclohexenyl
portion, the C-ring synthon, started with the Birch reduction of commercially
available m-methoxyphenethylamine (162), followed by tosylation of the amino
group and hydrolysis of the enol ether unit.
£ NH2 otS'NMeTS xS'NMeTSa,b,c d Br "?' eI~ .
MeO h 0
162 163 164
, ~NMeTsBr,XJ
HO
165
H Ph
CBS= Qj-Ph
B
I
Me
HO~ ~NMeTS......-_h_,i_
TBsoD
167
~~NMeTS
HoD
166
Reagents and Conditions: a) Li, NH3, tert-BuOH (97%); b) TsCI, NEt3' then HCI (81%); c) Mel,
K2C03, acetone (96%); d) Br2, NEt3 (91 %); e) CBS, catechol borane (84%); f) Na(Hg); THF-MeOH
(90%); g) m-CPBA (92%); h) Ti(OiPr)4 (85%); i) TBSCI, imidazole, DMF (78%).
Scheme 8. Parker's synthesis ofC-ring fragment of morphine 167.
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Since the development of an appropriate protocol for the asymmetric reduction of
compound 163 could not be accomplished, Parker resorted to an indirect strategy
based on the asymmetric reduction of a 2-bromocyclohexenone derivative. Reduction
of compound 164 with the Corey-Bakshi-Shibata (S)-oxazaborolidone-catechol
borane reagent (CBS)100 afforded alcohol 165 in excellent yield with enantiomeric
excess ranging from 82% to 96%. Removal of the bromine from alcohol 165 by metal
halogen exchange was not successful, but reduction with sodium amalgam proved to
be suitable. Peracid-mediated epoxidation yielded the cis-epoxy alcohol intermtediate
166, which was further treated with titanium isopropoxide to furnish the desired
cyclohexenediol167, as shown Scheme 8.
x5.NMeTsHO "'" +
T880
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Meo~
HO~SPh
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a
Meo~
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Q~•..b NMeTos
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169
Reagents and Conditions: a) PBU3, DEAD (83%).
Scheme 9. Parker's preparation of radical cascade precursor 169.
The key intermediate 169 was successfully assembled by Mitsunobu reaction of C-
ring fragment 167 and bromoisovanillin derivative 168 (A ring fragment) as shown in
Scheme 9.
Removal of the silyl protecting group afforded compound 170, which proved to be a
suitable substrate for the radical-initiated tandem cyclization reaction. Homolytic
cleavage of the.carbon halogen bond in 170 mediated by tributyltin hydride and 2,2'-
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azoisobutyronitrile afforded aryl radical 171. This first species underwent a radical
closure to form the dihydrofuran ring and generated a new radical at the C-14 carbon,
which was trapped by the ~-carbon of the styrene unit to give a resonance stabilized
benzylic radical intermediate. Elimination of the phenylthiolate radical afforded
intermediate 173 as a single diastereomer with correct configuration at the newly
formed carbon centers. It was previously shown in various model studies that only the
vinylthiophenol functionality gave excellent stereoselectivity in the radical mediated
closures, whereas other radical acceptors failed to produce a single diastereomer.7b,7c
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Reagents and Conditions: a) 10% HF, CH3CN (78%); b) n-Bu3SnH, AlliN, toluene (30%); c) Li,
NH3, tert-BuOH (85%); d) DMSO, (COCI)2, NEt3 (80%).
Scheme 10. Parker's final transformation to hydrocodone (12).
Although the reductive desulfonation of olefinic sulfonamides had not previously
been reported to affect ring closure, dihydroisocodeine was obtained after treatment
of tosylamine 173 with lithium and ammonia. Swern oxidation of the C-6 hydroxy
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group completed this creative synthesis of hydrocodone (12) in thirteen steps from m-
methoxyphenethylamine.
Trost (2002, 2005)8
In 2002, Trost and Tang reported the enantioselective synthesis of (-)-codeine (2) and
morphine (1). The key strategies include an asymmetric allylic alkylation (AAA) to
connect the A and C rings of morphine alkaloids in an enantioslective fashion, and
two sequential Heck cyclizations to form the furan heterocycle, as well as the Bring
of morphine alkaloids.
OHCy,I ~Br OMe
OH
+
a
174
L=
175 176
Ib,c
-.?" 0
OMe
177
Reagents and Conditions: a) cat. PdL, NEt3, DCM (72%); b) p-TsOH, CH(OMe)3, MeOH; c)
DIBAL-H, toluene, - 78°C (85% over two steps).
Scheme 11. Trost's asymmetric allylic alkylation of compound 175.
The synthesis began with the palladium catalyzed AAA of bromoisovanillin (174)
and allylic ester 175 (available in two steps from glutaraldehyde) to give aryl ether
176 in 88% enantiomeric excess. Protection of the aldehyde, followed by reduction of
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the ester functionality afforded alcohol 177. The a,~-unsaturatednitrile was prepared
by applying a modified Mitsunobu protocol with acetone cyanohydrin followed by
liberation of the aldehyde under acidic conditions.
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Reagents and Conditions: a) PPh3, acetonecyanohydrin, DIAD; b) p-TsOH, THF, H20 (76% over
two steps); c) Pd(OAc)2, dppf, Ag2C03, toluene (91 %); d) CBr4, PPh3, DCM (91 %); e) n-Bu3SnH,
toluene (88%); f) Pd(OAc)2, dppp, Ag2C03, toluene (65%).
Scheme 12. Trost's synthesis of nitrile intermediate 182.
Intramolecular Heck cyclization produced the quaternary C-13 center of the morphine
skeleton in excellent yield. Corey-Fuchs homologation of aldehyde 179, followed by
chemoselective reduction of the E-vinyl bromide provided precursor 181 for the
second Heck cyclization. Palladium catalyzed closure of the B-ring of the morphine
skeleton gave compound 182 in 65%. Selenium dioxide mediated oxidation of the
allylic carbon of the C-ring and subsequent DIBAL-H reduction of the enone in THF
gave allylic alcohol 183 with the correct stereochemistry at C-6.
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Reagents and Conditions: a) Se02, dioxane, sand (75%); b) DIBAL-H, THF, Et20 (99%); c) DIBAL-
H, DCM, Et20, then NH4Br, MeNH2followed by NaBH4 (quant.); LDA, THF, 150-W tungsten bulb
(57%).
Scheme 13. Trost's final transformation to codeine (2).
Nitrile 183 was converted to amine 184 in a one pot transformation as follows:
DIBAL-H mediated nitrile reduction was accomplished by switiching the solvent
from THF to DCM, which afforded an imine aluminium complex. Addition of
ammonium bromide to the reaction mixture destroyed excess DIBAL-H, as well as
freeing the primary imine functionality. Subsequent treatment with methylamine
furnished the more stable secondary imine, which was immediately treated with
sodium borohydride to yield compound 184 in quantitative yield. The closure of the
remaining D-ring is probably the most remarkable step in Trost's synthesis.
Subjecting a solution of compound 184 to six equivalents of LDA to irradiation with
a commercial 150-W tungsten light bulb led to intramolecular amination of the
styrene to form (-)-codeine (2). Demethylation of codeine (2) with boron tribromide
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as reported by Rice,102 finished the synthesis of (-)-morphine in 16 steps from
commercially available materials.
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Figure 29. Enantioselective synthesis of (-)-galanthamine (186).
Trost also applied compound 179 to the total synthesis of (-)-galanthamine (186) and
therefore his strategy allowed for the synthesis of two different classes of alkaloids,
morphine as well as amaryllidaceae alkaloids (Figure 29).
Hudlicky (1992 to present)
Over the last 20 years the Hudlicky group has explored various approaches to
morphine alkaloids based on a wide range of strategies. The common feature of all
approaches is the application of starting materials generated by enzymatic
transformations. In 1968 Gibson and coworkers reported the isolation of a soil
bacterium Pseudomonas putida which utilized ethylbenzene or toluene as its only
carbon source. I03 Subsequent studies by the Gibson group led to the isolation of a
mutant strain designated Pseudomonas putida F39/D, which converted aromatic
compounds to their corresponding enantiomerically pure cis-cyclohexadienediols.104
In order to improve the efficiency of this remarkable enzymatic transformation
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Gibson prepared a genetically engineered Escherichia coli, which provided
synthetically useful amounts of the metabolites from fermentation. 105
6 X~OH~OH alkaloidsterpanessugars
cyclitols
Figure 30. Application of cis-cyclohexadienediols to natural product synthesis.
Since Gibson's initial discovery in 1968 over 400 different homochiral
cyclohexadienediols derived from microbial oxidation have been reported in
Iiterature. 106
The synthetic utility of dihydroxylated metabolites from arenes was first shown in
Ley's racemic synthesis of pinitol in 1987,107 followed by Hudlicky's creative
syntheses of prostaglandin intermediates in 1988.108 Many applications followed with
the group of Hudlicky being very active in the field reporting the total syntheses of a
wide variety of natural products, such as alkaloids, terpenes, cyclitols and sugars. 106
A brief review of Hudlicky's efforts towards a practical synthesis of morphine
alkaloids utilizing cis cyclohexadienediol derivatives as starting materials will be
presented on the following pages.
Intramolecular Diels Alder Cyclization Strategyl09
The natural 1,2-disposition of the diol functionality makes the metabolites derived
from dihydroxylation perfect synthons for the C-ring fragment of morphine alkaloids.
Closer inspection of the morphine skeleton reveals that the entire morphine skeleton
52
could be assembled by two metabolites linked together at the C-5 postion.
Intramolecular Diels-Alder reaction, followed by rearomatization of the A-ring would
furnish the phenanthrene core of morphine alkaloids as shown in Figure 31.
187 188
Figure 31. Retrosynthetic analysis of Hudlicky' s intramolecular Diels - Alder
approach to morphine alkaloids.
In 1992 Hudlicky and coworkers published a model study, which employed a Diels-
Alder cyclization or a Diels-Alder and Cope rearrangement sequence to obtain
tricycles 192 and 196.
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Figure 32. Hudlicky's Diels-Alder model studies towards the synthesis of morphine
alkaloids.
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Dienediol 190, obtained by whole-cell mediated dihydroxylation of toluene served as
starting material for both studies. Intramolecular Diels-Alder reaction of tetraene 193
gave compound 194. The proposed Cope rearrangement could only be effected after
deprotection of the alcohol functionality followed by oxidation. Heating of compound
195 in xylenes to 250°C gave a single diasteremore, which was further reduced to
give alcohol 196, which possess four stereocenters of the morphine skeleton in the
correct configuration.
In a similar model study triene 191 was rapidly assembled from toluene diol 190 and
intramolecular Diels-Alder cyclization gave tricyclic compound 192. The assignment
of the stereochemistry of compound 192 was based on NOE-correlations and was
revised in 1998, after a more advanced model study was conducted. Incorporation of
the ethylamino bridge in the more advanced study was easily achieved by substitution
of the starting, material for whole cell fermentation from toluene to (2-
azidoethyl)benzene (197). Selective reduction of the unsubstituted double bond,
followed by protection of the distal hydroxyl group as its silyl ether led to the
isolation of azide 199. The precursor for the intramolecular Diels-Alder reaction
compound 200 was rapidly assembled by reaction with sorbyl bromide, followed by
Staudinger reduction and protection of the resulting primary amine. Heating
compound 200 in toluene in a sealed tube to 230°C for 20 hours gave the tricyclic
intermediate 201, which was further deprotected by TBAF treatment to yield
compound 202.
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Reagents and Conditions: a) Escherichia coli JMI09 (pDTG601); b) potassium azodicarboxylate
(PAD), AcOH, MeOH (72%); c) THS-CI, imidazole, DMF (99%); d) NaH, sorbyl bromide, THF
(62%); e) PhP3, H20 (66%); f) AC20, py (quant.); g) toluene, sealed tube. 230°C (62%); h) TBAF,
THF.
Scheme 14. Hudlicky's synthesis of tricyclic compound 202.
X-ray single crystal structure analysis of free alcohol 202 revealed that the
intramolecular Diels-Alder reaction had proceeded through an exo-transition state and
not through an endo-transition state as originally assumed. At this point, repetition of
the previously reported cyclization of intermediate 191, followed by liberation of the
free hydroxyl group, allowed for the isolation of crystalline compound 204. X-ray
crystal structure analysis of compound 204 revealed that the cyclization proceeded
through the expected exo-transition state, in analogous fashion to amide 200.
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Figure 33. Structural revision of compound 192.
Although this approach did not allow for the total synthesis of morphine, it highlights
the efficient combination of enzymatic and traditional organic transformations to
produce tricyclic compound 201, which contains all of the five stereocenter of
morphine alkaloids in thei~ correct absolute configuration.
Radical cyclizations
Inspired by Parker's strategy, the Hudlicky group designed a tandem radical
cyclization approach to morphine alkaloids. The homochiral diol 5, available from
whole cell fermentation of ~-bromoethylbenzene(205), was chosen as the starting
material because the configuration of each hydroxyl group can be easily manipulated
by Mitsunobu reactions. Diimide reduction and selective protection of the distal
hydroxyl group followed by Mitsunobu inversion of the allylic hydroxyl group
furnished compound 206. Alkylation of this material with oxazolidone and hydrolysis
of the benzoate group gave the C-ring fragment of the morphine alkaloid. The
aromatic portion was installed by a low yielding second Mitsunobu reaction to set the
stereochemistry of the C-5 center. Treatment of compound 208 under radical
conditions gave a complex mixture of more than six compounds.
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Reagents and Conditions: a) Escherichia coli JM109 (pDTG601) (10g/L); b) PAD, AcOH, MeOH
(80%); c) TBSOTf, Hlinig's base, DCM (47%); d) BzOH, n-Bu3P, DEAD, THF (84%); e) NaOH; f) 2-
oxazolidone, NaH, DMSO (71 %); g) 2-bromo-6-methoxy phenol, n-Bu3P, DEAD, THF (28% over two
steps); h) (TMS)3SiH, AIBN, benzene, 140 °C, sealed tube (15%).
Scheme 15. Hudlicky's first generation radical cyclization approach.
Separation of the mixture by chromatography gave predominantly diastereomer 209
in modest yield, whose epi-C-14 configuration was established by NMR analysis.
The presence of a second diastereomer 210 was also detected, however the minute
amounts did not allow for an unambiguous identification.
A second generation approach was designed which addressed the problems of
stereoselectivity as well as the low yield of the tandem radical cyclization closure.
The approach relied on two independent radical cyclizations. The first radical
cyclization was designed to give an advanced isoquinoline intermediate, which was
further reacted with an appropriate aromatic portion to allow for the second radical
based ring closure. o-Bromo-~-bromoethylbenzene (211) was subjected to
biodihydroxylation and was further converted to the precursor for the first radical
57
cyclization 214 in three steps. Exposure of compound 214 to n-Bu3SnH and AIBN
provided two octahydroisoquinolines 215 and 216, in a ratio of 2 : 1 in favour of the
isomer possessing the epi-C9 configuration.
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Reagents and Conditions: a) Escherichia coli JMI09 (pDTG601) (0.2g/L); b) PAD, AcOH, MeOH
(50%); c) 2,2-dimethoxypropane, p-TsOH (90%); d) 2-oxazolidone, NaH, DMSO (38%); e) n-
BU3SnH, AIBN, benzene, reflux (87%).
Scheme 16. Hudlicky's second generation radical cyclization approach.
The lack of stereocontrol was attributed to the negligible steric effect of the acetonide
moiety. Because of the greater availability of the epi-isomer 216, Hudlicky and
coworkers decided to pursue the synthesis of ent-morphine.
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Reagents and Conditions: a) Dowex 50X8-100, MeOH (94%); b) TBSOTf, Hiinig's base, DCM
(85%); c) 2-bromo-6-methoxy phenol, n-Bu3P, DEAD, THF (94%); d) n-Bu3SnH, AIBN, benzene,
reflux (47%); e) DIBAL-H, DCM, (87%); f) TBAF, THF (quant.); g) (COCI)2, DMSO, NEt3' DCM
(66%); h) TFA (58%); i) MsCI, NEt3 (87%);j) AICh, benzene.
Scheme 17. Hudlicky's syntheses of ent-morphinans 221 and 223.
The A-ring fragment was installed via Mitsunobu alkylation to furnish the precursor
for the second radical cyclization, ether 217. As expected, exposure of aryl bromide
217 to n-Bu3SnH and AIBN provided a single diastereomer in 47% yield. It has to be
mentioned that the combined yields of both ring closures were higher than those of
the radical cascade from the first generation and the second cyclization proceeded
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stereospecifically to give a single diastereomer. The synthesis of the complete ent-
morphinan skeleton was achieved by reduction of the oxazilidinone unit to give the
required amino methyl group, as well as a primary alcohol at C-lO. Double Swern
oxidation of the diol intermediate yielded the ketoaldehyde 220, which was treated
with trifluoromethane sulfonic acid to induce Friedel-Crafts closure of the C-lO - C-
11 bond. Alternatively, the C-lO - C-ll bond closure was affected by mesylation with
in situ chloride displacement to give compound 222, which upon treatment with
aluminium trichloride in benzene gave a mixture of morphinan 223 and the
corresponding free phenol.
Heck-cyclizations110
Since the results of the radical based approach showed that intermediates already
containing the C-9 - C-14 bond did not give the correct stereochemistry at C-14
center, the Hudlicky group investigated a Heck cyclization strategy. Similar to the
radical cyclization approaches, the B- and C- ring of the morphine skeleton were
envisioned to be derived from an isoquinoline synthon. Cyclohexadiene diol 5
derived from microbial dihydroxylation of ~-bromoethylbenzene(205) was chosen as
the starting material. It was readily converted to heterocycle 224 by reduction,
esterification of both hydroxyl groups, and displacement of the bromine with
oxazolidine-l,4-dione. Selective reduction of the more reactive amide carbonyl
followed by treatment of aluminium trichloride afforded the isoquinoline derivative
225 through an iminium ion cycloaddition. DBU mediated elimination of the alkyl
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chloride afforded diol 226, upon deprotection of the benzoate groups, as shown in
Scheme 18.
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Reagents and Conditions: a) Escherichia coli JM109 (pDTG601) (10glL); b) PAD, AcOH, MeOH
(80%); c) benzoic acid, DCC, DCM (83%); d) oxazolidine-1,4-dione, tetramethylguanidine, THF
(77%); e) NaBH4, MeOH, THF (quant.); t) AICh, DCM (57%, cis: trans = 3.7 : 1); g) DBU, DMSO
(25%); h) NaOMe, THF (85%); i) TsCl, py, DMAP (45%); j) benzoic acid, PPh3, DEAD, THF (84%);
k) NaOMe, MeOH, THF (65%).
Scheme 18. Hudlicky's Heck cyclization approach.
Bis-protected trans diol 227 was generated by tosylation of the distal alcohol
followed by Mitsunobu inversion of the allylic hydroxyl group. This protocol allowed
for the efficient synthesis of ~-epoxide 228 upon treatment of compound 227 under
basic conditions. The attachment of the A-ring fragment was achieved by regio and
stereoselective opening of epoxide 228 with the potassium salt of bromoguaicol 229
to give ether 230, which contains all the necessary carbons in the morphine skeleton
with the correct stereochemistry at C-5 and C-9. Intramolecular Heck cyclization
furnished pentacyclic carbamate 231 in good yield. DIBAL-H reduction followed by
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treatment with TBAF gave compound 232, which was then subjected to
hydrogenation.
o~ VI I ~Nro + KO OMe
o Br
230228 229
a,b ycBr J.. MeoD 0% " {'L;o _c~ H (' )=00:0 - ~..o~~o TBSO~ N
231Id,e
MeOI0l
O~··\OH
)5:~.. '. NMe'''H
o
234
g,h
Meo~
Jl? OH
o : r~"'" NMe.. '''HHO
233
Meo~
Jl? OH
......--__ 0: r~'~NMe
HOAJ
232
Reagents and Conditions: a) DME, 18-crown-6 (80%); b) TBSOTf, Htinig's base, DCM (74%);
c) Pd(PPh3)4, Proton Sponge™, toluene (74%); d) DIBAL-H, DCM (69%); e) TBAF, THF, H20 (77-
86%); t) H2, Pt02, AcOH (64%); g) (COCI)2, DMSO, NEt3, DCM; h) TFA (30% over two steps).
Scheme 19. Hudlicky's synthesis of 10-hydroxy-14-epi-hydrocodone (234).
Contrary to the expected sterochemical outcome, compound 233 was obtained with
the a-configuration at C-14 carbon. To complete the synthesis of the morphine
skeleton, the same protocol used for the final steps in the second generation radical
cyclization approach, was applied to compound 233. Double Swem oxidation
followed by treatment with trifluoromethanesulfonic acid finished the synthesis of
10-hydroxy-14-epi-hydrocodone 234 in 14 steps from diene diolS.
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2.2.4 Pharmacology of Morphine Alkaloids
Classification of Opioid Analgesics
Classification of opioids is usually made according to the receptors (Jl-, K-, and 8-
receptors) to which they bind, the consequences of the binding (agonist, partial
agonist, mixed agonist-antagonist, and antagonist) and their way of production
(opiates, semi-synthetic, and fully synthetic opioids).
Opioid Receptors
Opioids cause their biological response by binding to specific receptors in the human
body. Through careful structure-action analysis, the British medicinal chemist Arnold
Beckett postulated in the mid 1950s that morphine-like analgesics worked through
"analgesic receptors". III By the mid-1960s Goldstein and coworkers suggested that
the different actions of opioid agonists, antagonists, and mixed agonist-antagonists
could be best explained by their action with different opioid receptors. Their efforts to
prove this hypothesis failed because of the unavailability of radio-labelled ligands
with high enough specific activity.112 In 1973 three groups succeeded almost
simultaneously in proving the existence of different opioid binding sites in the central
nervous system. II3 The suspicion that morphine (1) was not a natural opioid receptor
ligand and only mimicked endogenous analgesic compounds was confirmed by
Kosterlitz and coworkers in 1975.114 They could show that extracts of mammalian
brain tissue contained factors that inhibited acetylcholine release from nerves
innervating the guinea pig ileum. The factors responsible for this action were
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identified as two peptidic enkephalins; met-enkephalin (Tys-Gly-Gly-Phe-Met) and
leu-enkephalin (Tys-Gly-Gly-Phe-Leu). Morphine (1) showed similar inhibition rates
in this study and the effect could be reversed by the addition of a known morphine
anatagonist such as naloxone (13). Soon after the discovery of the two enkephalins
other peptidic endogenous opioid receptor ligands could be identified. There are three
families of endogenous opioid peptides; enkephalins, dynorphins, and ~-endorphins.
These peptides are known as endorphins, a shortened form of endogenous
morphinoids. 115 In contrast, an opioid is any exogenous drug (natural or synthetic)
that binds to an opioid receptor and produces morphine-like effects. The analgesic
potency of the various opioids or endorphins correlates with the affinity of the
substance for the opioid receptor. There is general agreement on the existence of at
least three different types of opioid receptors: Jl, K, and 8-receptors. 116 All of the
opioid receptors were isolated, purified, sequenced and cloned in the mid 1990s.117
The comparison of the amino acid sequences of the three opioid receptors revealed
that they show high structural homology with each other. Pain relief effects are
mediated by all three receptor types but to a different degree. 118 Overall, it seems that
the Jl-receptor agonists display not only the best and strongest analgesic actions but
also the highest abuse liability. Jl-Receptor ligands, such as morphine, exert powerful
effects on the brain, the brain stem (where it slows respiration) and the spinal cord
(where it exerts a strong analgesic action). In contrast, the 8-receptors are thought to
modulate the activity of Jl-receptors and have a lower efficiency in mediating pain
relief. K-Receptors are known to mediate analgesic effects in peripheral tissues.66
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All opioid receptors belong to a superfamily of G protein-coupled receptors, all of
which posses seven membrane-spanning regions. The primary action of opioid
receptor activation is reduction or inhibition of neurotransmission, which occurs
largely through opioid-induced-presynaptic inhibition of neurotransmitter release.
Gutstein and coworkers demonstrated that opioids strongly activate important
intracellular cascades, which induce changes in cellular function to the level of
nuclear proteins. Changes were different for each receptor type and that may explain
the differences in receptor function. 119
Agonists
Substances which bind to a receptor and induce changes in the cell characteristic of
the natural ligand for the receptor are called agonists. All strong opioid analgesics,
morphine representing the prototype, have agonistic effects on the Jl-receptor. Despite
the desired analgesic effects, Jl-receptor agonism results in respiratory depression,
euphoria, sedation, nausea, addiction, and constipation. Examples of opioid agonists
are the naturally occurring opiates morphine (1) and codeine (2), as well as the semi-
synthetic opioids diacetylmorphine (10), oxycodone (11), and hydrocodone (12).
HOMI~
o :-:".~NMe
HO"'V
MeoMI~o :-:".~NMe
HO"'V
NMe
morphine
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codeine
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diacetylmorphine
10
oxycodone
11
hydrocodone
12
Figure 34. Opioid agonists.
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Oxycodone (11) was first synthesized by Freund and Speyer in 1916.10a Treatment of
thebaine (4) with hydrogen peroxide under acidic conditions led to the isolation of
oxycodeinone (235), which was further subjected to hydrogenation to give
oxycodone (11) in two steps, as shown in Scheme 20. The original protocol has been
exhaustively optimized by academic as well as industrial research groups and
numerous oxidative conditions have been reported. 120 Similar to morphine (1),
oxycodone (11) is used for the treatment of medium to severe pain. 121
MeoM~·Ih-
o :<:"'~NMe
MeoA)
thebaine
4
oxidation
235
reduction
Meo~.
,Ma :o~NMe
oxycodone
11
Scheme 20. Synthesis of oxycodone (11) from thebaine (4).
The first synthesis of hydrocodone (12) was reported by Mannich and Lowenheim in
1920.10b Nowadays hydrocodone is mainly manufactured by three different routes.
Reduction of codeine (2) to dihydrocodeine (236) followed by oxidation of the
alcohol functionality yields hydrocodone (12). 122 Alternatively codeine can be
isomerized to hydrocodone upon treatment with transition metal catalysts. 123 The
third approach utilizes thebaine (4) as starting material. .Diimide reduction, followed
by hydrolysis of the enol ether functionality of 8,14-dihydrothebaine (237) yields
hydrocodone (12),124 as shown in Scheme 21.
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Scheme 21. Synthesis of hydrocodone (12).
Partial Agonists and Mixed Agonist-Antagonist
In contrast to pure agonists, which have a strong activity at the Jl-receptor, partial
opioid agonists have a lower activity at the same receptor and therefore lower
analgesic activity. Buprenorphine, the prototype of a partial opioid agonist, has
limited stimulation of the Jl-receptor, binds very strongly to the receptor and has a
very long duration of action. As a partial agonist there is a ceiling to its analgesic
effectiveness as well as to its potential for inducing euphoria and respiratory
depression. Buprenorphine (238) preparations are mainly used for the treatment of
opioid dependency. 125
A mixed agonist-antagonist opioid produces an agonistic effect at one receptor and an
antagonistic effect at another. Preferable for clinical purposes are Jl-receptor
antagonists and K-receptor agonists, such as the semi-synthetic opioid nalbuphine
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(239), as drugs for opioid-dependent individuals. The problems associated with
mixed agonist-antagonist opioids are the incidences of adverse psychotomimetic side
effects, such as dysphoria, anxiety reactions, and hallucinations, limiting their
therapeutic use but increasing their attraction for illicit use.66
buprenorphine
238
nalbuphine
239
Figure 35. Partial agonists and mixed agonist-antagonist opioids.
Antagonists
Pure antagonists have high affinity for a receptor but after binding they elicit no
change in cellular functioning. In the case of opioids, the antagonist, such as the semi-
synthetic opioids naltrexone (13) and naloxone (243), competes with the Jl-agonist for
the receptor, precipitating withdrawal in an opioid-dependent person and reversing
any analgesia caused by the agonist.66
The syntheses of naltrexone (13) and naloxone (243) follow the same strategy since
only the N-substituents differ in both semi-synthetic opioid antagonists. Various
protocols have been reported and generally thebaine (4) or oripavine (108) are chosen
as starting materials. 126 They are further transformed to the corresponding 14-
hydroxylated analogues oxycodone (11) or oxymorphone (242). Demethylation of the
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tertiary amine followed by alkylation furnishes the N-alkyl 14-hydroxylated opioids.
In the case of the N-alkyl noroxycodone derivatives 240 and 241 an additional step,
the 3-0-demethylation is necessary for the synthesis of the opioid antagonists, as
shown in Scheme 22.
MeO MeO MeO
oxidation demethylation
NMe reduction alkylation
MeO a a
thebaine oxycodone R =cyclopropylmethyl 240
4 11
R =allyl 241
Idemethylation
HO
oxidation demethylation
NMe reduction alkylation
MeO a a
oripavine oxymorphone R =cyclopropylmethyl
108 242 naltrexone 13
R =allyl
naloxone 243
Scheme 22. Syntheses of naltrexone 13 and naloxone 243.
Naloxone (243) is the prototype opioid antagonist with only effects on opioid-
dependent people. Naloxone is neither an analgesic nor subject to abuse. Its duration
of action is very brief (in the range of 15 to 20 minutes), therefore it must be
administered at short intervals. Naloxone is predominantly used for the treatment of
acute opioid intoxication (overdoses) to reverse the opioid-induced respiratory
depression.
69
The actions of naltrexone (13) resemble those of naloxone, but it has a long duration
of action as well as being absorbed well orally. Naltrexone is used for the treatment
of heroin dependency as well as alcoholism.66
Goldberg and coworkers and, more recently, Cantrell and coworkers reported the
syntheses of methylnaltrexone from naltrexone (13) with appropriate methylating
reagents such as methyl iodide or methyl bromide. 127,128 Although quaternized
morphine alkaloids occur as two diastereomers (the quaternized nitrogen represents
an additional chiral center) both groups remained silent about the possible
diastereomeric salts and reported a single isomer. In 2006, the first two
"diastereoselective" syntheses of (R)- and (S)-methylnaltrexone were reported. 129 The
reaction of naltrexone with methylbromide yielded predominantly (R)-
methylnaltrexone (244),126a presumably the same compound as reported by Chantrell
and Goldberg and the addition of cyclopropylmethylbromide to oxymorphone gave
the (S)-isomer 245. 126b
-
Br~~+ OH
OH
(R)-methylnaltrexone
244
(S)-methylnaltrexone
245
Figure 36. (R)- and (S)-methylnaltrexone.
Not surprisingly, the (S)-isomer of methylnaltrexone exhibited different activities
than those reported previously in the literature. These findings are in accordance with
Bianchetti and coworkers, who studied the in vivo as well in vitro activity of three
pairs of diastereoisomers of quaternary opioid antagonists derived from levallorphan,
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nalorphine, and naloxone. 130 Only the diastereomers prepared by methylation of the
alkylated morphine derivative showed antagonistic activities.
As a quaternary amine, methylnaltrexone has restricted ability to cross the blood-
brain barrier131 and therefore reverses the undesired side effects of opioids that are
mediated by receptors located in the periphery, without compromising centrally
mediated effects of opioid analgesia or precipitating Iwithdrawal. 132
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3. Discussion
Presented here are our latest efforts in the exploration of the reactivity of the Burgess
reagent with epoxides as well as our most recent accomplishments in the synthesis of
morphine alkaloids and derivatives. Additional novel methodologies, especially
designed for the synthesis of opioids, will be discussed.
3.1 Burgess Reagent
3.1.1 Introduction
The Hudlicky group was able to propose a mechanism to account for the formation of
7-membered sulfamidates from the reaction of the Burgess reagent with either
epoxides or 1,2-diols21 and suggested that the latter compounds yield, in some cases,
7-membered sulfamidates and not regioisomeric pairs of 5-membered sulfamidates,
as has been erroneously reported. 18
In the case of 1,2-diols derived from various styrenes, the 7-membered sulfamidates
are minor products, but their relative amounts increase with deactivation of the
aromatic ring. 18 The discrepancies in the initial structural assignments are shown in
Figure 37. It was proposed that 7-membered sulfamidates may be derived from
epoxides and not from the starting diols. That the in situ formed epoxides may indeed
be the intermediates has been proven by performing the reaction on optically active
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styrene oxide as well as on the optically pure diol derived from styrene.21 In each
case, an inversion of configuration occurred at the benzylic center.
0 MeO
oA ~'s=:=o )=N,,?18 crc~ ~l~O)II + I~
100 101 102
minor major
Reference 18:
0 0~'s=:=0 \\ 0crc~ ~1'<::::~ 101 101
major OH major
assumed ~OH actual+ .. .- +
0 I~ MeO\\~O
)=N,,?0-8, 104~NC02Me ~~O1'<:::: ~ 0
~ I~
246 102
minor minor
Reference 21 :
0 0
\\"-0 \\"-0MeO CN-8"- d Meab2:: \ actual0 0 assumed.. )II
98 22 247
Figure 37. Sulfamidate formation from oxiranes and 1,2-diols. Assumed (reported)
and actual (corrected) products.
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3.1.2 Reactive Options of the Burgess Reagent with Epoxides
The reaction of the Burgess reagent with oxiranes derived from cyclic compounds
was of special interest because it could serve as a source of both cis- and trans-amino
alcohols (Figure 38).22 As sulfamidates possess similar reactivity to cyclic sulfates133
at the oxygenated center, we r~asoned that such a transformation would provide for
eventual access to homochiral amino alcohols in both diastereomeric series.
248
(+) and (-) 247
249
(+) and (-)
Figure 38. Proposed syntheses of cis- and trans-amino alcohols from cyclic sulfate.
In order to study the extent of asymmetric induction, we tested Jacobsen's134 salen
catalyst (251) as well as the scandium chelate of the C2-symmetric bipyridine135 252
reported to act as an activating Lewis acid in reactions with epoxides. The use of 0.1
equivalents of Jacobsen's catalyst (251) along with Burgess reagent (18) and
cyclohexene oxide in THF or diethyl ether at either room temperature or reflux led to
low yields (20%) of racemic sulfamidates, with no sign of asymmetric induction.
Similar results were obtained when cyclohexene oxide was reacted with the Burgess
reagent in the presence of 0.1 equivalents of Bolm's catalyst (252) in either THF or
DCM at room temperature. In order to determine the enantiomeric excess of the
products, cyclic sulfamidate 247 was treated with ammonium benzoate in DMF,
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followed by acid hydrolysis to yield protected amino alcohol 249. Basic hydrolysis of
the benzoate ester followed by EDC mediated esterification with (R)-(+)-Mosher's
acid gave a mixture of diastereomers (1:1) as assessed by 19p_NMR and GC/MS
analysis.
22
+ a
+ Et3NS02NC02Me ..
18 251 or 252
247
b,C •
249
251
OH
252 250
Reagents and Conditions: a) THF, 48 hrs; b) PhC02-NH4+, DMF, 45 DC, 12 hrs; c) THF, H20, conc.
H2S04, rt, 6 hrs; d) 1M NaOH in MeOH, 2 hrs; e) (R)-(+)- Mosher's acid, EDC, DMAP, DCM, 0 DC to
rt, 18 hrs.
Scheme 23. C2-symmetric catalysts 251 and 252.
One possible explanation for the complete lack of asymmetric induction in this
reaction may be that the Burgess reagent itself acts as a Lewis acid, competing with
and displacing the actual catalyst from the activated epoxide. Since 2.3 equivalents of
the reagent are used and the concentration of the catalyst is only 10 mole percent, it is
easy to see how the probability of developing a chiral substrate-catalyst complex is
reduced, leading to the racemic product mixture which we observe.
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At this stage of the project we have determined that the sulfamidates 247 are cis, not
trans fused as originally reported in Hudlicky's 2003 publication.21 The proof of the
cis configuration of the cyclic sulfamidates derived from the reaction of the Burgess
reagent with epoxides was easily achieved by preparing both authentic samples of cis
and trans fused cyclic sulfamidates. The synthesis was straightforward and is shown
in Scheme 24. cis-Sulfamidate 247* was prepared from cis-aminoalcohol 253,
generated from the commercially available trans-isomer using Jacobsen's protocol. 136
Protection of the amine with methylchloroformate followed by reaction with
thionylchloride and oxidation with ruthenium (III) chloride and sodium periodate,
furnished cis-sulfamidate 247*. The trans-isomer 98, was generated from
commercially available 255 in a similar fashion. It became clear that 247 (Scheme
24) was identical to 247* and not 98. This argument eliminates the possibility of
direct intramolecular sulfonation, which we have studied by dilution experiments and
by varying substrate to reagent ratios. In all cases, it was the cis-isomer of
sulfamidate that was formed from epoxides and not the expected trans-isomer. Thus
the mechanism operating on epoxides is similar in concept but not the same as that
operating on diols. trans-Cyclohexane diol 259 yielded exclusively cis-sulfamidate
247, whereas cis-cyclohexane diol did not give the corresponding cyclic sulfamidate
since the bis-sulfonated intermediate cannot undergo a SN2 displacement. Two other
observations are worth noting: First, the trans-sulfamidate yielded 258 upon
treatment with ammonium benzoate and not the expected "inverted" cis-disposed
benzoate. Second, methylamine in acetonitrile also provided the free sulfamidate 258
under very mild conditions.
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d \\--0 CXOH 25818 Meab 18----..... ~ ""OH
22 247 259
Reagents and Conditions: a) methyIchioroformate, NaHC03, CHCI3/H20; b) SOCI2, CH3CN, -40°C;
c) RuCh·H20, NaI04, CH3CN/H20; d) Ac20; e) SOCI2; f) 10% HCI; g) PhC02-NH4+, DMF, 45 °c, 12
hrs, then THF, H20, conc. H2S04, rt.
Scheme 24. Preparation of standards 98 and 247*.
Possible mechanistic options for the reaction of the Burgess reagent with epoxides are
shown in Figure 39. Two different pathways of the reaction of oxiranes with the
Burgess reagent are possible.
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18
98
22
18
261
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247
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Figure 39. Possible mechanistic options for the formation of cis-sulfamidates from
epoxides.
The activation of the epoxide to give compound 261 is likely and supported by
preliminary calculations.137 Another option is the direct nucleophilic attack of the
Burgess reagent yielding compound 260, although this process has a higher activation
energy than the formation of 261. In both cases, an intramolecular attack is rather
unlikely; instead a second equivalent of the Burgess reagent reacts to give
intermediate 262. Rather than ejecting triethylamine by an intramolecular sulfonation,
alkoxide 260 reacts with the second equivalent of the reagent to produce 262, formed
also from the opening of activated epoxide 261. Displacement of the Burgess reagent
then occurs from the site of initial oxirane opening. A similar mechanism has also
been proposed for the reaction of 18 with diols and Hudlicky and coworkers have
shown that epoxides may be intermediates in these reactions.21 A study of
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concentration and stoichiometry dependence indicated that indeed at least two
equivalents of 18 are essential; with one equivalent of the reagent the yields were
halved.
3.1.3 Chiral Version of the Burgess Reagent and its Reactions with Epoxides138
After finding that the two C2-symmetric catalysts proved to be completely ineffective
in the asymmetric synthesis of five membered sulfamidates from epoxides, we turned
to the chiral-auxiliary-based approach, recognizing that in this fashion both
enantiomers of the products could be obtained and converted to valuable amino
alcohol derivatives (both cis and trans).22
Several chiral auxiliary versions of the Burgess reagent have been prepared, such as
the menthol analogue 21, as well as the camphor-derived carbamate 263 and the two
cyclic forms 265 and 266 prepared from diene diol 264 (Figure 40).139 However, the
reaction of the Burgess variants derived from diene diol 264 with oxiranes proved
erratic and we therefore focused on the investigations of reactions of the menthyl as
well as camphor derivatives of the Burgess reagent. Both versions of the Burgess
reagent 21 and 263 were reacted with cyclohexene oxide producing a 1: 1 mixture of
diastereomers of cis-fused sulfamidates (Scheme 25). The separation of diastereomers
at this stage, derived from either the menthol or camphor version of the Burgess
reagent was arduous, and the mixtures were converted to their benzoate derivatives,
because the sulfamidates resemble cyclic sulfates in their reactivity. 133
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21
265
~O.H.UOH
264 266
Figure 40. Chiral versions of the Burgess reagent.
No suitable conditions could be found for the separation of the benzoates bearing the
camphor auxiliary group, however separation of benzoates 267a and 267b bearing the
menthol auxiliary group was achieved by flash column chromatography. Conversion
of 267a and 267b to the known cyclic carbamates 269a and 269b provided evidence
of excellent enantiomeric excess in both amino alcohol products (optical rotations of
269a and 269b were higher than reported literature values). 140 Accurate
determinations of enantiomeric purity were made by 19p NMR evaluation of Mosher
amides 270a and 270b and comparison with Mosher amide data obtained for the
racemate of 269. A moderate yield of the allylic amine derivative 268 was obtained
from the reaction of sulfamidates 23a and 23b with ammonium benzoate. Simply
heating a mixture of 23a and 23b in DMP at 45°C for 18 hours provided 268 in
moderate yield (55%) along with recovered starting material.
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~ 268 (470/0)
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~HC02M*()OBZ
~ d, e
270a
f
-4lIIIf--
(+) 269a
98% ee
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930/0ee
Reagents and Conditions: a) THF reflux, 1.5 hrs; b) PhC02-NH4+, DMF, 45°C, 12 hrs; c) THF, H20,
conca H2S04, rt, 6 hrs; d) 1M NaOH in MeOH, 2 hrs; e) NaH, THF reflux, 18 hrs, f) n-BuLi, 0 °C, 30
min, (8)-(+)- Mosher's acid chloride, -78°C to rt.
Scheme 25. Reaction of the menthol based Burgess-type reagent with cyclohexene
oxide.
A more detailed study of this reaction revealed that treatment of 23a and 23b under
strongly acidic conditions (6N Hel : dioxane; 1: 1) led to the isolation of racemic 268
in nearly quantitative yield. This is another useful result as it allows for the direct
conversion of epoxides to derivatives of allylic amines. In cases where the
diastereomers are more easily separated, both enantiomers of allylic amine
carbamates should therefore become available. The results from the reactions of other
oxiranes with menthyl Burgess reagent 21 are summarized in Table 1.
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Table 1. Reactions of various oxiranes with the menthyl chiral-auxiliary version of
the Burgess reagent.
Oxirane Sulfamidatesa Benzoates ee(%)6 or de(%)C
0 0
\\-0 \\..-0
NHC02M* ~HC02M*M'ab M*O CN-S-d 2 ~ \ 6··"OBZ0"° (yoBZ,'" (+) 98 and (-) 93b
22 23a 23b 267a 267b
30% 49%
0 0
\\"-0 \\ 0M'°!fb M*O CN-S~ NHC02M* ~HC02M*d 2::: \ O···\OBZ0·,0 dOBZ 98 and 93c"
271 272a 272b 273a 273b
37% 52%
0 0
\\-0 \\..-0 NHC02M* O:'zMob M*O CN-S-d 2::: \ (~r.oBZ0'°,.' 93 and 92c
274 275a 275b 276a 276b35% 75%
C\\~O C\\~O
M*O CN-S:;.-" M*02CN- S:;.-" NHC02M* NHC02M*
<Z 2 ~'o ~b ~\\OBZ ~OBZ
C4Hg C4Hg C4Hg C4Hg C4Hg
277 278a d 278b 279ad 279bd22% 36%
0 0M*OCN)~O M*OCN~~O NHC02M* ~HC02M*
d &'0 2 ~ \ 6··,\OBZ0'° crOBZ..,'I (+) 94 and (-) 84e
280 281a 281b 282a 282b
36% 51%
a) yields are isolated and unoptimized; b) enantiomeric excess determined by Mosher's amide
formation of cyclic carbamates, derived from the corresponding benzoates by hydrolysis and
cyclization; c) diastereomeric excess determined by GCIMS of benzoates after separation by flash
column chromatography; d) not separable by flash column chromatography; e) diastereomeric excess
determined by GCIMS of separated benzoates after hydrogenation.
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The moderate isolated yields of cis-sulfamidates reflect the difficulty of isolation and
separation of the diastereomers, not an uncommon problem in auxiliary group-
mediated resolutions. In all cases, the cis-sulfamidates were converted to trans-
benzoates via inversion with ammonium benzoate at the oxygenated carbon and the
enantiomeric or diastereomeric excess were determined after separation by column
chromatography. Benzoates 282a and 282b were hydrogenated (Pd/C, MeOH, 3 atm
of H2) to 267a and 267b, respectively, and their identity as well as their optical purity
evaluated by direct comparison with benzoates 267a and 267b, establishing also that
no allylic mode of the oxirane opening had occurred. The products 279a and 279b
from the reactions of n-butyl oxirane proved inseparable from each other.
100 283 284 285
1 _______
c
Reagents and Conditions: a) Burgess reagent (21), THF reflux, 1.5 hrs; b) PhC02- NH4+, DMF, 45
DC, 12 hrs; c) 50% KOH.
Scheme 26. Formation of sulfonyl urea derivative 285.
As expected, the reaction of styrene oxide and Burgess-type reagent 21 yielded
predominately the seven-membered sulfamidate 283, which was treated with
ammonium benzoate to yield a mixture of two diastereomers identified by 2D-NMR
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tentatively as 285, produced by protonation of sulfimidate 283 and displacement with
ammonia. Attempts to hydrolyze the sulfonyl group under basic conditions resulted in
the formation of racemic styrene oxide 100, in agreement with previous results.21
~R
: NHC02M*(J b.
a r 282b R = Bz
~ 286 R=H
(+)-8alanol
287
..
.......1---
c ..
288
-P~ OBn~.H .H~:- Na 0 .'d 291
OBn
9-f.° .~ ~
- N
- "OH
= HBOH JAB = 3.5 Hz
289 >95:5
Reagents and Conditions: a) 1 N NaOH, MeOH; b) NaH, THF, reflux; c) p-benzyloxy benzoyl
chloride, NEt3' DMAP, DCM, 0 °c - rt; d) OS04, NMO, H20, DCM, rt; e) NaI04, acetone, H20, rt;
then BnNH2, MeOH, NaCNBH3, AcOH, 3A mol. sieves, -78°C; f) 0.3 N NaOH, MeOH, -20°C.
Scheme 27. Formal synthesis of (+)-balanol.
Encouraged by the ease with which the trans-amino alcohol derivatives were
obtained, two other members of the group, Bradford Sullivan and Jacqueline Gilmet,
under the guidance of Professor Hudlicky, applied this methodology to the formal
synthesis of both (-)- and (+)-balanol. Benzoates 282a and 282b possess the absolute
stereochemistry of (-)- and (+)-balanol, respectively and only oxidative cleavage of
the olefin followed by reductive amination is required to produce the balanol core.
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Diastereomer 282b was converted to the cyclic carbamate 287 by treatment with IN
NaOH followed by sodium hydride in THF, as shown in Scheme 27.
Osmium tetraoxide-mediated oxidation generated the cis diol 289 in a >95:5 ratio of
diastereomers. Oxidative cleavage with sodium periodate was successful in
furnishing the dialdehyde species (not shown) which was immediately transformed
into hexahydroazepine derivative 290 under reductive amination conditions in the
presence of benzylamine. Mild basic hydrolysis provided free alcohol 291, whose
preparation equates a formal synthesis of (+)-balanol. The same strategy was applied
to the formal synthesis of (-)-balanol, which was was recently published. 141
3.1.4 Reactivity of the Burgess Reagent with Thiols142
Our interest in the exploration of the reactivity of the Burgess reagent continued and
the next step was to study the reactivity of the Burgess reagent (18) with thiols, as a
means of forming alkenes from such compounds, suggested to us by a visiting
speaker143 We were, however, surprised to find no evidence of olefin or
thiocarbamate formation when we reacted decane-I-thiol (292) with one equivalent
of the Burgess reagent. Instead, a nearly quantitative yield of disulfide 293 was
isolated. Examination of other thiols (
Table 2) revealed the reaction to be a general and high yielding method for primary
thiols and thiophenol derivatives. In contrast, the reaction of the Burgess reagent with
branched aliphatic thiols (entries 5 and 8) afforded a mixture of both symmetrical
disulfides144 and trisulfides145 in moderate yields.
85
Table 2. Burgess reagent-promoted disulfide formation.
RSH +
o
+ II -
Et3N-n-N-C02Me
o
benzene, r.t.
)81
2 hrs
RS-SR
Entry
2
3
4
5
6
7
Thiol
CH3(CH2)gSH
292
(YSH
CI~
294
V SH
296
~SH
~
300
0rSHV
303
0rSH~Br
305
Product
301 (3 : 1) 302
~VS'S~
304 r7'yBr
~S'S~
Br 306
Yield (%)
95
93
92
90
39
96
95
8 (-S-S-< 85
9
10
307
(YSH
Meo~
310
308 (3 : 1) 309
~oMe
(Ys'sN
Meo~
311
~~S/S~
V 313
90
93
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The reaction of decane-I-thiol (292) was optimized, as shown in Table 3 and we
attempted to determine the mechanism of the reaction and to identify the reduced
component in the sequence.
Although the oxidation proceeded cleanly at 50°C in one hour, we found that higher
yields were obtained at room temperature in the same time. The reaction was further
accelerated by first forming the thiolate anion (entries 5-8, Table 3). The order of
addition of either the Burgess reagent or the thiol was shown to be inconsequential, as
long as there was a slight excess of the Burgess reagent present in the reaction
mixture. The use of polar solvents, such as DMF (entry 4, Table 3), considerably
hindered the rate of oxidation.
A speculative mechanism for this transformation is shown in Figure 41. Initially, the
thiol reacts with the Burgess reagent either in an acid-base reaction to form thiolate
314 or via substitution to form inner salt 316. Intermediates 316 or 317, required for
intramolecular E2 elimination, are likely to be protonated by mercaptans to generate
thiosulfonyl carbamate 318. The difference in acidity between alcohols (pKa - 16),
aliphatic thiols (pKa - 11) and aromatic thiols (pKa -6) would not, at a first glance,
lead to an assumption that the sulfamidate anion 317 would be completely
protonated. This is not the case as is demonstrated by the high yields of disulfides
obtained. Although it is possible for the E2 pathway to proceed even with 1% relative
concentration of the active intermediate 317, this pathway appears unfavorable.
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Table 3. Optimization study for decane-I-thio!.
+
o
+ II -
Et3N-n-N-co2Me
o
Entry Thiol Burgess Conditions Addition Resultb(equiv) (equiv) Ordera
1.05 Benzene, rt then Standard 72% isolated yield50 0e (1 h)
2 1.05 Benzene, rt Standard 95% isolated yield(1 h)
3 2 Benzene, rt Standard 67% conversion(60 hrs)
4 1.05 DMF,rt Standard 50% conversion(24 hrs)
5 1.05 NaH, benzene, rt Standard >95% conversion(30 min)
6 1.05 NaH, benzene, rt Inverse >95% conversion(30 min)
7 1.05 NaH, benzene, Standard >95% conversion50 0e (30 min)
8 1.05 NaH, benzene, Inverse >95% conversion50 0e (30 min)
a) Standard addition: thiol added dropwise to Burgess reagent; Inverse addition: Burgess reagent added
dropwise to thiol; b) Ge/MS was used to measure % conversion.
Even when a large excess of NaH (10 equiv) was used in the reaction media, ensuring
a higher relative concentration of 317, no alkenes were detected when aliquots were
monitored by Ge/Ms. Instead, it is likely that thiosulfonyl carbamate 318 is attacked
by either the thiol or its conjugate base to form the disulfide and intermediate 320 or
its tautomer 321. We attempted to isolate compound 321 but were only able to
characterize the triethylammonium salt 322 (in crystalline form), probably resulting
from the immediate air oxidation of the labile intermediate 320. NMR experiments in
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d6-benzene showed the formation of a new species, which did not correspond to
either the Burgess reagent or compound 322. As the compound disappeared upon
exposure to air, the formation of triethylammonium salt 322 was observed.
RSH +
+ ~ -JO
Et3N-S-N\g OMe
RS
314
+
11
+ RH~OEt3N-S-NII
I 0 OMe
315
18
+
+ ~ _ 0RS-S-N~
H 8 OMe
316 ~
-~ HJO
S-N\ +~ OMe
319
RSH 1!
[
~ H 0H-S-N~g OMe
320
[0], El3Nj
+ - R HJO
Et3NH O-S-N\g OMe
322
RSSR ......11II(1---
+ RS
314
[0]
~
1!
~ ~HJO
RS + RS----yS-N\g OMe
314 318
~HJ?
/S-N\
HO OMe
321
323
~ -_J?
RS-S-N\g OMe
317
/
Figure 41. Suggested mechanistic options for the oxidation of thiols to disulfides
with the Burgess reagent.
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Various methods for the synthesis of symmetrical and unsymmetrical trisulfides have
been developed by Harpp.145a-d Typical procedures include the alkoxide
decomposition of sulfenylthiocarbonates;145a the reaction of thiols with sulfur
dichloride to yield an intermediate thiosulfenyl chloride which reacts further with
thiol to afford trisulfides; 145b the reaction of disulfides with triphenylmethanesulfenyl -
chlorides with disulfides· 145c, and the reaction of thiols with
triphenylmethanethiosulfenyl chloride to yield unsymmetrical trisulfides. 145d By
analogy with the mechanism proposed by Harpp,145a-d it is feasible that the sulfur
atom of the newly formed disulfide is free to attack thiosulfonyl carbamate 318 to
form a sulfonium salt. Loss of a stable carbocation by solvolysis (as in the case of 2-
propanethiol and 2-methyl-2-propanethiol) would then lead to a symmetrical
trisulfide, see Figure 42.
solvolysis
.. R-S-S-S-R
Figure 42. Suggested mechanistic options for the oxidation of disulfides to trisulfides
with the Burgess reagent.
That thiosulfamidates react rapidly with mercaptans is surprising, although a similar
reaction has been observed for thiosulfonates. In 1988, Fuchs146 reported the
formation of disulfides from thiols and thiosulfonates. The reaction only took place
when thiosulfonate formation was sufficiently slow, compared to the reaction of
excess mercaptan with the thiolsulfonate. When the more reactive sulfonyl bromides
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were used, the rate of sulfonylation was sufficiently fast and subsequent substitution
leading to disulfides was not observed.
The electrophilic character of the Burgess reagent resembles that of a sulfuryl
chloride. As it was difficult to compare the reactivity of sulfonyl chlorides, such as
324 with sulfamidyl chlorides 325, and sulfuryl chloride 326, we conducted a
comparative study with decanethiol.
Table 4. Reactivity comparison of various substituted sulfuryl chlorides and the
Burgess Reagent in benzene at room temperature.
2
3
4
o
II
CI-S-Ar
II
o
324
Reagent
Burgess Reagent
18
324
325
326
o
II
CI-S-NH-C02MeII
o
325
Time (hrs)
24
24
o
II
CI-S-CI
II
o
326
Conversionb
100%
0%
10%
40%
a) decane-l-thio! was used as substrate; b) GC/MS was used to measure % conversion.
Whereas the yield of disulfide is quantitative when Burgess reagent is used, it is
formed in only 40% yield with sulfuryl chloride 326 after one hour (Table 4).
Leino144f reported the formation of symmetrical disulfides with sulfuryl chloride in
methylene chloride and slower reactivity when the reaction was conducted in
benzene. Although sulfonyl chlorides such as 324146 have been reported to oxidize
thiols to disulfides, these reactions require the addition of a stoichiometric amount of
a base such as triethylamine. The Burgess reagent requires no external base in its
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reactions with thiols to produce disulfides. The ease of preparation and the high yield
of disulfides by this method compare favorably with other procedures in the
literature. 144
3.2 Morphine Alkaloids
3.2.1 Introduction
The supply of morphine and morphine-derived products depends on the isolation of
major constituents from the opium poppy. Quite surprisingly, usable amounts of the
morphine alkaloids can only be harvested fro,m plants grown in a few specific
geographic areas. Many of the countries situated in these geographic areas suffer
from serious political turmoil, making the steady supply of morphine alkaloids
uncertain. One o~ the long-standing goals of the Hudlicky group is the development
of an efficient synthesis of morphine alkaloids which would rival the cost of its
isolation from natural sources. Professor Hudlicky's strategy towards the synthesis of
morphine alkaloids is unique since starting materials are obtained by an enzyme-
mediated reaction. Cyclohexadiene diols derived from microbial dihydroxylation
have been successfully employed in the synthesis of the morphine skeleton by the
Hudlicky group, as discussed in the historical chapter of the current thesis.
The presented research discusses an enantiodivergent synthesis of codeine that
combines strategies from previously reported syntheses by the Hudlicky, Parker and
Trost groups. The unification of these three distinct approaches led to a total synthesis
of (+)-codeine in 14 steps from commercially available ~-bromoethylbenzene,
featuring a Mitsunobu inversion and two intramolecular Heck cyclizations. A formal
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synthesis of (-)-codeine will also be presented, which intercepts an intermediate in the
(+)-codeine approach. The key step in the synthesis of the natural isomer of codeine
represents a regioselective nucleophilic opening of a homochiral epoxide (Figure 43).
(-)-2
NMe ~.-- HO", 2f
HO"'O
5 (+)-2
Figure 43. Enantiodivergent syntheses of codeine (2).
Professor Hudlicky's research interest in morphine alkaloids is not limited to their
total synthesis. The highly addictive properties, as well as the undesired side effects
of morphine (1) prompted researchers to investigate the medicinal properties of
structural derivatives. Efforts aimed at increasing the analgesic potency, while
decreasing addiction liability, have had mixed outcomes. The first reported semi-
synthetic opioid diacetylmorphine, better known as heroin, was first marketed as a
non-addictive morphine substitute.. Subsequent research led to the discovery of more
useful semi-synthetic opioids, such as the Jl-receptor agonists hydrocodone and
oxycodone, Jl-receptor antagonists naltrexone and naloxone, and the mixed agonist-
antagonist opioid nalbuphine. In cooperation with Noramco Inc., a subsidiary of
Johnson & Johnson, the Hudlicky group initiated a program directed toward the
development of novel methodologies suitable for the conversion of opiates into
higher value products.
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MeoD
o~o~N:'[Pdj, w H66H./
12 ~ MeoD ~
O~\~NMe
MeoA)
Me0)CA
1//
o :O~NMe
~o
14
Meo~ ./O~ /[Irj
Meo~NMe
237
4
""'- MeO~[Rul~ O~
-:".~NMe
MeO"'V
327
Figure 44. Functionalization of thebaine (4).
Progress towards the development of a regioselective hydrogenation of the C-8/C-14
olefin of thebaine (4) will be presented. A one-pot procedure for the conversion of
thebaine (4) to neopinone ketal (14) was achieved and subsequent research has led to
a one-step conversion of thebaine (4) to hydrocodone (12).
In addition to our investigations of the chemistry of thebaine, a novel
demethylationiacylation procedure of hydrocodone (12) was developed. Alongside
this, two novel demethylation procedures of hydrocodone (12) will be discussed.
o
R = alkyl, O-alkyl
15
Pd(II)
12
Pd(II) or Cu(II)
NMe
16
NH
Figure 45. Functionalization of hydrocodone (12).
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3.2.2 Enantiodivergent Synthesis of Codeine147
The failure to deliver chiral synthons in both enantiomeric series is said to be the
common disadvantage in chemoenzymatic synthesis. The synthesis presented here
will highlight the versatility of enzymatically derived dienediols in natural product
synthesis, as well as the ease of preparation of both enantiomers of codeine (2) from a
single metabolite derived from microbial dihyroxylation.
MeO
HO
(+)-2
hydroamination
====>
MeO
TSSO'"
Meo)L;UsI r
Heck .0 .0
..\,-1" ====> 0 Sr
NMePg cyclizations ~NMepg
TBSO"'U
328 329
II MitsunobuUcoupling
Sr Sr
HO,,·cS
Mepg
6 microbial¢:::::= HO'l~dihydroxylation HO'" ~ TSSO'\'
205 5 330
Figure 46. Retrosynthetic analysis of (+)-codeine (2) approach.
The strategy for the total synthesis of (+)-codeine is based on the formation of
homochiral monoprotected diol 330, whose source would be the microbial
dihydroxylation of ~-bromoethylbenzeneand subsequent installation of the N-methyl
amine unit via SN2 reaction. Mitsunobu coupling with bromoisovanillin should
provide 329, the precursor for the first Heck cyclization upon transformation of the
aldehyde to a vinyl bromide. This is anticipated to furnish the phenanthrene core of
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the morphine alkaloids via a second Heck coupling. Adjustment of the
stereochemistry of the hydroxyl group at C-6 by an oxidation-reduction sequence
should give Trost's intermediate for the final visible light-promoted hydroamination
reaction.
The combination of Trost's Heck cyclization strategy and Parker's Mitsunobu
coupling procedure will allow for an efficient and short synthesis of (+)-codeine. In
contrast to Parker's synthesis, our precursor for the Mitsunobu reaction will be
enantiomerically pure, since it will be derived from microbial dihydroxylation. In
addition, our C-ring fragment will already have the N-methyl amine unit and the
hydroxyl functionality in place, making it more efficient than Trost's, who had to
generate both functional groups in additional reactions later in the synthesis.
x ·
205 5 331 332
Figure 47. Initial approach to (+)-codeine.
The proposed approach to (+)-codeine was initially started by fellow group members
Dr. Kevin Finn and Dr. Alvaro Takeo Omori. They successfully established an
efficient route to advanced intermediates of structure 331, however deprotection of
the acetyl group proved to be unsuccessful, as shown in Figure 47, and the approach
was aborted a few steps before the end. 148
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The obvious solution to this problem was the utilization of an alternative protecting
group. In the second generation approach to {+)-codeine,. Dr. Alvaro Takeo Omori,
Dr. Robert Carroll and I, under the guidance of Professor Hudlicky, chose to protect
the N-methyl amine functionality as its Boc carbamate (Scheme 28).
Br Br Br Br
6 a 6cOH b e teOAC------.. ------.. teoH ------..~ OH OH OAe
205 5 333 334
Id
NMeBoe NMeBoe NHMe
e teoHHO/,:6 = teoH ...--
HO" OH OH
336 335
Reagents and Conditions: a) E. coli JM 109 (pDTG601A) (10 gIL); b) potassium azodicarboxylate,
AcOH (60%); c) AC20, NEt3' DMAP, 0 °C (52%); d) MeNH2 (g), K2C03, THF, sealed tube; e)
(BOC)20, NEt3' DMAP, 0 °C (56% over two steps).
Scheme 28. Preparation of diol 336.
The synthesis started with the microbial dihydroxylation of ~-bromoethylbenzene
using E. coli strain JMI09 {pDTG601A),lo5 which gave the homochiral diol5 in 10 g
per litre cell broth. Potassium azodicarboxylate mediated reduction of the distal
double bond furnished intermediate 333 in 60% yield, which was treated with acetic
anhydride and triethylamine to give bisacetate 334.
Treatment of compound 334 with methylamine, in the presence of potassium
carbonate, yielded the secondary amine with concomitant hydrolysis of the acetate
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groups. The crude reaction mixture was treated with Boc anhydride to give the Boc
protected amine 336 in 56% yield after flash column chromatography.
Me~
HOyCHO
Br
Meo~
b ~CHO
----. 0 Br~NMeBoc
TBSO"'U
336
340
e
6
MeO
174
Br
~
339
337
d
~
338
Reagents and Conditions: a) TBSCI, imidazole, DCM, -78°C to rt (88%); b) DIAD, n-Bu3P,
bromoisovanillin, THF, 0 °C (55%); c) Pd(OAc)2, Ag2C03, dppf, toluene, 110°C (82%); d)
PPh3CHBr2, tBuOK, THF, -30°C (49%); e) Pd(OAc)2, Ag2C03, dppp, toluene, 110°C (44%).
Scheme 29. Mitsunobu coupling and Heck cyclizations towards the synthesis of (+)-
codeine (2).
Protection of the distal hydroxyl group of compound 336 with TBSCI gave the
precursor for the Mitsunobu reaction. Bromoisovanillin (174) was reacted with
compound 6 in the presence of tri-n-butyl phosphine and DIAD to give aryl ether 337
in 55% yield. Palladium (II)-catalyzed Heck cyclization furnished aldehyde 338 in
good yield, which was converted to vinyl bromide 339 by a Wittig type reaction
(approximately 1 : 1 ratio of cis to trans isomer). The second Heck cyclization gave
the complete phenanthrene core in moderate yield. Adjustment of the stereochemistry
of the C-6 hydroxyl group was accomplished by deprotection of the alcohol
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functionality with TBAF followed by an oxidation-reduction sequence. Removal of
the N-tert-butyl carbamate was easily achieved using TFA in methylene chloride.
This sequence allowed for the interception of Trost's intermediate 184 in the opposite
enantiomeric configuration. Application of Trost's reported experimental procedure
(LDA deprotonation of the amine, followed by light-mediated hydroamination of the
styrene bond) to produce (+)-codeine (2) failed in our hands despite numerous
attempts and in spite of receiving detailed protocols and advice from Dr. Tang, who
conducted the synthesis while in Trost's group.
Mea
--L
a
342
1c
Mea
d
.---
HO
343
341
(+)-184
e
.---
340
(+)-codeine (2)
Reagents and Conditions: a) TBAF, THF, rt (88%); b) IBX, DMF, rt (92%); c) NaBH4, CeCh·7H20,
MeOH, 0 °C (89%); d) TFA-DCM (1 : 4), 0 °C to rt (88%); e) Hg(OAc)2, Et3N, THF, 48 h then LAH,
2h, rt (18%).
Scheme 30. Final steps in the synthesis of (+)-codeine (2).
Further experimental details provided by Dr. Tang, a former coworker of Professor
Trost, still did not lead to any success in the formation of the desired product. Unable
to repeat Trost's procedure, we employed an oxymercuration reaction of the styrene
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double bond to yield an oxymercurium ion, which was trapped intramolecularly by
the ethyl amino side chain. This procedure gave (+)-codeine as well as a mixture of
two diastereomeric C-10 acetates. The acetates were easily reduced by LAH at room
temperature and this procedure allowed for the completion of the synthesis of (+)-
codeine in 14 steps from ~-bromoethylbenzene.
Total synthesis of (..)..codeine (2)
Having accomplished the synthesis of (+)-codeine, we were set to employ the same
key intermediate 6 in the total synthesis of (-)-codeine. The strategy is outlined in
Figure 48.
MeO~ ~r~o Br '~NMeBoc
TBSO"'U
entseries
8
j Heckcyclizations
(+)-codeine (2)
single
Mitsunobu 6NMeBOC doubleHO" ~ -M-its-u-nO-bu.....TBSO":
6
MeoHJr
Q,"':~NMeBOC
TBSO"U
natural series
344
11 Cyc~:~ons
Meo~
,MQC?~'-'. NMe
HO'\'· ~
(-)-codeine (2)
Figure 48. Initial strategy towards the enantiodivergent syntheses of codeine (2).
As demonstrated before, a single Mitsunobu inversion of the allylic alcohol led to the
enantioselective synthesis of the ent-isomer of codeine; a double Mitsunobu inversion
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strategy therefore should lead to precursor 344, which would allow for the synthesis
of (-)-codeine. The synthesis of the naturally occurring isomer was envisioned to be
more efficient than the synthesis of the (+)-isomer, since the stereochemistry of the
C-6 hydroxyl group would not have to be adjusted later in the synthesis.
6
a
-------
NMeBoc
6:0BZOTBS
345
b
-------
346
c
--..
Me0'l(1
~CHOqc)'Br
--.: ~ NMeBoc
TBSO'\
347
less than 50/0
Reagents and Conditions: a) DIAD, nBu3P, benzoic acid, THF, 0 °C (83 %); b) NaOMe, MeOH, O°C
(55%); c) bromoisovanillin, various conditions.
Scheme 31. Double Mitsunobu sequence.
The allylic alcohol of compound 6 was inverted using benzoic acid under standard
Mitsunobu conditions. Cleavage of the ester functionality gave precursor 346 for the
second Mitsunobu coupling, which provided the desired product in less than 5%
yield.
c
--..
lMeBoc = ,,~MeBOC
00 0),·0
336 348 349 (+)-7
Reagents and Conditions: a) DIAD, Ph3P, p-nitrobenzoic acid, toluene, 0 °C to rt (71 %); b) NaOMe,
MeOH, 0 °C (76%); c) DIAD, nBu3P, bromoisovanillin, THF, 0 °C to rt (45%).
Scheme 32. Preparation of epoxide (+)-7.
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This result was not entirely unexpected since the steric bulk of the TBS protecting
group prevents the nucleophile from attacking the allylic carbon. As an alternative
approach we envisioned a double Mitsunobu inversion, without the use of any
protecting groups, as shown in Scheme 32.
Regi~selective inversion of the allylic alcohol was achieved following a procedure by
Banwell and coworkers149 which gave the monoprotected diol 348 in good yield
without further optimization. Saponification of the benzoate ester using sodium
methoxide in methanol yielded trans-diol 349, which was further subjected to
Mitsunobu conditions, applying bromoisovanillin as a nucleophile. Unfortunately, no
aryl ether was detected in the reaction mixture, but epoxide (+)-7 was isolated in 45%
yield. The formation of epoxides from 1,2-trans-diols has been reported
previously. 150
Meo~
,MQc?~..~. NMe
HO'" .b
Me0'0 Me0J('1
~CHO ~CHO
a Br ====> a Br
)5"NMeBoc 'DNMeBoc
TBSO HO
(-)-2 (-)-337 350
II epox~deUopening
205
microbial
<===
dihydroxylation
HO',: ~MeBOC
HO"O
336
<===
7
Figure 49. Retrosynthetic analysis of (-)-codeine (2) approach.
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Although the formation of epoxide (+)-7 was not anticipated, its preparation gives
access to the synthesis of (+)-codeine. The regioselective opening of epoxide (+)-7
with an appropriate aromatic nucleophile would allow for the connection of the
unsaturated C-ring fragment and the aromatic A-ring fragment of morphine alkaloids.
It has to be mentioned that a similar strategy was applied previously in Professor
Hudlicky's synthesis of lO-hydroxy-14-epi-hydrocodone (234).110 With that in mind,
we revised our initial strategy for the synthesis of (-)-codeine and the alternative route
is shown in Figure 49.
The major difference from the first generation approach is the alternative connection
of the A-ring fragment to the C-ring fragment via a 1,2-trans diaxial epoxide opening
instead of the previously envisioned second Mitsunobu inversion.
In order to synthesize epoxide (-)-7, two different routes were investigated. First, diol
336 was treated with tosylchloride in the presence of DMAP and triethylamine in
DCM. After extensive optimization, the reaction yielded a rather disappointing 35%
yield of the desired distal protected diol 351, with 45% starting material recovered
and small amounts of the proximally protected diol. In order to validate the new
route, compound 351 was subjected to Mitsunobu conditions and bisprotected diol
352 was isolated in moderate yield.
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NMeBoc 3~teoHOH ~336
348
Reagents and Conditions: a) TsCl, NEt3' DMAP, DCM, 0 °c to rt; b) DIAD, PPh3, benzoic acid,
THF,O C; c) NaOMe, MeOH, 0 °C (88%).
Scheme 33. Synthesis of epoxide (-)-7.
Treatment of benzoate 352 under basic conditions led to the saponification of the
benzoate with concomitant formation of epoxide (-)-7. The overall yield for the
formation of epoxide (-)-7 could be dramatically increased by first performing the
Mitsunobu inversion (71 % yield) followed by protection of the distal alcohol (73%
yield).
Having established a high yielding route to epoxide (-)-7, we were in a position to
perform the key reaction of the synthesis. We decided to focus our attention on a
model study which would allow us to quickly assess the feasibility of the
regioselective 1,2-trans diaxial opening of vinyl oxiranes. We chose cyclohexadiene
oxide (280), which can be easily prepared from commercial available
cyclohexadiene, as the vinyl oxirane and phenol as the nucleophile. The results are
summarized in Table 5. The results clearly show that the desired regioselective
epoxide opening can be achieved under basic conditions. The best results were
obtained when compound 280 was treated with phenol in the presence of potassium
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carbonate or basic alumina or when treated with potassium phenolate (entries 3-6,
Table 5).
¢
fiYoV
356
+
355354353
+
280
d
Table 5. Model study for the reaction of vinyloxirane 280.
Q ~o--O&OH + u
Entry Conditions a Yield 354 Yield 355 Yield 356
3 equiv phenol, melt, rt 10% b 20%b 45%b
2 3 equiv phenol, acidic A120 3,Et20, reflux
43%b traces b
3 3 equiv phenol, basic A120 3, Et20,
reflux
85% c
4 3 equiv phenol, neutral A120 3,Et20, reflux
82% c traces C
5 3 equiv phenol, Si02, Et20, reflux 55% C 23% C
6 3 equiv potassium phenolate,DME, 80°C, 18-crown-6 95%C
7 3 equiv phenol,K2C03, Et20,
reflux
89% C
a) Reaction time was 18 hours; b) Isolated yield by flash column chromatography; c) Yield determined
by GC/MS.
Having established suitable conditions for the regioselective epoxide opening of
compound 280 with phenol, we focused our attention on the reaction of homochiral
epoxide (-)-7 and bromoisovanillin (174). Unfortunately, applying the previously
successful reaction conditions from our model study (entries 3, 6 and 7, Table 5) did
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not allow for the isolation of any aryl ether derivative, until we applied potassium
phenolate (357) instead of the potassium salt of bromoisovanillin as nucleophile.
(-) - 7 357
a
----..
PhO", ~MeBOC
HOX)
358
Reagents and Conditions: a) 18-crown-6, DME, 80°C (78%).
Scheme 34. Regioselective opening of epoxide (-)-7 with potassium phenolate.
We speculated that the electron withdrawing effect of the aldehyde of
bromoisovanillin reduced the nucleophicility of the potassium salt of
bromoisovanillin. To remedy this, we prepared acetal-protected potassium phenolate
360 as shown in Scheme 35.
Meoill
HOYCHO
Br
174
a
----..
Meo~
HO~O
Br oJ
359
b
----..
Meo~
KO~O
Br oJ
360
Reagents and Conditions: a) ethylene glycol, TsOH, THF, reflux (65%); b) KOH, EtOH (quant.).
Scheme 35. Preparation of potassium salt 360.
Various conditions for the reaction of epoxide (-)-7 and potassium salt 360 were
screened and led finally DME and DMF (1:1) as solvent and a reaction temperature
of 90 °C. These conditions effected the aryl ether formation in low yield. To our
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surprise, expected compound 361 was isolated only as minor product, along with
compound 350, as shown in
Table 6.
Table 6. Reaction of epoxide (-)-7 with potassium salt 360.
<S
NMesoc Meolll
A
~ + KO~O)
Br 0-1
a
---....
Meo~
~CHO
o Br
......",.~
HO~NMeBoc
Meo~Jeyo
+ Q, Sr oJ
HO~NMesoc
(-) -7 360 350 361
3 DMF, 90°C, 5 days
2 DME-DMF 1:1,90 °C, 4 days
4 DMF-HMPA 1:1, 90°C, 5 days
Entry Conditionsa
DME, 18-crown-6, 80°C, 7 days
Yield 350 Yield 361 recovered 8M(-)-7
traces traces 85%b
21%b 7%b 45%b
10%C 13%C
6%C 8%c
5 DME-HMPA 1:1, 90°C, 5 days
6 HMPA, 90°C, 5 days
a) two equivalents of 360 were used in all reactions; b) isolated yield by flash column
chromatography; compounds 350 and 361 were inseparable by flash column chromatography;
c) determined by IH NMR of crude reaction mixture after work up.
Since compounds 350 and 361 proved to be inseparable by flash column
chromatography and an additional deprotection step would be necessary to finish the
synthesis of (-)-codeine, we reinvestigated the reaction of epoxide (-)-7 and
potassium salt 362. Optimization of the previously applied conditions led to the aryl
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ether 350 in 75 % yield, along with compound 363, tentatively assigned as shown. It
was observed that compound 363 is formed exclusively at higher reaction
temperatures and a mechanism which accounts for the formation of compound 363 is
proposed in Scheme 36.
Me0)C;l!Me:OC~:)j CHO~ 0):)",1:CHO +OHC~Q". ~MeBOC00 ~ ,,~ NMeBoc lA ))
HO 0
(-) -7
363a
362 350
H Br !MeBOC
~:X)
MeO):
363b
363
tentatively assigned
J
Reagents and Conditions: a) 18-crown-6, DME-DMF 1:1, 80 °C, 48 hours (75%); b) TBSCI,
imidazole, DCM (61 %).
Scheme 36. Preparation of aryl ether 350 and proposed mechanism for the formation
of compound 363.
Subsequent protection of the hydroxyl functionality of compound 350 with tert-
butyldimethylsilyl chloride gave the protected ether 364 in 61 % yield (Scheme 37).
Analytical data (lH and 13C NMR, IR, MS) of compound 364 were found to be
identical to those of compound 337, only differing in the sign of their optical rotation
(compound 364 Un21 = -55.8 (c 0.325, CHCl3), compound 337 un22 = +59.1 (c 0.35,
CHCl3)). Having matched an enantiomer of one of the intermediates of the route to
(+)-codeine, the total synthesis of (-)-codeine was completed by repetition of the
steps reported for the synthesis of (+)-codeine. Pd-catalyzed Heck-cyclization of
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compound 364 gave furan (-)-338 in 91 % yield followed by Wittig reaction to give
compound (-)-339 in similar yield to the (+)-codeine route.
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~CHO
o Br
DNMeBOC
HO
Meo~
~CHO
o Br'''\~NMeBoc
TBSOAJ
350 364 {-)-338
(-)-339
Meo~ ~r~o :~-'~NMeBOC
TBSOAJI
e d
.....-- .-...--
NMeBoc NMeBoc
HO TBSO
{-)-341 {-)-340
1f
MeO ~ MeO ~Ih- g,h,i h-
NMeBoc
q,
NMe
0 HO"
{-)-342 (-)-codeine (2)
Reagents and Conditions: a) TBSCI, imidazole, DCM (61%); b) Pd(OAc)2, Ag2C03, dppf, toluene,
110°C (91 %); c) PPh3CHBr2, tBuOK, THF, -30°C (40%); d) Pd(OAc)2, Ag2C03, dppp, toluene, 110
°c (45%); e) TBAF, THF, rt (72%); f) IBX, DMF, rt; g) NaBH4, CeCh·7H20, MeOH, 0 °C; h) TFA-
DCM (1 : 4), 0 °C to rt; i) Hg(OAc)2, Et3N, THF, 48 h then LAH, 2h, rt (8% over four steps).
Scheme 37. Synthesis of (-)-codeine (2).
Alcohol (-)-341 was prepared in comparable yield to the (+)-codeine route by
previous established conditions with the .Heck cyclization of vinyl bromide (-)-339 in
45% yield and the deprotection of the alcohol functionality of intermediate (-)-340 in
72% yield. In contrast to the oxidation of alcohol 341, which proceeded in nearly
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quantitative yield, the IBX-mediated oxidation of (-)-341 gave a mixture of two
compounds (ratio of 1:1). The discrepancy between these two experiments is
explained by the use of an additional 0.3 equivalents of IBX for the oxidation of
intermediate (-)-341, which reaction was not complete employing one equivalent of
oxidizing reagent. No suitable conditions were found to effectively separate these two
compounds and the identification of compound (-)-:-342 is based on a small amount of
purified product. In order to complete the synthesis, the mixture was first subjected to
reductive conditions followed by treatment with trifluoroacetic acid. In both
experiments an inseparable mixture of compounds was isolated with nearly
quantitative mass recovery. Oxymercuration of the mixture, followed by treatment
with lithium aluminium hydride allowed for the synthesis of (-)-codeine (2) (8% yield
for the last fOUf steps) after elaborative purification of the final reaction mixture.
The total synthesis of (-)-codeine (2) was achieved in 17 steps from ~­
bromoethylbenzene compared to 14 steps for the synthesis of the (+)-isomer. The
synthesis of both isomers of codeine highlights the versatility of enzymatically
derived dienediols in enantiodivergent natural product synthesis.
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3.2.3 Regioselective Hydrogenation of Thebaine151
The conversion of thebaine into valuable morphinane derivatives, such as oxycodone
(11) or hydrocodone (12) has attracted much attention from the chemical community
over the last 100 years. Freu9 and Speyer discovered the conversion of thebaine (4) to
14-hydroxycodeinone (235) by simple treatment of thebaine (4) with formic acid and
hydrogen peroxide (Figure 50).10a An alternative approach to 14-hydroxycodeinone
(235) is the addition of singlet oxygen to yield an opioid endoperoxide, whose
reduction yields the desired intermediate for the production of oxycodone 11.152 The
dienol ether unit in thebaine has been transformed to neopinone ketal 365 by
Rapoport153 and by Dauben (Figure 50). 154 As the diene unit in thebaine is polarized,
we reasoned that it could be possible to effect a regioselective reduction of the C-8 C-
14 olefin through a directed catalytic hydrogenation of thebaine155 under various
conditions, in order to provide for a direct conversion of thebaine to hydrocodone
(12) via 8,14-dihydrothebaine 237, as shown in Scheme 38.
365
neopinone ketal
MeOM1.0o :\~NMe
MeoA)
4
MeoM~
1.0
o :o~NMe
235
14-hydroxycodeinone
Figure 50. Functionalization of thebaine (4).
Although 8,14-dihydrothebaine can be obtained from thebaine by reduction with
diimide (generated from hydrazine and oxygen) in 79% yield without
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chromatography on a 0.1 mole scale,124 the need for an environmentally-benign
catalytic method, as well as a safer process, still exists. A regioselective
hydrogenation of thebaine to 237 would provide a more convenient alternative for the
conversion of thebaine to hydrocodone (12).
Meo~
,Mo :
-I:. .~NMe
MeoA)
4
d
237
MeoM.~Ih-
o :~NMe
o
12
MeoM~1,&
o :";.'.~NMe
Meo)J
327 367
368 369
Reagents and Conditions: a) H2, MeOH (45%); b) 2N HCl (82%); c) H2, MeOH (38%); d)
RhCl(PPh3)3, EtOH (20%).
Scheme 38. Hydrogenation of thebaine (4).
Hydrogenation of thebaine, using Crabtree catalyst (5 mol%) 368156 in methanol at 55
psi hydrogen pressure, led to the regioselective saturation of the C-8 C-14 olefin to
produce enol ether 237 in 45% yield. Improved yields were achieved at lower
pressure, as indicated in Table 7 (entries 1 - 4). Ratios were determined by IH-NMR
in CDCI3, by comparison of the intensities of H-5 protons of the morphine alkaloids
(thebaine (4), 5.29 ppm (s); 8,14-dihydrothebaine (237), 4.84 ppm (8); codeine
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methylether (327), 4.99 ppm (d, J = 5.8 Hz); and tetrahydrothebaine (367), 4.68 ppm
(d, J =5.0 Hz)), as well as separation of the relevant morphinans by HPLC.
Table 7. Hydrogenation of thebaine (4) with Crabtree's catalyst 368 in methanol.
368 Yield of Yield of
Entry H2 Time Conversibna
mol % 237a 367a
5 55 psi 16 hrs 19% 9% 5%
2 5 55 psi 96 hrs 75% 43% 25%
3 10 55 psi 192 hrs 85% 44% 27%
4 15 55 psi 288 hrs 95% 45% 27%
5 5 150 psi 16 hrs 10% 3% 2%
6 5 400 psi 64 hrs 78% 24% 18%
a Conversion and yields were determined by IH-NMR and HPLC.
The use of rhodium catalyst 369157 provided an interesting contrast to the results
obtained with Crabtree's catalyst 368, in the regioselectivity of hydrogen addition, as
shown in Table 8. Up to 38% yield of allylic ether 327 was obtained in addition to the
fully saturated natural isomer tetrahydrothebaine (367), which in our hands were
inseparable by column chromatography. The enol ether 327 was isomerised in
preliminary experiments using Wilkinson's catalyst in refluxing ethanol to yield 237
in 20% yield with 80% recovery of unreacted starting material. A similar method for
the isomerisation of codeine to hydrocodone has previously been published. 123
Hydrolysis of 237 using 2 N HCI yielded hydrocodone (12) in 82 % isolated yield
after flash column chromatography. Tetrahydrothebaine (367) is a significant
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byproduct produced by over-reduction of thebaine under most of the conditions that
were tried and is likely to be formed in any process developed in the future that uses
catalytic hydrogenation. Rice described a practical method for the conversion of
tetrahydrothebaine to dihydromorphine with hydrobromic acid in acetic acid, thereby
converting this byproduct into a valuable compound. I58
Table 8. Hydrogenation of thebaine over rhodium catalyst 369.
Yield of Yield of
Entry H2 Solvent Time Conversiona
327a 367a
1 atm EtOH 18 hrs 100% 0% 60%
2 1atm DCM 18 hrs 100% 0% 90%
3 1 atm CHCl3 18 hrs 80% 0% 0%
4 1 atm MeOH 18 hrs 40% 38% 0%
5 1 atm MeOH 27 hrs 85% 33% 30%
6 1 atm MeOH 36 hrs 100% 0% 85%
7 2atm MeOH 5 hrs 10% 8% 0%
8 1 atm MeOH, 30°C 5 hrs 9% 7% 0%
9 1 atm MeOH, 30°C 18hrs 100% 0% 60%
10 1 atm MeOH, 0 °C 5 hrs 0% 0% 0%
a) The conversion and the yields were determined by IH-NMR.
Other catalysts investigated during these studies include RhCI(PPh3)3 (Wilkinson's
catalyst), RuCI2(PPh3)3, Pd2(dba)3, PdCI2(PPh3)2, Lindlar's catalyst, and 5 % Rh/Al.
In the case of Wilkinson's catalyst and RuCI2(PPh3)3, no conversion was obtained in
methanol at atmospheric pressure of hydrogen after 18 hours. The use of other
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catalysts under the same conditions led (after 18 hours) to complete consumption of
starting materials, yielding compounds not structurally related to 237, 327 or 367.
Tetrahydrothebaine 367 was obtained in 8% yield with Pd2(dba)3, in 10% yield for
PdCI2(PPh3)3, and in 26 % yield with Rh/Al. With Lindlar's catalyst, dihydrothebaine
237 was obtained in 8% yield along with 10 % of tetrahydrothebaine 367. In addition,
the combination of PdCl2 and sodium borohydride
l led to the isolation of phenolic
compound 370 in 40% yield.
MeO ~I 0
a HO
NMe NMe
MeO MeO'"
4 370
Reagents and Conditions a) NaBH4, PdCh, MeOH (40%).
Scheme 39. Formation of compound 370 from thebaine (4).
In conclusion, some level of regioselectivity in hydrogenation of the C-8 C-14 olefin
was demonstrated by using catalysts capable of coordinating to the nitrogen atom of
thebaine.
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3.2.4 Conversion of Thebaine to Neopinone Ketal and Direct Synthesis of
Hydrocodone159
Thebaine is an ideal precursor to all C-14 hydroxylated derivatives and is easily
transformed to 14-hydroxycodeinone by treatment with formic acid/hydrogen
peroxide. lOa Most C-14 hydroxylated derivatives are accessible through this and other
procedures. The ICH (International Conference on Harmonisation) suggested to
strictly limit the amount of a,~-unsaturated ketone containing compounds in
pharmaceutical preparations. Therefore the development of new routes to active
pharmaceutical ingredients that avoid the production of such intermediates and/or
impurities are of high interest to the chemical community.12 A logical alternative
intermediate for C-14 hydroxylations would be the ~, y-unsaturated species such as
neopinone and its derivatives, which still offer the potential to functionalize C-14 via
selective transformations of the C-8 C-14 olefin. We investigated the transformation
of thebaine (4) to neopinone ketal derivative 14 and its further transformation into
valuable morphine derivatives.
4
NMe
14
NMe
Figure 51. Preparation of neopinone ketal derivative 14.
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The conversion of thebaine to neopinone ketal 365 has been demonstrated by
Rapoport153 and Dauben154 who used mercuric acetate to activate the dieneol ether at
the kinetically favored a-position as shown in Figure 52.
4
NMe
Hg(OAc)2
AcO
HgOAc
371
NMe
MeOH
372
NMe
OMe
365
Figure 52. Formation of neopinone ketal derivative 365.
NMe
It is well established that dienol ethers or a,~-unsaturated ketones may be converted
to the corresponding ~,y-unsaturated ketals via kinetic protonation at the a-position
and subsequent intra- or intermolecular trapping of the oxonium ion, as demonstrated
by Heathcock's synthesis of a-bulnesene. 160
To our knowledge, the unsaturated ethylene glycol ketal 14, derived from neopinone
has not been previously reported. A screening of various conditions revealed that
exposure of thebaine (4) to ethylene glycol in chloroform in the presence of TsOH led
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to the conversion to its corresponding ketal 14, accompanied by a second species
tentatively assigned as 379, Scheme 40.
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14
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379
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MeO~
,Mq-.~oM NMe
12
Reagents and Conditions: a) TsOH, ethylene glycol, CHCh (45%); b) H2, Pt/C (10%), CHCl3
(quant.); c) H2S04, MeOH (75%).
Scheme 40. Conversion of thebaine (4) to hydrocodone (12) via neopinone ketal 14.
The /17-8 isomeric ketal was not detected in the reaction mixture. Encouraged by this
result, we converted 14 to 380 by hydrogenation at atmospheric pressure, followed by
acid catalysed hydrolysis to hydrocodone (12). Subsequent work demonstrated that
14 can be directly converted to 12 using a one-pot hydrogenation and hydrolysis
procedure. The incompatibility of thebaine with strong protic acids is ,well
documented/61 as evident by the competing acid-induced pathways observed during
the synthesis of 14. We examined alternative conditions for the collapse of the enol
ether of thebaine (4) in order to generate 14. The use of bromine as a 'pseudo-proton',
in the presence of ethylene glycol, led to the bromo ketal 381 (proposed structure),
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which could be potentially be converted to hydrocodone (4) by hydrogenation and
hydrolysis, Scheme 41.
Table 9. Reaction conditions for the formation of neopinone ketal 14.
Entry Conditions Thebaine Yield 14 (%) based on
consumption (%) IHNMR
3.3eq TsOH (dry), 10eq 100 45 (isolated)glycol, CHCh
2 3.3eq TsOH.H20, 10eq glycol, 65 17CHCI3,4AMS
3 3.3eq polyphosphoric acid, 100 N/A10eq glycol, CHCh
4 3.3eq oxalic acid.2 H20, 10eq 0 N/Aglycol, CHCl3
5 3.3eq acetic acid (glacial), 0 N/A10eq glycol, CHCh
6 3.3eq TsOH.H20, 10eq glycol, 100 16EtOAc
7 3.3eq TsOH.H20, 10eq glycol, 100 20EtOAc,4AMS
8 3.3eq TsOH.H20, 10eq glycol, 100 21EtOAc,4AMS, 0.16M
9 3.3eq TsOH.H20, 10eq glycol, 59 6EtOAc, 4A MS, 5hrs, 0.04M
10 3.3eq TsOH.H20, 10eq glycol, 100 8EtOAc, 4A MS, 0.04M
11 3.3eq TsOH.H20, 10eq glycol, 100 10PhMe, 40°C
12 3.3eq TsOH.H20, 10eq glycol, 100 12PhMe, 60°C
13 3.3eq TsOH.H20, 10eq glycol, 100 multiple productsPhMe, 120°C
14 3.3eq TsOH.H20, 10eq glycol, 100 81,2-dichlorobenzene
15 5eq TsOH.H20, 10eq glycol, 100 36CHCh
16 10eq TsOH.H20, 10eq glycol, 100 17CHCl3
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Br
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NMe
b
c
a
NMe
Reagents and Condi,tions: a) Br2' ethylene glycol, CHCh; b) Pd(OAc)2, ethylene glycol, CHCh; c)
Pd(OAc)2, THF, H20; d) H2(4 hrs) then aq. H2S04•
Scheme 41. One pot conversion of thebaine (4) to hydrocodone (12).
When Pd(OAc)2, in the presence of ethylene glycol, was used with the dual purpose
of acting initially as a proton surrogate and later as a hydrogenation catalyst,
hydrocodone (12) was obtained in a one-pot sequence from thebaine in 17% yield, at
the expense of the formation of phenol 382. Since the formation of ketal intermediate
383 is not necessary for the conversion of thebaine (4) to hydrocodone (12), we
reasoned that the hydrolysis step could be avoided if the reaction was performed
under aqueous conditions. Indeed, treatment of thebaine in aqueous THF with
stoichiometric amounts of Pd(OAc)2 led rapidly to the same presumed intermediate
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384, which was immediately treated with one atmosphere of hydrogen gas to yield
hydrocodone (12) in 43% yield, with the attendant diminishment of byproduct 382.
Encouraged by the promising results with Pd(OAc)2 in aqueous media, we started to
screen conditions for an one-pot conversion of thebaine (4) to hydrocodone (12).162 A
wide series of common hydrogenation catalysts were screened and various acids were
tested for the conversion of thebaine (4) to hydrocodone (12). Treatment of thebaine
in 10 - 20% aqueous HCI under one atmosphere hydrogen in the presence of 5% w/w
Pd/C (10%) provided, after extensive optimization, hydrocodone (12) in 63% yield.
Also recovered from the reaction mixture was phenol 382 (20%) and
tetrahydrothebaine (367) (8%). A detailed time study of this transformation is shown
in Graph 1.
Mea ~
1 ~HO
NMe NMe
a a
acid 12 382
NMe Pd/C (10% )H2 1 atm, 18 hrs.
Mea Mea
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NMe NMe
MeO'\' a
367 385
Figure 53. Hydrogenation of thebaine (4).
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Graph 1. Hydrogenation of thebaine (4).
The graph shows that formation of tetrahydrothebaine (367) and phenol 382 only
occured during the initial four hours of the reaction, after which time they have
reached a maximum concentration. We suspected that one of the side-products
formed during the reaction may modify the reactivity of the catalyst. Therefore we
conducted several experiments, such as poisining of the catalyst .with the observed
sideproducts, tetrahydrothebaine 367 or phenol derivative 382. In another set of
experiments we conducted the hydrogenation with triethylamine, triphenyphosphine,
or thiourea in attempts to modify the catalyst and get selective reduction. None of
these variations improved the yield of hydrocodone (12).
Variation of the applied hydrogen pressure, as well as performing the reaction at
higher temperature, decreased the yield of hydrocodone (12) in favour of the
formation of tetrahydrothebaine (367). Delay of the addition of hydrogen gas (30
122
min, 60 min, 2 hours, or 6 hours) led to the formation of increased amounts of meta-
thebainone 385.
All these variations failed to improve the yield of hydrocodone, but led to the
discovery of procedures which gave a wide range of morphine alkaloids in high
purities (Table 10).
Table 10. Hydrogenation of thebaine (4).
hydrocodone tetrahydro- phenol meta-Entry Conditions 12 thebaine 382 thebainone367 385
PdlC (10%), H2
(1 atm),20% 63% 20% 8% 0%
aqueous. HCI, 18 hrs
PdlC (10%), H2
2 (1 atm), 20% 0% 18% 73% 0%
aqueous. HCOOH,
18 hrs
Rh(COD)(PPh2C4HgP
3 Ph2)+ BF4-, H2 0% 90% 0% 0%
(1 atm), DCM, 18 hrs
Pt/C (1 %), vanadium
4 doped, 20% aqueous. 15% 5% 0% 75%HCI, H2 (1 atm),
18hrs
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3.2.5 Palladium-catalyzed N-demethylation / N-acylation of Morphine
alkaloids163
The direct conversion of hydrocodone to oxycodone would be of interest due to the
higher commercial value of oxycodone. During the screening of oxidative conditions,
we isolated a novel morphine derivative. The compound was identified as N-acetyl
norhydrocodone 386.
Me:~
o~NMe
12
o 0
)lo~
..
Pd(OAc)2
Figure 54. Formation of N-acetyl norhydrocodone 386.
N-Demethylation and/or N-acylation reactions of morphine-type alkaloids have been
extensively studied. The standard procedures for N-demethylation of substrates,
including morphinan-derived compounds, include the use of cyanogen bromide (the
von Braun reaction),164 the reaction of a tertiary amine with chloroformates followed
by hydrolysis,165 as well as a photochemical demethylation procedure. 166 Other
methods that have been used to effect demethylation include Polonovski-type
reactions. 167,168
12
NMe
387
Figure 55. Formation N-formyl norhydrocodone 387.
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Precedent for a Pd-catalysed oxidative demethylation procedure using stoichiometric
amounts of Pd/C, appears in a single report by Chaudhuri,169 however our repetition
of this procedure with hydrocodone resulted only in the isolation of the N-formyl
derivative 387 in 17% yield (Figure 55). We therefore decided to develop
methodology that would be applicable to the N-demethylation I N-acylation of
morphinans.
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Figure 56. X-ray structure crystal structure of novel N-acetyl norhydrocodone 386.
Initial experiments using stoichiometric amounts of palladium led to the use of
benzene as solvent. Further investigation of reaction conditions demonstrated dioxane
to be a superior solvent, with an optimum catalyst loading of 0.2 equivalents.
Exhaustive experiments demonstrated that the influence of light, dissolved oxygen
and moisture had no effect on the outcome of the reaction. Early attempts at
optimization indicated that the use of coordinating solvents, such as acetonitrile and
methanol, led to reduced yields. The use of PdCl2 in place of Pd(OAc)2 resulted in a
dramatic decrease in yield. Less economical Pd (0) sources offered no further
advantages. The most significant experiments are summarized in Table 11.
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Table 11. Optimization of conditions for N-demethylation / N-acetylation of
hydrocodone (12).
Entry
2
3
4
5
6
7
8
9
10
11
Conditionsa
Pd(OAc)2 (1.2 equiv),MeCN, AC20, 80° C
PdCl2 (1.2 equiv), benzene, AC20, 8~0 C
Pd(OAc)2 (0.2 equiv), benzene, AC20, 80° C
Pd(dba)2 (0.5 equiy), benzene, AC20, 80° C
Pd(OAc)2 (0.2 equiv), dioxane (dry), AC20, 80° C
Pd(OAc)2 (0.2 equiv), dioxane (wet), AC20, 80° C
Pd(OAc)2 (0.2 equiv), toluene, AC20, 80° C
Pd(OAc)2 (0.2 equiv), MeOH, AC20, rt, 3 days
PdCl2(0.2 equiv), Dioxane, AC20, 80° C
Pd(PPh3)4 (0.2 equiv), Dioxane, AC20, 80° C
Pd(dba)2 (0.2 equiv), Dioxane, AC20, 80° C
Yield of 386b
0%
50%
67%
76%
80%
80%
67%
15%
17%
76%
72%
a) reaction time 15 hrs, unless otherwise noted; b) yields refer to clean isolated material.
An interesting observation common to all conditions was the isolation of two
conformers in a ratio of approximately 3: 1 in favour of the natural, equatorially
substituted isomer.
After the success of the N-demethylation acylation procedure using acetic anhydride,
we explored the reactivity of a series of anhydrides that resulted in the isolation of a
novel range of N-acylated norhydrocodone derivatives, as shown in Table 12.
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Table 12. Synthesis of new N-acyl hydrocodone derivatives.
12
Pd(OAch, anhydride,
NMe dioxane reflux
a
equatorial substitution
natural
b
axial substitution
unnatural
Entry Anhydride Product R Time Yielda Ratio
b
(hrs) a:b
acetic anhydride 386 Ac 15 80% 3 : 1
2 cyclopropylmethyl 388 V 24 76% 3 : 1anhydride
3 iso-butyric anhydride 389 COCH(CH3)2 24 13% 13 : 4
4 n-propyl anhydride 390 COCH2CH3 24 53% 3 : 1
5 decanyl anhydride 391 CO(CH2)gCH3 120 36% 3 : 1
6 dodecanylanhydride 392 CO(CH2)lOCH3 120 43% 7:2
a) Yields refer to clean isolated material; b) determined by NMR.
Substitution of an anhydride for a dicarbonate, such as dimethyldicarbonate, resulted
in the isolation of the N-demethylated carbamate species 393, in 33% yield as a
mixture of two isomers (6:4 in favour of the equatorial isomer). We have also
demonstrated that di-tert-butyldicarbonate (Boc-anhydride) can be used in this
transformation (15% yield).
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Figure 57. Formation of N-carbamate norhydrocodone derivatives.
In order to demonstrate the generality and the practicality of this methodology, we
extended the study to include other N-methylated heterocycles, including atropine and
its derivatives. We wished to demonstrate the compatibility of the method with a
range of functional groups such as ketones and esters. The results of the
demethylation I acylation sequence with tropane-type alkaloids are shown in Table
13.
The optimized conditions for the conversion of hydrocodone (12) to N-acetyl
norhydrocodone 386 applied to tropane 395 gave only trace amounts of the acylated
tropane derivative 396 and therefore more vigorous conditions were applied. The
isolation of olefinic compound 403 can be explained by the elimination of the
primary acetate formed under the reaction conditions.
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Table 13. N-Demethylation / N-acylation of tropane alkaloids.
Entry Substrate ConditionsPd(OAc)2 (0.2 equiv)
Yielda
(conversionb)
2
Me
~O
395
Me
N
cL
397
a) AC20 neat, 80 CC, 14 hrs
b) PhH, AC20, 80 CC, 60 hrs
c) MeOH, AC20, rt, 3 days
AC20 neat, 80 CC, 14 hrs
Ac
~O
396
Ac
N
cL
398
a) 72% (1 00%)
b) 48% (60 0/0)
c) no reaction
3
Me
~
OH
399
AC20 neat, 80 OC, 14 hrs
Ac Me
~~
OAc OAc
400 401
430/0 35%
4
Me
II~ HO~tv PhH, AC20, 80 CC, 60 hrs
° "::
0 1 .6-
402
Ac
~~
~U
403
85%
a) Yields refer to pure isolated material; b) determined by Ge/Ms.
Speculative ideas on the mechanism of this reaction are outlined in Figure 58.
Insertion of Pd (0), formed under the reaction conditions, into a molecule of acetic
anhydride produces acyl-palladium species 404, according to published precedent. 170
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Figure 58. Suggested mechanism of N-demethylation using Pd(OAc)2.
Quaternisation of the basic nitrogen and regeneration of a Pd (0) species is followed
by release of acetate, which is subsequently methylated by the quaternized salt.
Conducting the reaction in the absence of a palladium source yielded only starting
material, while in the absence of anhydride and with stoichiometric amounts of
Pd(OAc)2, norhydrocodone (8) was obtained, Scheme 42. This demethylation
reaction occurred only in the case of hydrocodone (12), and was unsuccessful if
applied to other morphine derivatives such as morphine (1), codeine (2), or
oxycodone (11).
12
NMe
Pd(OAch (2.5 equiv.),
benzene ref!., 36 hrs
16
NH
Scheme 42. N-demethylation of hydrocodone (12).
This result led to the investigation of novel procedures for the N-demethylation of
morphine alkaloids and will be discussed in the following section.
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3.2.6 Demethylation of Morphine Alkaloids!7!
The demethylation of morphine alkaloids holds immense commercial potential for the
production of morphine-derived antagonists, such as naltrexone (13), nalbuphine
(239), and other medicinally significant compounds. Semisynthesis of these
derivatives from opium-derived natural products traditionally involve standard
procedures for demethylation with subsequent formation of carbamate or acyl
derivatives that then permit oxidative procedures for the introduction of a C-14
hydroxyl group. From this point, further functionalization can be achieved to yield
the desired synthetic opioids.
239
MeO ~
1.0
q.. ~
MeO
4
NMe
13
Figure 59. Naltrexone (13) and nalbuphine (239).
We investigated alternative conditions for the synthesis of the nor-series of
compounds, avoiding forcing and expensive conditions, such as those currently
applied in industrial processes. During mechanistic studies of the novel one-pot
demethylation / acylation procedure, we observed that treatment of hydrocodone (12)
with catalytic amounts of palladium (II) salts resulted in the recovery of small
amounts of the N-demethylated derivative 16. Increasing the quantities of palladium
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salt in the reaction resulted in elevated yields of the demethylated product 16, as
shown in Table 14.
Table 14. Demethylation of hydrocodone using Pd(OAc)2 in benzene.
NMe NH
Entry
2
3
4
5
12
Conditionsa
Pd(OAc)2 (0.2 equiv), 81 0 C, 15 hrs
Pd(OAc)2 (1.2 equiv), 81 0 C, 36 hrs
Pd(OAc)2 (2.5 equiv), 81 0 C, 36 hrs
Pd(OAc)2 (1.0 equiv), PPh3 (4 equiv), 81 0 C, 4 days
Pd(OAc)2 (0.2 equiv), PPh3 (0.8 equiv), 810 C, 4 days
16
Norhydrocodone (16)6
3% (92% rec. SM)
20% (70% rec. SM)
40% (55% rec. SM)
4% (90% rec. SM)
3% (90% rec. SM)
a) benzene was used as solvent, b) isolated yield after flash column chromatography.
The use of Pd (0) sources or addition of excess phosphine ligands, in an attempt to
support the catalytically-active species, proved unsuccessful and resulted in almost
complete inhibition of the reaction. Extending the reaction time resulted in no
increase of yield beyond that observed after 36 hours.
The application of the Pd(OAc)2 demethylation procedure proved to be unsuccessful
for other morphine alkaloids, such as morphine (1), codeine (2), or thebaine (4). In all
cases, decomposition of the starting material was observed. For this reason, we set
about finding a more general set of reaction conditions that would also avoid the
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stoichiometric quantities of palladium required by the initial reaction. We envisioned
that oxidizing conditions would allow for the demethylation of morphine alkaloids.
One obvious choice was the use of Fenton's reagent, iron sulfate and hydrogen
peroxide. 172 Various variations of the originally reported conditions proved unsuitable
for this conversion.
2
NMe
a
405
NH
Reagents and Conditions: a) CU(OAC)2, (NH)4S20g,CH3CN: H20; 5 :1, rt, 16 hrs (22%).
Scheme 43. N-Demethylation of codeine 2.
Exhaustive screening of metal salts known to have been applied previously to
oxidative demethylation-type reactions proved discouraging, until we applied a
combination of copper acetate and ammonium peroxysulfate in a mixture of
acetonitrile and water as solvent. These conditions were successful for the
demethylation of hydrocodone (12), as well as codeine (2). Norhydrocodone (16) was
isolated in 64% yield from 12 after optimisation (Table 15), whereas norcodeine
(405) was obtained in 22% yield from 2 (Scheme 43).
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Table 15. Optimization of the copper-mediated demethylation of hydrocodone 12.
12
NMe
16
NH
Entry
2
3
4
5
CU(OAC)2 (Nl4)2S20 g
0.5 equiv 2 equiv
1 equiv 2 equiv
0.5 equiv 4 equiv
1 equiv 4 equiv
2 equiv 4 equiv
Norhydrocodone
Hydrocodone
(12)
(16)
(recovered SM)
20% 64%
36% 46%
24% 55%
36% 38%
64% 10%
All reactions were carried out at room temperature under an atmosphere of air, utilizing CH3CN : H20
5 : 1 as solvent with nine hours of reaction time.
Optimisation of these conditions involved testing of various solvent mixtures,
screening various copper salts (CuCI, CuI, CuCI2.2H20, CUC03, CuS04.5H20, CuO)
as well as varying the equivalents of both copper acetate and ammonium
peroxysulfate.
Further variation of reaction conditions included conducting the reaction under
oxygen as well as inert gas atmosphere, variation of the oxidant, alteration of the
reaction temperature, as well as changing the catalyst and oxidant. Unfortunately,
none of these variations showed beneficial effects (Table 16).
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Table 16. Variation of the N-demethylation procedure.
Hydrocodone N-oxide 405
Entry
2
3
4
5
6
Variablea
Air
Oxygen atmosphere
Argon atmosphere
H20 2(10 equiv) as oxidant
Reaction temperature 50°C
Reaction temperature 60 °C
Norhydrocodone
(16)b
64%
53%
50%
42%
37%
Hydrocodone
(12)b
10
15%
18%
32%
51%
a) Reaction conditions: 2 equiv Cu(OAc)2, 4 equiv (NH)4S20S, CH3CN : H20; 5 :1, rt, 16 hrs; b)
isolated yield after flash column chromatography.
Unlike the conditions reported by Scammels,167 which require the initial formation
and isolation of the corresponding N-oxide before its subsequent demethylation, the
present process is a one-pot procedure. In fact, we found that prior formation of the
corresponding N-oxide 406 and subsequent treatment with CU(OAC)2 and (NH4)2S20g
resulted in no reaction, indicating that perhaps our process follows a different
mechanism.
MeO I~
CU(OAC)2 ,&-
NMe or Pd(OAch NH
° °12
16IH20 2
670/0 A <OAch,(NH4hS20a
MeO ~
~
406
Figure 60. Probing the mechanism of the copper mediated demethylation procedure.
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In summary, we developed convenient conditions for the demethylation of
hydrocodone, which may also be applied to codeine. The true advantage of this
method is the elimination of toxic and expensive reagents, while at the same time
providing a one-pot, one-step conversion using cheap and easily accessible reagents.
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4. Conclusions and Future Work
In the course of the studies summarizes in this dissertation, we were able to design an
enantiodivergent synthesis of codeine (2). The common feature of these syntheses is
the use of a cyclohexadiene diol derivative, obtained from microbial cis-
dihydroxylation of ~-bromoethylbenzene. In both cases, the homochiral C-ring
fragment of codeine was constructed efficiently with the methyl amine and hydroxyl
functionalities in place. The connection of the aroma~ic part to the C-ring fragment
was achieved by Mitsunobu coupling, in the case of the (+)-codeine synthesis, and by
the conversion of the cis-diol to a ~-epoxide and its regioselective epoxide opening
for the synthesis of (-)-codeine. The complete phenanthrene core of morphine
alkaloids was constructed by Heck cyclizations similar to Trost's approach.8 Unable
to repeat Trost's procedure for the closure of the D-ring, we successfully designed an
oxymercuration reduction sequence to obtain the complete core of morphine
alkaloids. Optimization of this final transformation will be required in order to
increase the overall yield of both syntheses.
In addition to the syntheses of codeine (2), novel methodologies were investigated
directed towards the conversion of naturally-occurring opiates into more valuable
opioids. Initial studies on the hydrogenation of thebaine revealed that the use of
Crabtree's catalyst led to the regioselective hydrogenation of the CS/C14 olefin,
whereas hydrogenation with a commercially available rhodium catalyst gave codeine
methyl ether in acceptable yield. Furthermore, we were successful in developing a
one pot procedure for the conversion of thebaine (4) into a novel neopinone ketal
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derivative. Subsequent studies led to a one pot conversion of thebaine to the
commercially available analgesic hydrocodone (12).
Studies directed towards the conversion of hydrocodone to oxycodone led to the
isolation of N-acetyl norhydrocodone (386). Optimization of the N-demethylation /
N-acylation reaction conditions and substitution of acetic anhydride by a wide range
of anhydrides and dicarbonates led to the isolation of novel N-acyl and N-carbamate
norhydrocodone derivatives. We could demonstrate the generality and practicality of
this novel methodology by the conversion of other N-methylated heterocycles,
including atropine, to their corresponding acylated derivatives. A novel palladium-
catalyzed demethylation procedure for hydrocodone was discovered while studying
the mechanism of the N-demethylation / N-acylation reaction. Further investigations
on the demethylation of morphine alkaloids led to the discovery of a copper-based
procedure, which was successful when applied to hydrocodone, as well as codeine.
Future work in this area should focus on the application of these novel methodologies
to the syntheses of opioid antagonists, such as naltrexone (13), naloxone (243), or
nalbuphine (239).
In addition, we have shown that the reaction of the Burgess reagent with aliphatic
epoxides gives cis-fused cyclic sulfamidates and not trans-fused sulfamidates as
originally reported. We successfully prepared the first chiral version of the Burgess
reagent and demonstrated that homochiral derivatives of both cis- and trans-amino
alcohols can be obtained from epoxides in an enantiodivergent fashion. Application
of the asymmetric version of the Burgess reagent allowed for the design of an
enantiodivergent synthesis of balanol.
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5. Experimental Section
5.1 General Experimental Details
All non-aqueous reactions were carried out in an argon atmosphere using standard
Schlenk techniques for the exclusion of moisture and air. DCM and acetonitrile were
distilled from calcium hydride. THP, benzene, dioxane, toluene, diethyl ether, and
DME were distilled from sodium with benzophenone ketyl as indicator immediately
before use. Methanol and ethanol were distilled from magnesium turnings and iodine
under nitrogen, either directly into the reaction vessel, or stored over activated 3A
molecular sieves. Liquid reagents were distilled prior to use, and commercial solids
were used as supplied. Analytical thin-layer chromatography was performed on
Silicycle 60 A 250 Jlm TLC plates with P-254 indicator. Flash column
chromatography was performed using Natland 200-400 mesh silica gel. Melting
points were recorded on a Hoover Unimelt apparatus and are uncorrected. IR spectra
were obtained on a Perkin-Elmer One PT-IR spectrometer. Optical rotation was
measured on a Perkin Elmer 341 polarimeter. IH_, 19p_ and 13C-NMR spectra were
recorded on a Bruker (300 MHz or 600 MHz) spectrometer. All chemical shifts are
referenced to TMS or residual undeuterated solvent (CHCI3, DCM). GC/MS data was
obtained on a Perkin-Elmer Clarus 500 Gas Chromatograph and Mass Spectrometer
using a Perkin Elmer Elite-5MS column, 10 m, 0.25 mmID, 2 mL/min helium flow.
Separation by HPLC was either performed on a Hitachi L-6000 HPLC using a
Hitachi L-4000H UV detector (254 nm) with a Phenomenex primespher 5 C18 HC
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250 x 10 nun column; 2 ml/min flow; 5 mM KH2P04, 0.1 % NEt3, pH = 2.8 adjusted
with 2N HCl : MeOH (80:20) or performed on an Agilent 1100 series HPLC using a
Phenomenex primesphere 5 C18 HC, 150 x 4.6 nun column and 1.3 ml/min flow.
Compounds were detected at 280 nm and opioids were eluted with a gradient of 5
mM KH2P04, 0.1% NEt3, pH = 2.8 adjusted with 2N HCl and MeOH. Combustion
analyses were performed by Atlantic Microlabs, Norcross, GA. Mass spectra were
recorded on Kratos/MsI Concept IS mass spectrometer at Brock University.
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5.2 Experimental Procedures
General procedure for the reaction of oxiranes with Burgess reagent.
To a stirred solution of oxirane (4.0 mmol) in THF (20 mL) was added
(methoxycarbonylsulfamoyl)triethylammonium hydroxide, inner salt (18) (2.38 g, 9.2
mmol) at rt in a single portion. The resulting reaction mixture was immediately
brought to reflux by submerging it into a preheated oil bath (70 °C). The reaction
mixture was stirred until complete consumption of the oxirane (TLC), then cooled to
rt and filtered through a plug of silica to remove salts formed during the reaction. The
reaction solution was then concentrated and the resulting residue was purified by
flash column chromatography using an appropriate solvent gradient (hexanes : ethyl
acetate) to yield the corresponding sulfamidate product(s).
General procedure for the reaction of oxiranes with menthyl Burgess reagent 21.
To a stirred solution of oxirane (2.0 mmol) in THF (5 mL) was added 21 (4.60 mmol)
at rt in a single portion. The resulting reaction mixture was immediately brought to
reflux by submerging it into a preheated oil bath (70 °C). The reaction mixture was
stirred until complete consumption of the oxirane (TLC), then cooled to rt and filtered
through a plug of silica to remove salts formed during the reaction. The reaction
mixture was then concentrated and the resulting residue was purified by flash column
chromatography using an appropriate solvent gradient (hexanes : ethyl acetate) to
afford a 1: 1 mixture of diastereomers.
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General procedure for the syntheses of benzoates from sulfamidates.
To a stirred solution of sulfamidate (1.25 mmol) in dry DMF (5 mL) was added
ammonium benzoate (346 mg, 2.50 mmol). The solution was heated at 55 °C and
stirred for 18 hrs before the solvent was evaporated, and the resulting residue was
dissolved in THF (3 mL). Three drops of water and three drops of conc. H2S04 were
added, and the reaction mixture was stirred at rt for 12 hrs. The reaction mixture was
diluted with water and the pH was adjusted to 9, using a saturated aqueous solution of
NaHC03, before the layers were separated. The aqueous layer was extracted with
DCM (3 x 5 mL), then the organic layers were combined and washed with brine (1 x
5 mL), dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated.
The resulting diastereomers were separated by flash column chromatography
(hexanes: ethyl acetate) using an appropriate solvent system.
General procedure for the formation of disulfides.
To a solution of Burgess reagent (18) (1.05 equiv) in benzene (1 molar) was added
dropwise the corresponding thiol (1 equiv) dissolved in benzene at rt The progress of
the reaction was followed by GC/MS. After complete conversion of the starting
material (approximately 30 min to 1 hour) the reaction mixture was filtered through a
plug of silica (hexanes). The crude product was either triturated with hexanes or
purified by flash column chromatography.
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General procedure for N-demethylation I acylation reaction.
To the tertiary amine (0.1 mmol, 1.0 equiv) dissolved in an appropriate anhydride (1
mL) and dioxane (1 mL) was added Pd(OAc)2 (0.01 mmol, 0.1 equiv). The mixture
was heated at 80°C for 18 h, cooled to room temperature and filtered through a plug
of silica with DCM : MeOH: NH40H, 80:20: 1 as eluent. The volatiles were removed
in vacuo, and the residue was suspended in saturated aqueous NaHC03. The aqueous
phase was extracted with DCM (three times), and the organic extracts were combined
and washed with 1M aqueous HCI and brine. The organic layer was dried over
anhydrous magnesium sulfate, filtered and the volatiles were removed under reduced
pressure to yield the crude product, which was subjected to flash column
chromatography (DCM : MeOH, gradient) to give the pure acylated compound.
General procedure for Pd(OAc)2-mediated demethylation.
To a solution of the tertiary amine (0.1 mmol, 1.0 equiv) in benzene (1 mL) was
added Pd(OAc)2 (0.25 mmol, 2.5 equiv). The mixture was heated at reflux for 36 h,
cooled to room temperature, and filtered through a plug of silica with DCM : MeOH :
NH40H, 80:20: 1 as eluent. Following the removal of volatiles under reduced
pressure, the residue was suspended in aqueous NaHC03, then extracted with CHCI3•
The organic layer was dried over magnesium sulfate and filtered, then the volatiles
removed in vacuo. Flash column chromatography (silica gel; CHCl3 : MeOH :
NH40H, 96:4: 1) of the crude material affords analytically pure demethylated product.
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General procedure for CU(OAc)2-mediated demethylation.
To the tertiary amine (0.1 mmol, 1.0 equiv) dissolved in CH3CN : H20; 5 : 1 (1 mL),
was added Cu(OAc)2 (0.2 mmol, 2.0 equiv) and (NH4)2S20g (0.4 mmol, 4.0 equiv).
The mixture was stirred at room temperature for 12 h, then. the reaction was
quenched with aqueous 10% Na2S203. The organic solvent was removed under
reduced pressure, the residue was basified to pH 9 with concentrated aqueous
NH40H, then extracted three times with DCM. After combining the organic layers,
drying over anhydrous magnesium sulfate, and filtration, the volatiles were removed
in vacuo. Flash column chromatography (silica gel; CHCI3: MeOH : NH40H, 96:4:1)
of the crude material afforded analytically pure demethylated product.
247
cis-Hexahydro-2,2-dioxide-3H-1,2,3-benzoxathiazole-3-carboxylic acid methyl
ester (247).
Compound 247 was prepared in 64 % yield (604 mg) as colorless crystals following
the general procedure for reactions of oxiranes with the Burgess reagent 18, using
cyclohexene oxide as starting material. mp 97 - 98°C (ethyl acetate/hexanes); Rf 0.49
(hexanes: ethyl acetate, 1:1); IR (film) Vrnax: 2943,1743,1385,1183 cm-I; IH NMR
(300 MHz, CDCI3) b: 5.00 (bs, 1H), 4.22 (bs, 1H), 3.90 (bs, 3H), 2.33 (bs, 2H), 1.45 -
1.85 (m,4H), 1.16 - 1.33 (m, 2H) ppm; I3C NMR (75 MHz, CDCI3) b: 150.4, 80.0,
58.3,54.7,27.4, 27.2, 22.0, 19.1 ppm; HRMS (FAB) (M+H+) calcd for CgH140sNS:
144
236.0593, found 236.0608; Anal calcd for CgH130sNS: C 40.84% H 5.70%, found C
40.98% H 5.70%.
Alternatively, compound 247 was prepared by following procedure. To a solution of
oxathiazolidine 254 (300 mg, 1.37 mmol) in CH3CN (5 mL) was added sequentially,
ruthenium(III)chloride hydrate (catalytic amount), sodium periodate (439 mg, 2.05
mmol) and water (5 mL) at 0 DC. The reaction mixture was warmed to rt and was
stirred at ambient temperature for an additional 3 hrs. The reaction mixture was
extracted three times with Et20. The organic layers were combined, washed with
water, then brine, and dried over anhydrous magnesium sulfate. Filtration,
evaporation of the solvent, and purification by flash column chromatography
(hexanes : ethyl acetate, 4:1) afforded 287 mg (82%) of compound 247* as white
solid after recrystallization from hexanes/ethyl acetate. The analytical data obtained
for compound 247* is identical to data of compound 247.
249
trans-2-Methylcarbonylamino-cyclohexylester benzoic acid (249).
To a solution of benzoxathiazole 247 (550 mg, 2.34 mmol) in dry DMF (10 mL) was
added ammonium benzoate (651 mg, 4.68 mmol). The solution was heated at 55°C
until TLC analysis indicated full conversion of the starting material (18 hrs). The
solvent was evaporated and the residue was dissolved in THF (6 mL), three drops of
water and three drops of conc. H2S04 were added. The reaction mixture was stirred at
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rt for 3 hrs, before the pH was adjusted to 8, using saturated aqueous NaHC03
solution. The layers were separated and the aqueous .layer was extracted three times
with DCM. The organic layers were combined, washed with water and brine. The
solution was dried over anhydrous sodium sulfate and filtered. The solvent was
evaporated under reduced pressure and the residue was purified by flash column
chromatography (hexanes : ethyl acetate, 9:1) affording 265 mg (41%) of compound
249 as colorless oil. Rf 0.55 (hexanes : ethyl acetate, 2:1); IR (film) Vrnax: 3339,3064,
2940, 2861, 1714, 1538, 1452, 1320, 1279, 1235, 1115, 713 em-I; IH NMR (300
MHz, CDCI3) 3: 8.04 (d, J =7.5 Hz, 2H), 7.50 - 7.58 (m, 1H), 7.43 (t, J =7.5 Hz,
2H), 4.83 (m, 2H), 3.71 - 3.88 (m, 1H), 3.53 (s, 3H), 2.02 - 2.24 (m, 2H), 1.69 - 2.02
(m, 2H), 1.49 - 1.68 (m, 1H), 1.18 - 1.48 (m, 3H) ppm; I3C NMR (75 MHz, CDCI3)
8: 167.0, 156.8, 133.2, 130.3, 129.9, 128.5, 75.9, 54.5, 52.2, 32.6, 31.3, 24.6, 24.2
ppm; HRMS (FAB) (M+H+) calcd for C15H20N04: 278.1392, found 278.1382.
250
trans-2-((8)-3,3,3-Trifluoro-2-methoxy-2-phenylpropanoyloxy)
cyclohexylmethyl-carbamate (250).
To a solution of carbamic acid methyl ester 256 (40 mg, 0.23 mmol) dissolved in
DCM (3 mL) were added sequentially 1-ethyl-3-(-3'dimethylaminopropoyl)
carbodiimide'HCL (49 mg, 0.25 mmol),4-dimethylaminopyridin (3 mg, 0.02 mmol),
and (R)-(+)-Mosher's acid (54 mg, 0.23 mmol) at 0 °C. The reaction mixture was
cooled for one additional hour and the solution was stirred at rt for two days until
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TLC analysis indicated full consumption of starting material. The reaction mixture
was diluted with DCM and washed with saturated aqueous solution of NH4CI,
saturated aqueous solution of NaHC03, and brine. The organic layer was dried over
anhydrous magnesium sulfate, filtered and the solvent was evaporated under reduced
pressure. Flash column chromatography (hexanes : ethyl acetate, 2: 1) of the residue
afforded 31 mg (40%) of compound 250 as colorless oil.1H NMR (300 MHz, CDCI3)
8: 7.47 - 7.56 (m, 2H), 7.34 - 7.42 (m, 3H), 4.53 - 4.97 (m, 2H), 3.43 - 3.78 (m, 7H),
1.91 - 2.17 (m, 2H), 1.17 - 1.86 (m, 6H) ppm; 13C NMR (75 MHz, CDCI3) 8: 156.6,
156.5, 132.6, 129.93, 129.90, 128.8, 127.6, 125.5, 55.7, 54.2, 52.5, 52.3, 33.0, 32.8,
31.3, 30.9, 30.1, 29.3, 24.4, 24.2, 24.1 ppm; 19F (282 MHz, CDCI3) 8: -72.08 (3F), -
72.42 (3F).
cis-Hexahydro-2-oxide-3H-l,2,3-benzoxathiazole-3-carboxylic acid methyl ester
(254).
To a solution of thionylchloride (0.83 mL, 11.41 mmol) in CH3CN (60 mL) was
added a solution of carbamic acid methyl ester 248 (0.79 g, 4.56 mmol) in CH3CN
(20 mL) dropwise at -35°C over 10 min. The reaction mixture was stirred at -35 °C
for 5 min, before pyridine (1.84 mL, 22.82 mmol) was added dropwise. The reaction
mixture was warmed to rt over 3 hrs. The solvent was evaporated and the residue was
triturated with Et20. The suspension was filtered and the filtrate was concentrated
under reduced pressure. Purification of the residue by flash column chromatography
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(hexanes: ethyl acetate, 5:1) afforded 0.63 g (63%) of compound 254 as colorless oil.
Rf 0.75 (hexanes : ethyl acetate, 1:1); IR (film) Vrnax : 2943,2867, 1730, 1442, 1359,
1328, 1288, 1187, 1148 cm-I; IH NMR (300 MHz, CDCI3) (two rotamers) 8: 5.24 -
5.31 (bs, 0.66H), 4.66 (q, J = 4.0 Hz, 0.33H), 3.94 - 4.12 (m, IH), 3.84 (s, IH), 3.82
(s, 2H), 2.09 - 2.34 (m, 2H), 1.54 - 2.45 (m,4H), 1.33 - 1.52 (m, IH), 1.08 - 1.31 (m,
IH) ppm; 13C NMR (75 MHz, CDCI3) (two rotamers) 8: 152.9,85.0,80.0,55.6,54.1,
53.7, 53.6, 28.8, 28.4, 27.9, 26.8, 22.6, 22.2, 19.6, 19.5 ppm; MS (EI) m/z (%): 219
(12), 171 (16), 155 (29), 154 (26), 140 (65), 127 (44), 126 (13), 124 (16), 77 (100),
75 (16),64 (33); HRMS (EI) calcd for CgHI3N04S: 219.0565, found 219.0561.
256
trans-[2-Hydroxycyclohexyl]- carbamic acid methyl ester (256).
Methyl chloroformate (0.3 mL, 3.94 mmol) was added dropwise to a vigorously
stirred solution of trans-2-aminocyclohexanol hydrochloride (255) (0.5 g, 3.30 mmol)
and NaHC03 (0.83 g, 9.9 mmol) in a 1:1 mixture of CHCl3 and water (30 mL). The
mixture was stirred at rt for 1 hour, before the reaction mixture was neutralized with
IN HCl. The aqueous layer was extracted three times with DCM. The organic layers
were combined, washed with brine, and dried over anhydrous magnesium sulfate.
Filtration, evaporation of the solvent and recrystallization from hexanes/ethyl acetate
furnished the title compound as colorless solid (498 mg, 87%). mp 109 - 111°C
(hexanes/ethyl acetate); IR (film) Vrnax : 3436, 3156, 2942, 2863, 2253, 1708, 1517,
1452, 1517, 1452, 1384 cm-I; IH NMR (300 MHz, CDCI3) 8: 4.75 - 5.15 (bs, IH),
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3.66 (s, 3H), 3.21 - 3.46 (m, 1H), 2.98 - 3.18 (bs, 1H), 1.91 - 2.12 (m, 2H), 1.60 -
1.79 (m, 2H), 1.05 - 1.41 (m, 4H) ppm; I3C NMR (75 MHz, CDCI3) 8: 158.4, 75.6,
57.5,52.9,34.6,32.2,25.1,24.5 ppm; MS (EI) mlz (%): 173 (1),141 (18), 114 (75),
112 (22), 102 (12),98 (100), 88 (42), 69 (26), 56 (51), 51 (66); HRMS (EI) calcd for
CgHI5N03: 173.1052, found 173.1053; Anal calcd for CgHI5N03: C 55.47% H
8.73%, found C 55.16% H 8.73%.
257
cis-Hexahydro-2-oxide-3H-l,2,3-benzoxathiazole-3-carboxylic acid methyl ester
(257).
To a solution of'thionylchloride (0.84 mL, 11.55 rnrnol) in CH3CN (60 mL) was
added a solution of compound 256 (0.80 g, 4.62 rnrnol) in CH3CN (20 mL) dropwise
at - 35°C over 10 min. The reaction mixture was stirred at the same temperature for 5
min, before pyridine (1.8 mL, 23.11 rnrnol) was added dropwise. The reaction
mixture was warmed to rt over 3 hrs. The solvent was evaporated and the residue was
triturated with Et20. The suspension was filtered and the filtrate was concentrated
under reduced pressure. Flash column chromatography (hexanes : ethyl acetate, 5:1)
of the residue afforded the title product 257 as colorless solid (0.79 g, 78%). mp 51 -
54°C (hexanes/ethyl acetate); Rf 0.52 (hexanes : ethyl acetate, 2: 1); IR (film) Vrnax:
3368, 2954, 2254, 1733, 1572, 1444, 1384, 1328, 1300 cm-I; IH NMR (300 MHz,
CDCI3) 8: 4.71 (dt, J = 11.2, 4.1 Hz, 1H), 3.83 (s, 3H), 3.13 (dt, J = 13.4, 3.1 Hz, 1H),
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2.61 - 2.74 (m, 1H), 2.20 - 2.34 (m, 1H), 1.79 - 2.02 (m, 2H), 1.69 (dq, J = 11.9,4.2
Hz, 1H), 1.19 - 1.54 (m, 3H) ppm; I3C NMR (75 MHz, CDC13) 8: 154.7,86.8,63.2,
54.0, 29.8, 29.5, 24.3, 23.9 ppm; MS (EI) mlz (%): 219 (5), 140 (10), 114 (100), 81
(12),59 (24),44(17); HRMS (EI) calcd for CgHI3N04S: 219.0565, found 219.0565;
Anal calcd for CgHI3N04S: C 43.82% H 5.98%, found C 44.12% H 6.05%.
98
trans-Hexahydro-2,2-dioxide-3H-1,2,3-benzoxathiazole-3-carboxylic acid methyl
ester (98).
To a solution of oxathiazolidine 257 (140 mg, 0.64 mmol) in CH3CN (3 mL) was
added sequentially, ruthenium(lll)chloride hydrate (catalytic amount), sodium
periodate (205 mg, 0.96 mmol) and water (3 mL) at O°C. The reaction mixture was
warmed to rt and stirred at ambient temperature for an additional three hrs. The
reaction mixture was extracted three times with Et20. The organic layers were
combined and washed with water and brine, then dried over anhydrous magnesium
sulfate. Filtration, evaporation of the solvent and purification by flash column
chromatography (hexanes : ethyl acetate, 5: 1) afforded 130 mg (87%) of the title
compound 98 as colorless oil. Rf 0.55 (hexanes : ethyl aceate, 2: 1); IR (film) Vmax:
3367, 2958, 2870, 2255, 1746, 1444, 1384, 1329, 1299, 1193 cm-I; IH NMR (300
MHz, CDC13) 8: 4.39 (dt, J = 11.1, 4.2 Hz, 1H), 3.88 (s, 3H), 3.73 - 3.84 (m, IH),
2.59 - 2.73 (m, 1H), 2.19 - 2.31 (m, 1H), 1.81 - 2.05 (m, 2H), 2.05 (dq, J =12.2,4.1
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Hz, 1H), 1.30 - 1.58 (m, 3H) ppm; 13C NMR (75 MHz, CDCI3) 8: 151.6, 84.6,64.7,
54.9,29.0,28.3,23.7,23.5 ppm; MS (EI) m/z (%): 235 (1), 155 (37), 150 (100), 140
(12), 124 (13), 114 (19), 101 (52), 98 (26), 95 (22), 81 (44), 69 (24), 59 (53); HRMS
(EI) calcd for CgH13NOsS: 235.0514, found 235.0519. Anal calcd for CgH13NOsS: C
40.84% H 5.57%, found C 41.18% H 5.84%.
o
\\ 0HN-S~
:: \0°
258
trans-Hexahydro-2,2-dioxide-3H-1,2,3-benzoxathiazole (258).
To a solution of benzoxathiazole 98 (640 mg, 2.72 mmol) in DMF (5 mL) was added
ammonium benzoate (757 mg, 5.44 mmol) in one portion. The reaction mixture was
heated at 75°C until full conversion of starting material was indicated by TLC (24
hrs). The solvent was evaporated and the residue was dissolved in THF (3 mL). Three
drops of water and conc. H2S04 were added and the reaction was allowed to stir at 60
°C for 3 hrs. The mixture was cooled to rt and the pH of the reaction mixture was
adjusted to pH 9 using a saturated aqueous solution of NaHC03. The reaction mixture
was extracted three times with DCM. The organic layers were combined, washed
with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated
under reduced pressure and the residue was purified by flash column chromatography
(hexanes : ethyl acetate, 4: 1) affording 440 mg (91 %) of the title compound 258. mp
94 - 97°C (hexanes/ethyl acetate); Rf 0.60 (hexanes : ethyl acetate, 1:1); IR (film)
Vmax: 3256,2953,2869,1794,1642,1458,1448,1406,1364, 1342, 1331, 1278, 1231,
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1192, 1138, 1101, 1074, 1052, 1001,950 cm-I; IH NMR (300 MHz, CDCI3) 8: 4.91
(d, J =9.0 Hz, 1 H), 4.30 (dq, J =10.0,5.2 Hz, 1H), 3.41 - 3.47 (m, 1H), 2.20 - 2.27
(m, 1H), 2.09 - 2.18 (m, 1H), 1.84 - 1.97 (m, 2H), 1.70 (dq, J = 12.0,4.0 Hz, 1H),
1.36 - 1.44 (m, 3H) ppm; 13C NMR (75 MHz, CDCI3) 8: 90.1,63.2, 28.5, 27.7, 23.8,
23.4; HRMS (EI) calcd for C6H1IN03S: 177.0456, found 177.0454.
21
N"N-Diethyl-N-[[[[[(IR,2S ,5R)-5-methyl-2-(I-methylethyl) cyclohexyl]oxy]
carbonyl] amino]sulfonyl]-ethanaminium, inner salt (21).
To a stirred solution of chlorosulfonyl isocyanate (5.21 g, 36.8 mmol) in benzene (15
mL) was added a solution of (-)-menthol (5.00 g, 32 mmol) in benzene (15 mL)
dropwise over 30 min while keeping the internal temperature between 25 - 30 °C,
using an ice-water bath. The reaction mixture was then stirred at rt for an additional
30 min, before ice cold hexane (40 mL) was added while cooling the reaction mixture
to 0 - 5 °C. The product was filtered and washed with ice cold hexanes (2 x 20 mL)
and dried under reduced pressure to yield 8.29 g (87%) of (-)-menthol sulfamoyl
chloride as colorless crystals (87%). mp 86 - 88 °C (hexanes); [a]D23 -64.5 (c 0.8,
CHCI3); IH NMR (300 MHz, CDCI3) 8 8.38 - 8.55 (bs, 1H), 4.81 (td, J = 11.2, 4.6
Hz, 1H), 2.07 - 2.16 (m, 1H), 1.83 - 2.01 (m, 1H), 1.61 - 1.77 (m, 2H), 1.39 - 1.58 (m,
2H), 1.04 - 1.22 (m, 2H), 0.93 (t, J =6.8 Hz, 6H), 0.83 (d, J =6.8 Hz, 3H) ppm. (-)-
Menthol sulfamoyl chloride was used without further purification for the next step.
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To a stirred solution of triethylamine (6.53 mL, 47.0 mmol) in benzene (20 mL) was
added- a solution of (-)-menthol sulfamoyl chloride (7.00 g, 23.5 mmol) in benzene
(40 mL) dropwise over 1 hour, keeping the internal temperature between 10 - 15°C,
using an ice-water bath. The reaction mixture was stirred at rt for an additional 30
min and then filtered to remove the triethylamine hydrochloride salt. The filtrate was
evaporated under reduced pressure, then dissolved in THF (50 mL) at 30°C and
cooled to 0 - 5 °C and treated with hexanes (50 mL) to precipitate out 7.24 g (85%) of
the title compound 21 as a colorless solid. mp 87 - 89°C (THF/hexanes); [a]n23 -48.7
(c 0.48, CHCI3); IR (film) Vmax: 3426, 3020, 2958, 2872, 1682, 1457, 1389, 1369,
1340, 1285, 1253, 1216, 1105, 982, 922, 891 em-I; IH NMR (300 MHz, CDCI3) b:
4.51 (td, J = 11.0,4.6 Hz, 1H), 3.45 (q, J =7.7 Hz, 6H), 3.14 - 3.26 (m, 1H), 1.93 -
2.08 (m, 2H), 1.65 (d, J = 11.9 Hz, 2H), 1.30 - 1.44 (m, 11H), 0.92 - 1.03 (m,2H),
0.87 (t, J =7.7 Hz, 6H), 0.76 (d, J =6.6 Hz, 3H) ppm; I3C NMR (75 MHz, CDCI3) b:
157.7,76.4,50.7,47.3,46.7,41.3,34.6,31.8,26.4, 23.7, 21.2, 16.6,9.8,8.8 ppm.
23a 23b
(3aR,7as)-rel-2,2-Dioxide-3D-1,2,3-benzoxathiazole-3-carboxylic acid
hexahydro-5-methyl-2-(I-methylethyl)cyclohexyl ester (23a and 23b).
Following the general procedure for the reaction of oxiranes with menthyl Burgess
reagent using cyclohexene oxide (196 mg, 2.00 mmol) as starting material gave 215
mg (30%) of a 1: 1 mixture of diastereomers 23a and 23b after purification by flash
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column chromatography (hexanes : ethyl acetate, 15: 1 to 3: 1) as colorless oil. Rf 0.65
(hexanes : ethyl acetate, 3:1); [a]n23 -52.2 (c 1.00, CHC13); IR (film) Vmax: 3401,2958,
2873,2254, 1728, 1457, 1383, 1314,908,738 cm-I; IH NMR (300 MHz, CDC13) 8:
4.98 - 5.04 (bs, 1H), 4.73 (dt, J = 10.7,4.5 Hz, 1H), 4.15 - 4.27 (m, 1H), 2.28 - 2.40
(m,2H), 1.97 - 2.17 (m, 2H), 1.43 - 1.89 (m, 9H), 1.02 - 1.37 (m, 4H), 0.94 (d, J =
3.1 Hz, 3H), 0.92 (d, J =3.1 Hz, 3H), 0.80 (d, J =16.6 Hz, 3H) ppm; I3C NMR (75
MHz, CDC13) 8: 149.9,79.7,79.3,58.2,58.1,47.2,47.1,41.0,40.9, 34.3, 31.8, 27.6,
27.5, 27.4, 26.1, 23.5, 23.4, 22.30, 22.25, 21.3, 21.2, 19.3, 16.4, 16.3 ppm; HRMS
(EI) calcd for CI7H29NOsS: 359.1766, found 359,1761; Anal calcd for C 56.80% H
8.12%, found C 57.12% H 8.30%.
267a
~HC02M*()OB2
267b
(IR,2S,SR)-S-Methyl-2-(I-methylethyl)cyclohexyl ester, [(IR,2R)-2-
(benzoyloxy)cyclohexyl]-carbamic acid (16a) and (IR,2S,SR)-S-methyl-2-(I-
methylethyl)cyclohexylester,[(IS,2S)-2-benzoyloxy)cyclohexyl]-carbamic acid
(16b).
Following the general procedure for the syntheses of benzoates using a mixture of
23a and 23b (449 mg, 1.25 mmol) as starting materials gave a mixture of two
diastereomers 246 mg (49%), which was separated by flash column chromatography
(DCM: MeOH, 200:1). Compound 267a: mp 111 - 113 °C (ethyl acetate/hexanes);
Rf 0.50 (DCM : methanol, 100:1); [a]n20 -77.8 (c 1.05, CHC13); IR (film) Vmax: 3434,
3368, 3019, 2954, 2868, 1711, 1603, 1585, 1513, 1452, 1370, 1318, 1279, 1216,
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1115, 1038, 1028, 757, 712,668 em-I; IH NMR (300 MHz, CDCI3) 8: 8.07 (d, J =7.7
Hz, 2H), 7.55 (t, J =7.2 Hz, IH), 7.43 (t, J =7.7 Hz, 2H), 4.83 (dt, J = 10.6,4.5 Hz,
1H), 4.59 (d, J =9.3 Hz, 1H), 4.34 - 4.46 (m, 1H), 3.76 - 3.90 (m, 1H), 2.07 - 2.19
(m, 2H), 1.73 - 1.93 (m, 3H), 1.13 - 1.69 (m, 10H), 0.91 - 1.06 (m, 1H), 0.86 (d, J =
10.0 Hz, 3H), 0.75 (d, J = 6.6 Hz, 3H), 0.46 - 0.68 (m, 4H); I3C NMR (75 MHz,
CDCI3) 8 167.1, 156.5, 133.4, 130.6, 130.2, 128.7,76.6,74.7,54.3,47.5,41.2, 34.6,
32.8,31.5,26.6,25.0, 24.5, 23.8, 22.2, 21.1, 16.8; HRMS (EI) ealed for C24H3SN04:
401.2566, found 401.2579; Anal ealed for C24H3SN04:C 71.79% H 8.79%, found C
71.82% H 8.80%. Compound 267b: mp 138 - 141 °C (ethyl aeetate/hexanes); Rf
0.45 (DCM : MeOH, 100:1); [a]n20 -15.8 (c 1.05, CHCI3); IR (film) Vrnax : 3685,3435,
3020,2956,2869, 1711, 1515, 1452, 1318, 1279, 1216, 1115, 1039,929,759,714,
669 em-I; IH NMR (300 MHz, CDCI3) 8: 8.05 (d, J =7.7 Hz, 2H), 7.55 (t, J =7.1 Hz,
1H), 7.43 (t, J =7.7 Hz, 2H), 4.86 (dt, J =10.6,4.5 Hz, 1H), 4.69 (d, J =9.3 Hz, 1H),
4.35 - 4.49 (m, 1H), 3.73 - 3.90 (m, 1H), 2.12 (d, J =12.5 Hz, 2H), 1.98 (d, J =11.9
Hz, 1H), 1.73 - 1.88 (m, 2H), 1.08 - 1.68 (m, 10H), 0.79 - 0.97 (m, 5H), 0.55 (d, J =
6.4 Hz, 3H), 0.30 (d, J =6.4 Hz, 3H) ppm; I3C NMR (75 MHz, CDCI3) 8: 167.2,
156.3, 133.3, 130.4, 130.1, 128.7,76.0,74.6,54.4,47.6,41.8,34.6,33.2,31.7,31.6,
26.5, 24.9, 24.5, 23.9, 22.4, 20.7, 16.3 ppm; HRMS (EI) calcd for C24H3SN04:
401.2566, found 401.2575; Anal ealed for C24H3SN04: C 71.79% H 8.79%, found C
71.84% H 8.76%.
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268
[(lR,2R)-2,3-Cyclohexenyl]-carbamic acid menthol ester (268).
Additionally to the isolation of compounds 267a and 267b, a 1: 1 mixture of two
diastereomers (164 mg, 47%) of compound 268 wast obtained as colorless oil. Rf 0.55
(hexanes : ethyl acetate, 5:1); [a]n20 (+/-) 0 (c 1.00, CHCl3); IR (film) Vmax: 3323,
3026, 2938, 2838, 1699, 1529, 1450, 1310, 1241, 1193 cm-I; IH NMR (300 MHz,
CDCl3) 8: 5.75 (d, J =9.5 Hz, 1H), 5.54 (d, J =9.5 Hz, 1H), 4.35 - 4.59 (m, 2H), 4.00
- 4.17 (m, 1H), 1.76 - 2.04 (m, 5H), 1.51 - 1.65 (m, 4H), 1.34 - 1.50 (m, 2H), 1.15 -
1.29 (m, 1H), 0.77 - 1.07 (m, 9H), 0.73 (d, J = 6.7 Hz, 3H); I3C NMR (75 MHz,
CDCl3) 8: 156.1, 130.9, 128.4, 74.4, 47.8, 46.5, 41.9, 34.7, 31.7, 30.2, 26.7, 26.6,
25.2, 24.0, 23.9, 22.4, 21.2, 20.0, 16.9 ppm; HRMS (EI) calcd for C17H29N02:
279.2198, found 279.2194.
(+)-269a
(3aR, 7aR)-3H-Hexahydrobenzoxazolidin-2-one (269a).
Benzoic acid 2-menthylcarbonylamino-cyclohexylester 267a (260 mg, 0.65 mmol)
was dissolved in 1M NaOH in MeOH (30 mL) and the reaction mixture was stirred at
rt for 10 hrs. The reaction mixture was diluted with water (30mL) and extracted three
times with DCM. The organic layers were combined, washed with brine, dried over
anhydrous magnesium sulfate, filtered and the solvent was evaporated. Flash column
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chromatography (hexanes : ethyl acetate, 4: 1) of the residue afforded [(lR,2R)-2-
hydroxycyclohexyl]-carbamic acid menthol ester as colorless solid (152 mg, 79%).
mp 130 - 132°C (hexanes/ethyl acetate); Rf O.15 (hexanes: ethyl acetate, 1:1); [a]D20
-53.7 (c 1.35, CHCI3); IR (film) Vmax: 3685, 3620, 3020, 2870, 2401, 1693, 1510,
1477, 1451, 1423, 1215, 1046, 1024,929 cm-I; IH NMR (300 MHz, CDCI3) 8: 4.60 -
4.79 (bs, 1H), 4.53 (dt, J = 11.2, 4.0 Hz, 1H), 3.21 - 3.44 (m, 2H), 3.00 - 3.21 (bs,
1H), 1.79 - 2.09 (m, 4H), 1.54 - 1.75 (m, 2H), 1.38 - 1.53 (m, 2H), 0.66 - 1-38 (m,
17H) ppm; I3C NMR (75 MHz, CDCI3) 8: 158.1,75.8,75.4,57.2,47.7,41.7,34.6,
34.5, 32.2, 31.7, 26.6, 25.0, 24.4, 23.8, 22.4, 21.2, 16.8 ppm; MS (EI) m/z (%): 297
(1), 158 (10), 139 (27), 138 (17), 115 (19), 114 (28), 98 (100), 97 (21), 96 (19), 95
(23), 83 (90), 82 (14), 81 (43),71 (21), 70 (10), 69 (46), 67 (13); HRMS (EI) calcd
for CI7H3IN03: 279.2304, found 297.2298; Anal calcd for CI7H3IN03: C 68.65% H
10.51 %, found C 68.65% H 10.81 %.
[(lR,2R)-2-Hydroxycyclohexyl]- carbamic acid menthyl ester (140 mg, 0.47 mmol)
was dissolved in THF (5 mL) and sodium hydride (42 mg, 1.04 mmol) was added in
one portion. The reaction mixture was heated at reflux for 12 hrs until TLC indicated
complete conversion of starting material. The reaction mixture was quenched by the
addition of an aqueous saturated solution of NH4Cl. The aqueous layer was extracted
three times with ethyl acetate. The organic layers were combined, washed with brine,
dried over anhydrous magnesium sulfate, filtered, and the solvent was evaporated.
Flash column chromatography (hexanes : ethyl acetate, 2: 1 to 1: 1) of the residue
afforded (+)-269 as colorless solid (55 mg, 83%). mp 133 - 134°C (hexanes/ethyl
actate); [a]D22 +7.5 (c 1.0, EtOH); Rf 0.45 (hexanes : ethyl acetate, 1:1); IR (film)
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Vmax: 3684,3622,3020,1757,1521,1476,1423,1215,1034,929 cm-I; IH NMR (300
MHz, CDCI3) 8: 5.96 - 6.19 (bs, 1H), 3.81 (dt, J = 11.1,4.3 Hz, 1H), 3.16 - 3.33 (m,
1H), 2.05 - 2.20 (m, 1H), 1.93 - 2.05 (m, 1H), 1.67 - 1.90 (m, 2H), 1.49 - 1.65 (m,
1H), 1.14 - 1.47 (m, 3H) ppm; I3C NMR (75 MHz, CDCI3) 8: 161.2,84.2,61.3, 29.5,
28.9,24.1,23.9 ppm; MS (EI) m/z (%): 141 (32), 140 (11), 99 (6), 96 (5), 69 (42), 57
(15), 56 (100), 54 (8), 43 (40); HRMS (EI) calcd I for C7HIIN02: 141.0790, found
141.0788.
(-)-269b
(3aS, 7as)-3H-Hexahydrobenzoxazolidin-2-one (269b).
Benzoic acid 2-menthylcarbonylamino-cyclohexylester 267b (270 mg, 0.67 mmol)
was dissolved in 1M NaOH in MeOH (30 ml) and the reaction mixture was stirred at
rt for 10 hrs. The reaction mixture was diluted with water (30 mL) and extracted three
times with DCM. The organic layers were combined, washed with brine, dried over
anhydrous magnesium sulfate and the solvent was evaporated. Flash column
chromatography (hexanes : ethyl acetate, 4:1) of the residue afforded [(lS,2S)-2-
hydroxycyclohexyl]- carbamic acid menthol ester as colorless solid (179 mg, 89%).
mp 151 - 153°C (hexanes/ethylacetate); Rf 0.15 (hexanes : ethyl acetate, 1:1); [a]n 20
-58.2 (c 1.2, CHCI3); IR (film) Vmax: 3684,3621,3437,3020, 2939, 2869, 2400, 1693,
1510, 1477, 1451, 1424, 1389, 1215, 1046, 1023, 929 cm-I; IH NMR (300 MHz,
CDCI3) 8: 4.62 - 4.85 (bs, 1H), 4.55 (dt, J = 11.1,4.2 Hz, 1H), 3.21 - 3.42 (m, 2H),
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2.98 - 3.21 (bs, IH), 1.81 - 2.14 (m, 4H), 1.56 - 1.80 (m, 2H), 1.39 - 1.55 (m, 2H),
0.60 - 1.39 (m, 17H) ppm; 13C NMR (75 MHz, CDCI3) 8: 158.2, 75.8, 75.5, 57.3,
47.9, 41.8, 34.6, 34.5, 32.1, 31.8, 26.6, 25.0, 24.4, 23.8, 22.4, 21.2, 16.8 ppm; MS
(EI) m/z (%): 297 (1), 160 (8), 159 (8), 158 (9), 139 (24), 138 (17), 115 (19), 114
(28),98 (100), 97 (22),96 (23), 95 (30),83 (96), 82 (18),81 (49),71 (29), 70 (13),69
(54), 67 (17); HRMS (EI) calcd for C17H31N03: 279.2304, found 297.2303; Anal
calcd for C17H31N03: C 68.65% H 10.51%, found C 68.82% H 10.79%.
Following the same procedure as for the preparation of compound (+)-269a using
[(lS,2S)-2-hydroxycyclohexyl]-carbamic acid menthol ester (160 mg, 0.54 mmol)
and sodium hydride (32 mg, 1.33 mmol) as starting materials, gave 62 mg (82%) of
compound (-)-269b as colorless crystals. mp 131 - 133°C (hexanes/ethyl acetate);
[a]D 22 -7.4 (c 1.1, EtOH); HRMS (EI) calcd for C7H11N02: 141.0790, found
141.0785.
270a
(3aR, 7aR)-3-((S)-3,3,3-Trifluoro-2-methoxy-2-phenylpropanoyl)-
hexahydrobenzo[d]oxazol-2(3H)-one (270a).
To a solution of cyclic carbamate 269a (20 mg, 0.14 mmol) in THF (2 mL) at 0 °c
was added n-BuLi (2M in THF, 78 J.!L, 0.16 mmol) and the reaction mixture was
stirred at the sa~e temperature for one hour, before it was cooled to -78°C. (S)-(+)-
Mosher's chloride (43 mg, 0.17 mmol) was added and the reaction mixture was
159
warmed to rt over 14 hrs. The reaction was quenched by the addition of a saturated
aqueous solution of NH4Cl. The aqueous layer was extracted three times with ethyl
acetate. The organic layers were combined, washed with brine and dried over
anhydrous sodium sulfate. The organic layer was filtered and the solvent was
evaporated. The crude residue was analyzed by I9F NMR (282 MHz, CDCI3) 8: -
72.61 (IF), - 69.31 (0.035F). Compound 270b as well as a racemic standard were
prepared in the same manner, using 269b and a racemate of 269 as starting materials.
Compound 270b: I9F NMR (282 MHz, CDCI3) 8: - 72.61 (not detected), - 69.30 (IF),
Compound 270: - 72.61 (IF), - 69.30 (IF). The results were confirmed by GC/MS
analysis.
272a 272b
(3aR,6aS)-rel-2,2-Dioxide-3(3aH)-cyclopent-l,2,3-oxathiazolecarboxylic acid
tetrahydro-S-methyl..2-(I-methylethyl)cyclohexyl ester (272a and 272b).
Following the general procedure for the reaction of oxiranes with menthyl Burgess
reagent 21, using cyclopentene oxide (168 mg, 2.00 mmol) as starting material gave
305 mg (37%) of a 1:1 mixture of diastereomers after purification by flash column
chromatography (hexanes : ethyl acetate, 15: 1 to 3: 1). colorless oil; Rf 0.81 (hexanes :
ethyl acetate, 2:1); [a]D23 -79.2 (c 1.02, CHCI3); IR (film) Vrnax: 3400, 3019, 2962,
2400, 1731, 1522, 1423, 1383, 1307, 103-0,669 cm- I ; IH NMR (300 MHz, CDCI3) 8:
5.21 (t, J =5.3 Hz, 1H), 4.74 (dt, J = 10.9,4.4 Hz, 1H), 4.55 - 4.63 (m, 1H), 2.08 -
2.15 (m, 5H), 1.81 - 1.89 (m, 2H), 1.66 - 1.74 (m, 2H), 1.42 - 1.50 (m, 2H), 1.10 -
160
1.18 (m, 2H), 0.88 - 0.95 (m, 7H), 0.76 - 0.85 (m, 3H) ppm; I3C NMR (75 MHz,
CDCI3) 8: 150.1,83.8, 79.1, 78.3, 71.2, 61.4, 61.3, 46.7, 40.6, 40.5,33.9,32.75,32.7,
32.3,31.4,31.4,26.2,26.0,25.6,23.3,23.2,22.9, 22.6, 21.9, 20.8, 20.8 ppm; HRMS
(FAB) (M+H+) calcd for CI6H27NOsS: 346.1688, found 346.1659.
273a
~HC02M*C!'0BZ
273b
(IR,2S,5R)-5-Methyl-2-(I-methylethyl)cyclohexyl ester trans-2-
(benzoyloxy)cyclopentyl]-carbamic acid (273a and 273b).
Following the general procedure for the syntheses of benzoates using a mixture of
272a and 272b (433 mg, 1.25 mmol) as starting material gave a mixture of two
diastereomers (252 mg, 52%), which were separated by flash column
chromatography (DCM : MeOH, 200:1). Diastereomer 1: mp 85 - 86°C (ethyl
acetate/hexanes); Rf 0.73 (DCM: MeOH; 400:1); [a]n23 -99.6 (c 1.00, CHCI3); IR
(film) Vrnax : 3684,3019,2961,2400,1711,1512,1424,1031,929,669, 627 cm-I; IH
NMR (300 MHz, CDCI3) 8: 8.03 (d, J = 7.2 Hz, 2H), 7.42 - 7.52 (m, 3H), 5.16 (q, J =
5.8 Hz, 1H), 4.91 (bs, 1H), 4.40 - 4.48 (m, 1H), 4.03 - 4.12 (m, 1H), 2.19 - 2.23 (m,
2H), 1.73 - 1.85 (m, 5H), 1.51 - 1.58 (m, 7H), 1.20 - 1.25 (m, 2H), 0.67 - 0.85 (m,
7H) ppm; I3C NMR (75 MHz, CDCI3) 8: 156.0, 132.9, 130.2, 129.7, 128.3, 80.4,
75.0,47.3,41.3, 34.2, 31.3, 26.2, 22.0, 20.8 ppm; HRMS (FAB) (M+H+) calcd for
C23H33N04: 388.2488, found 388.2474. Diastereomer 2: mp 86 - 89°C (ethyl
acetate/hexanes); Rf 0.70 (DCM : MeOH, 400:1); [a]n23 -5.59 (c 1.05, CHCI3); IR
(film) Vrnax : 3436,3019,2960,2400,1711,1512,1037,929,669 cm-I; IH NMR (300
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MHz, CDCl3) 8: 8.02 (d, J =6.9 Hz, 2H), 7.50 - 7.57 (m, 3H) 5.11 - 5.19 (m, 1H),
4.78 - 4.82 (m, 1H), 4.52 - 4.57 (m, 1H), 4.11 - 4.14 (m, 1H), 2.11 - 2.21 (m,2H),
1.80 - 1.83 (m, 1H), 1.72 - 1.79 (m, 4H), 1.46 - 1.58 (m, 6H), 1.38 - 1.45 (m,4H),
0.80 - 1.25 (m, 6H) ppm; 13C NMR (75 MHz, CDCl3) 8: 156.0, 132.9, 130.2, 129.7,
128.3, 80.1, 74.7, 47.3, 41.4, 34.2, 31.3, 29.7, 26.2, 23.5, 22.0, 20.7, 16.3 ppm;
HRMS (FAB) (M+H+) calcd for C23H33N04: 388.2488, found 388.2481.
275a 275b
(3aR,8aS)-rel- 2,2-Dioxide-cyclohept-l,2,3-oxathiazole-3(3aH-)carboxylic acid
hexahydro-5-methyl-2-(I-methylethyl)cyclohexyl ester (275a and 275b).
Following the general procedure for the reaction of oxiranes with menthyl Burgess
reagent 21, using cyclohepteneoxide (224 mg, 2.00 mmol) as starting material gave
211 mg (35%) .of a 1: 1 mixture of diastereomers after purification by flash column
chromatography (hexanes : ethyl acetate, 15: 1 to 4: 1). colorless oil; Rf 0.57 (hexanes :
ethyl acetate, 4:1); [a]n23 -60.5 (c 0.75, CHCl3); IR (film) Vmax: 2958, 2931, 1729,
1457, 1381, 1332, 1307, 1190 cm- l ; IH NMR (300 MHz, CDCl3) 8: 5.00 - 5.17 (m,
1H), 4.72 (dt, J = 11.0,4.5 Hz, 1H), 4.21 - 4.36 (m, 1H), 2.20 - 2.37 (m, 1H), 1.63 -
2.18 (m, 10H), 1.35 - 1.58(m, 4H), 1.03 - 1.33 (m, 3H), 0.85 - 1.00 (m, 8H), 0.71 -
0.84 (m, 3H) ppm; 13C NMR (75 MHz, CDCl3) 8: 149.8, 149.8, 81.6, 81.6, 79.1,
79.0,63.1,63.0,46.8,46.7,40.6,40.5,33.9,31.5, 31.4, 30.2,30.2,29.2,28.6,28.5,
26.0, 25.9, 25.6, 23.3, 22.9, 22.6, 21.9, 21.6, 20.9, 20.8, 15.8 ppm; MS (FAB) mlz
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(%) 374 (M+H+): 139 (52), 137 (22),97 (19),95 (44), 83 (100), 81 (37),79 (11),77
(12), 69 (46), 67 (21), 57 (36), 55 (62), 53 (14); HRMS (FAB) (M+H+) calcd for
CI8H33NOsS: 374.2001, found 374.2018.
(IR,2S,5R)-5-Methyl-2-(I-methylethyl)cyclohexyl ester trans-2-
(benzoyloxy)cycloheptyl]-carbamic acid (276a and 276b).
Following the general procedure for the syntheses of benzoates using a mixture of
275a and 275b (468 mg, 1.25 mmol) as starting materials gave a mixture of two
diastereomers 276a and 276b 389 mg (75%), which were separated by flash column
chromatography (DCM : MeOH, 200: 1). Diastereomer 1: mp 89 - 91°C (ethyl
acetate/hexanes); Rf 0.55 (DCM : MeOH, 100:1); [a]D23 -105.1 (c 0.8, CHCI3); IR
(film) Vmax: 3363, 2930, 2867, 1714, 1602, 1585, 1526, 1452, 1370, 1316, 1279,
1239,1179, 1117, 1070, 1028 cm-I; IH NMR (600 MHz, CDCI3) 8: 7.98 (d, J =7.5
Hz, 2H), 7.46 (t, J =7.5 Hz, IH), 7.35 (t, J =7.5 Hz, 2H), 4.91 (dt, J =9.0, 3.4 Hz,
IH), 4.63 (d, J = 9.2 Hz, IH), 4.28 - 4.36 (m, IH), 3.83 - 3.93 (m, IH), 1.85 - 1.94
(m, 2H), 1.74 - 1.93 (m, 2H), 1.47 - 1.71 (m, 10H), 1.36 - 1.44 (m, IH), 1.16 - 1.27
(m, IH), 0.89 - 1.02 (m, IH), 0.81 - 0.88 (m, 2H), 0.77 (d, J = 7.0 Hz, 3H), 0.67 (d, J
= 6.8 Hz, 3H), 0.56 - 0.61 (m, 3H) ppm; I3C NMR (150 MHz, CDCI3) 8: 166.5,
155.9, 132.9, 130.3, 129.8, 128.3, 127.8,78.4,74.4,56.2,47.2,40.9,34.2,32.0,31.2,
26.2, 25.9, 23.9,23.5,22.4,21.9, 20.7, 16.5 ppm; MS (EI) m/z (%): 415 (1), 137 (13),
123 (11),111 (20),105 (100),97 (11),95 (27), 83 (44), 82 (11),81 (20),77 (23),71
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(25), 69 (26), 67 (10), 57 (29), 56 (26), 55 (30); HRMS (EI) calcd for C25H37N04:
415.2723, found 415.2715. Diastereomer 2: mp 121 - 124°C (ethyl
acetate/hexanes); Rf 0.50 (DCM : MeOH, 100:1); [a]n23 -37.6 (c 0.75, CHCI3); IR
(film)vm~:3369,2928,2866, 1714, 1524, 1452, 1369, 1315, 1279, 1180, 1116, 1070,
1028 cm-I; IH NMR (600 MHz, CDCI3) 8: 7.96 (d, J =7.4 Hz, 2H), 7.47 (t, J =7.4
Hz, IH), 7.35 (t, J = 7.4 Hz, 2H), 4.93 (dt, J = 8.7, 3.7 Hz, IH), 4.69 - 4.77 (m, IH),
4.29 - 4.40 (m, IH), 3.85 - 3.94 (m, IH), 1.77 - 1.93 (m,4H), 1.64 - 1.74 (m, 2H),
1.43 - 1.62 (m, 8H), 1.31 - 1.41 (m, IH), 1.04 .. 1.11 (m, IH), 0.76 - 0.88 (m, 5H),
0.66 - 0.73 (m, IH), 0.49 (d, J = 5.3 Hz, 3H), 0.27 (d, J = 0.48 Hz, 3H) ppm; I3C
NMR (150 MHz, CDCI3) 8: 166.6, 155.8, 132.9, 130.3, 129.7, 128.3, 127.8, 78.2,
74.3, 56.5,47.3, 41.5, 34.3, 32.2, 31.3, 27.5, 26.2, 24.0, 23.6, 22.4, 22.0, 20.4, 16.1
ppm; MS (EI) mlz (%): 415 (1), 155 (10), 138 (18), 137 (14), 123 (16), 111 (20), 105
(100),97 (11),96 (12), 95 (43),94 (10), 83 (47), 82 (16),81 (31),77 (23),71 (28),69
(34), 67 (14), 57 (32), 56 (25), 55 (37); HRMS (EI) calcd for C25H37N04: 415.2723,
found 415.2720.
q\~O q\~OM*02C~N-S\O~ M"02C~-S:
,.",0\
C4Hg C4Hg
278a 278b
2,2-Dioxide-l,2,3-oxathiazolidine-3-carboxylic acid 5-butyl-(lR,2S,SR)-S-methyl-
2-(1-methylethyl)cyclohexyl ester (278a and 278b).
Following the general procedure for the reaction of oxiranes with menthyl Burgess
reagent using 2-butyloxirane (200 mg, 2.00 mmol) as starting material gave 159 mg
(22%) of a 1: 1 mixture of diastereomers 278a and 278b after purification by flash
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column chromatography (hexanes : ethyl acetate, 20: 1 to 5: 1). colorless oil; Rf 0.68
(hexanes : ethyl acetate, 5:1); [a]D23 -51.7 (c 2.3, CHC13); IR (film) Vrnax: 3019,2961,
2400, 1730, 1384, 1316, 1215, 1046, 928, 724, 669 cm-I; IH NMR (300 MHz,
CDC13) 8: 4.71 - 4.84 (m, 1H), 4.58 - 4.71 (m, 1H), 3.90 - 4.09 (m, 1H), 3.57 - 3.71
(m, 1H), 2.10 (m, 3H), 1.52 - 1.77 (m,4H), 1.25 - 1.53 (m, 6H), 1.16 - 1.23 (s, 3H),
0.92 - 1.12 (m, 2H), 0.85 - 0.91 (m, 6H), 0.70 - 0.74 (m, 3H) ppm; I3C NMR (75
MHz, CDC13) 8: 149.8,79.9,79.2,50.6,46.7,40.5, 33.9, 32.1,31.4,29.7,26.6,25.8,
23.1,22.1,21.9,20.8,16.0,13.7 ppm; MS (EI) mlz (%) 361 (1), 176 (44),83 (88),42
(60),43 (39),54 (31), 55 (61); HRMS (EI) calcd for CI7H3INOsS: 361.1923, found
361.1920.
NHC02M*~,'OBZ
C4Hg
279a
~HC02M*
,-<OBZ
C4Hg
279b
(lR,2S,SR)-S-Methyl-2-(1-methylethyl)cyclohexyl ester [2-(benzoyloxy)hexyl]-
carbamic acid (279a and 279b).
Following the general procedure for the syntheses of benzoates using a mixture of
278a and 278b (451 mg, 1.25 mmol) as starting materials gave a mixture of two
diastereomers (181 mg, 36%), which were inseparable by flash column
chromatography. Mixture of two diastereomers: colorless solid; mp 121 - 124°C
(ethyl acetate/hexanes); Rf 0.50 (DCM : MeOH, 100:1); [a]n23 -37.6 (c 0.75, CHC13);
IR (film) Vrnax: 3684, 3401, 3019, 2961, 2400, 1713, 1517, 1423, 1215, 1046, 929,
641,669,627 cm-I; IH NMR (300 MHz, CDC13) 8: 7.97 (d, J =7.3, 2H), 7.46 - 7.54
(m, 1H), 7.33 - 7.43 (m, 2H), 5.03 - 5.20 (m, 1H), 4.70 - 4.86 (m, 1H), 4.35 - 4.54 (m,
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1H), 3.33 - 3.49 (m, 2H), 1.88 - 2.01 (m, 1H), 1.72 - 1.88 (m, 2H), 1.46 - 1.73 (m,
6H), 1.23 - 1.44 (m, 6H), 1.08 - 1.22 (m, 2H), 0.90- 1.06 (m, 2H), 0.77 - 0.88 (m,
3H), 0.64 - 0.75 (m, 4H), 0.58 (d, J = 6.9 Hz, 1H) ppm; I3C NMR (75 MHz, CDCl3)
8: 163.9, 154.0, 130.6, 127.2, 125.9, 72.2, 71.7, 44.9, 41.9, 38.9, 31.8, 29.0, 28.9,
28.8, 24.9, 23.8, 21.1, 20.1, 19.6, 18.3, 13.9, 13.9, 11.5 ppm; MS (EI) m/z (%) 403
(1),221 (15), 176 (13), 55 (61),54 (31),43 (37); HRMS (EI) calcd for C24H37N04:
403.2723, found 403.2720.
281a 281b
(3aR,7as)-rel-2,2-Dioxo-3a,6,7,7a-tetrahydro-2A6-'1,2,3-benzoxathiazole-3-
carboxylic acid-(IR,2S,SR)-2-isopropyl-S-methyl-cyclohexyl ester (281 and 281b).
Following the general procedure for the reaction of oxiranes with menthyl Burgess
reagent using cyclohexadiene oxide (192 mg, 2.00 mmol) as starting material gave
257 mg (36%) of a 1: 1 mixture of diastereomers 281a and 281b after purification by
flash column chromatography (hexanes : ethyl acetate, 15:1 to 3:1). white solid; mp
115 - 118 °C (hexanes/ethyl acetate); Rf 0.55 (hexanes : ethyl acetate, 4:1); [a]n23 -
54.5 (c 1.25, CHCl3); IR (film) Vmax: 3443, 3031, 2959, 2930, 2873, 1731, 1599,
1457, 1432, 1371, 1331, 1307, 1241, 1217, 1189, 1170, 1125 cm-I; IH NMR (300
MHz, CDCl3) (two rotamers) 8: 6.02 - 6.28 (m, 1H), 5.56 - 5.85 (m, 1H), 5.13 - 5.33
(m, 1H), 4.66 - 4.84 (m, 2H), 1.82 - 2.44 (m, 5H), 1.39 - 1.75 (m, 5H), 1.00 - 1.31 (m,
3H), 0.87 - 0.96 (m, 6H), 0.74 - 0.85 (m, 3H), ppm; I3C NMR (75 MHz, CDCl3) (two
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rotamers) 8: 147.9,135.0,129.5,119.0,117.9,81.7,81.6,79.2, 75.5, 75.3, 75.1, 74.6,
72.9, 72.8, 53.2, 53.2, 51.5, 45.2, 44.9, 44.8,44.7,38.6,37.9, 37.7, 32.0, 29.5, 29.3,
29.3, 24.2, 23.9, 23.7, 22.6, 22.1, 21.2, 20.3, 19.9, 18.9 18.8, 18.7 ppm; HRMS (EI)
calcd for CI7H27NOsS: 357.1610, found 357.1593.
282a
~HC02M*UOBZ
282b
(IS,6R)-(6-Hydroxy-cyclohex-2-enyl)-carbamic acid (IR,2S,5R)-2-isopropyl-5-
methyl-cyclohexyl ester (282a) and (IR,6S)-(6-hydroxy-cyclohex-2-enyl)-
carbamic acid (IR,2S,SR)-2-isopropyl-5-methyl-cyclohexyl ester (282b).
Following the general procedure for the syntheses of benzoates using a mixture of
281a and 281b (446 mg, 1.25 mmol) as starting materials gave a mixture of two
diastereomers 254 mg (51 %), which were separated by flash column chromatography
(DCM : MeOH, 400:1). Compound 282a: mp 103 - 105°C (ethyl aeetate/hexanes);
Rf 0.67 (DCM : MeOH, 400:1); [a]D 23 -100.8 (c 0.25, CHCI3); IR (film) Vmax: 3436,
3019,2962, 1713, 1602, 1511, 1424, 1277, 1117, 1048, 1028 em-I; IH NMR (300
MHz, CDCI3) 8: 8.07 (d, J =7.4 Hz, 2H), 7.56 (t, J =7.4 Hz, 1H), 7.44 (t, J =7.8 Hz,
2H), 5.85 (d, J = 10.2 Hz, 1H), 5.69 (dd, J = 9.5, 1.5 Hz, 1H), 5.04 - 5.11 (m, 1H),
4.66 (d, J =9.2 Hz, 1H), 4.52 - 4.62 (m, 1H), 4.46 (dt, J =10.7, 3.9 Hz, 1H), 2.25 -
2.28 (m, 2H), 2.08 - 2.11 (m, 1H), 1.96 - 2.00 (m, 1H), 1.88 - 1.93 (m, 1H), 1.59 -
1.72 (m, 4H), 1.26 - 1.42 (m, 2H), 1.21 - 1.25 (m, 1H), 0.98 - 1.04 (m, 1H), 0.87 (d, J
=7.1 Hz, 3H), 0.78 (d, J =6.6 Hz, 3H), 0.72 (d, J =5.8 Hz, 3H) ppm; I3C NMR (75
MHz, CDCI3) 8: 166.5, 156.2, 133.0, 130.2, 129.8, 129.5, 128.4, 128.3, 126.8, 77.2,
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74.8, 73.9, 51.7, 47.2, 41.0, 34.2, 31.2, 26.4, 26.3, 24.0, 23.5, 21.9, 20.8, 16.5 ppm;
HRMS (EI) calcd for C24H33N04: 399.2410, found 399.2403; Anal calcd for
C24H33N04: C 72.15% H 8.33%, found C 72.42% H 8.44%. Compound 282b: mp
107 - 109°C (ethyl acetate/hexanes); Rf 0.62 (DCM : MeOH, 400:1); [a]D23 +16.2 (c
0.4, CHCI3); IR (film) Vrnax: 3369,3033,2954,2928,2869, 1714, 1523, 1277, 1241,
1116, 1027 cm-I; IH NMR (600 MHz, CDCI3) b: 8.00 (d, J = 7.2 Hz, 2H), 7.56 (t, J =
7.5 Hz, 1H), 7.44 (t, J =7.8 Hz, 2H), 5.84 (d, J =8.6 Hz, 1H), 5.59 (dq, J =9.8, 2.2
Hz, 1H), 5.04 - 5.12 (m, 1H), 4.70 (d, J = 9.5 Hz, 1H), 4.55 - 4.61 (m, 1H), 4.49 (td, J
= 10.8, 3.7 Hz, 1H), 2.23 - 2.29 (m, 2H), 2.06 - 2.13 (m, 1H), 1.91 - 2.03 (m, 2H),
1.54 - 1.71 (m, 3H), 1.41 - 1.49 (m, 1H), 1.21 (t, J = 11.5 Hz, 1H), 0.85 - 0.97 (m,
6H), 0.65 (d, J = 6.6 Hz, 3H), 0.42 (d, J = 6.6 Hz, 3H) ppm; I3C NMR (75 MHz,
CDCI3) b: 166.5 156.0, 132.9, 130.1, 129.8, 129.3, 128.3, 127.0, 74.5, 73.7, 51.7,
47.3,41.4,34.2,31.3,26.6,26.2,24.0,23.5,22.0, 20.5,16.1 ppm; HRMS (EI) calcd
*MO
~N 0a \-7
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Compound 283.
Styrene oxide (500 mg, 4.16 mmol) and menthyl Burgess Reagent 21 (2.85 g, 9.57
mmol) were dissolved inTHF (15 mL) and heated at reflux for two hrs. The reaction
mixture was filtered through a plug of silica to remove salts formed during the
reaction. The solvent was removed under reduced pressure and the residue was
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purified by flash column chromatography (hexanes : ethyl acetate, 9:1) affording 495
mg (31 %) of colorless solid as a 1: 1 mixture of two diastereomers 283. mp 47 - 50°C
(pentane); Rf 0.72 (hexanes : ethyl acetate, 3:1); IR (film) Vrnax: 3362, 2961, 2929,
2873, 1794, 1727, 1598, 1585, 1496, 1458, 1398, 1371, 1336, 1304, 1195, 1181,
1165, 1131, 1097, 1079, 997, 962, 909 cm-I ; IH NMR (300 MHz, CDCI3) 8: 7.30 -
7.52 (m, 5H), 6.07 (dd, J = 11.1,4.2 Hz, IH), 4.75 (bs, IH), 4.57 - 4.68 (m, IH), 4.46
- 4.55 (m, IH), 2.11 - 2.25 (m, IH), 1.79 - 1.98 (m, IH), 1.69 (d, J = 11.4 Hz, 2H),
1.37 - 1.58 (m, 2H), 0.73 - 1.16 (m, 10H) ppm; I3C NMR (75 MHz, CDCI3) 8: 158.4,
158.1, 132.7, 132.6, 130.52, 130.50, 129.6, 129.1, 129.0, 127.2, 127.1, 127.0, 84.8,
84.7, 82.9, 82.8, 72.8, 72.7, 47.5, 47.1, 40.2, 40.0, 34.2, 31.8, 31.69, 31.66, 26.6,
26.4,23.6,23.5,22.3,21.1,21.0,16.7,16.4 ppm; MS (EI) mlz (%): 163 (5),139 (30),
138 (83), 137 (9), 123 (24), 121 (9), 120 (24), 119 (7), 105 (16), 104 (99), 103 (27),
97 (19),96 (17), 95 (65),91 (34),84 (8),83 (100), 82 (20),81 (51),77 (12),71 (20),
69 (45), 68 (9), 67 (14), 65 (9), 57 (36), 56 (11), 55 (49).
285
2-Hydroxy-2-phenylethylamino(menthyloxy)methylenesulfamate (285).
Cyclic sulfimidate 283 (mixture of two diastereomers in a ratio of 1:1, 150 mg, 0.39
mmol) was dissolved in dry DMF (1.5 mL) and ammonium benzoate (109 mg, 0.78
mmol) was added. The reaction mixture was heated at 50°C until complete
conversion of starting material (TLC, 18 hrs), before it was diluted with diethyl ether
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(25 mL). The organic layer was extracted ten times with water (0.5 mL), then washed
two times with a saturated aqueous solution of Na2C03, and brine. The organic layer
was dried over anhydrous magnesium sulfate, the solvent was evaporated under
reduced pressure and the residue was purified by flash column chromatography
(hexanes : ethyl acetate, 8:1 to 2:1) affording 125 mg (80%) of the title compound
285 as colorless oil. Rf 0.12 (hexanes : ethyl acetate, 1:1); [a]D23 - 48.5 (c 0.275,
CHCI3); IR (film) Vmax: 3448,3340,2956,2926,2871, 1631, 1548, 1496, 1446, 1372,
1322,1173,1097,986,954,917,863,815,759,700,661, 609, 541 cm-I; IH NMR
(500 MHz, CDCI3) 8: 7.28 - 7.46 (m, 5H), 7.06 (bs, 1H), 5.76 (bs, 1H), 5.06 (dt, J =
9.3,2.2 Hz, 1H), 4.80 (td, J =11.0,4.6 Hz, 1H), 4.24 (ddd, J =10.6,8.8, 2.8 Hz, 1H),
4.13 (ddd, J =18.2, 10.3,9.2 Hz, 1H), 2.68 (bs, 1H), 2.08 (d, J =12.5 Hz, 1H), 1.83 -
1.91 (m, 1H), 1.67 (d, J = 12.1 Hz, 2H), 1.32 - 1.51 (m, 2H), 0.99 (q, J = 11.6 Hz,
1H), 0.91 (d, J =5.8 Hz, 3H), 0.89 (dd, J =6.8, 1.0 Hz, 3H), 0.81 - 0.92 (m, 1H), 0.76
(t, J =6.5 Hz, 3H) ppm; I3C NMR (125 MHz, CDCI3) 8: 160.3, 138.5, 129.1, 128.7,
126.5, 79.5, 75.0, 72.1, 47.1, 40.7, 34.1, 31.5, 26.4, 23.3, 22.4, 21.2, 16.8 ppm;
HRMS (FAB) (M+H+) calcd for C19H30N20SS: 398.1875, found 398.1855.
+ - ~ H 0
Et3NH O-S-N-{
- 8 OMe
322
Sulfo-methylester carbamic acid triethlylammonium salt (322).
Compound 322 was isolated by diluting the crude reaction mixture with diethyl ether,
after following the general procedure for the formation of disulfides. A white
precipitate was formed, which was filtered and dried under reduced pressure. mp 93 -
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95°C (diethyl ether); IR (film) Vmax: 3483,3237,2989,2711,2499,1723,1647,1476,
1421, 1341, 1225, 1044, 948, 838 cm -1; IH NMR (300 MHz, CDCI3) 8: 9.20 (bs,
IH), 7.15 (bs, IH), 3.69 (s, 3H), 3.15 - 3.31 (m, 6H), 1.39 (t, J = 7.2 Hz, 9H); 13C
NMR (75 MHz, CDCI3) 8: 153.7, 52.2, 46.4, 8.4; HRMS (FAB) (M+H+) calcd for
• C6HI5N: C 37.49% H 7.86% N 10.96%, found C 37.67% H 7.83% N 10.76%.
HO',: (MaBoe
HO"O
336
(5S,6R)-[2-(5,6-Dihydroxy-cyclohex-l-enyl)-ethyl]-methyl-carbamic acid tert-
butyl ester (336).
Compound 334 (6.34 g, 20.8 mmol) was dissolved in THF (20 mL) and transferred to
a 50 mL thick-walled reaction vessel containing K2C03 (1.61 g, 11.6 mmol) and a
magnetic stirring bar. The reaction vessel was cooled to - 40°C, and the solution was
saturated with methylamine by bubbling gaseous methylamine from a lecture bottle
through the solution for 15 min. The reaction vessel was sealed, and the mixture
stirred at rt for 48 hrs. The vessel was cooled to -40°C before it was carefully opened.
Potassium salts were removed by filtration and rinsed with DCM (20 mL). The
solvent was removed and the residue was dissolved in DCM (50 mL). Boc anhydride
(8.53 g, 37.4 mmol) was added to the solution and the reaction mixture was cooled to
o °C. Triethylamine (5.20 mL, 37.4 mmol) and DMAP (0.24 g, 2.0 mmol) were
added to the reaction mixture, which was warmed to rt over 24 hrs. A saturated
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aqueous solution of NH4Cl was added and the layers were separated. The aqueous
layer was extracted with DCM and the organic extracts were combined. The organic
layer was washed three times with a saturated aqueous solution of Na2C03, brine, and
then dried over anhydrous sodium sulfate. The solution was filtered and the solvent
was removed under reduced pressure. Purification of the crude residue by flash
column chromatography (hexanes : ethyl acetate ,I 6: 1 to 1:2) afforded the title
compound 336 as colorless oil. (2.51 g, 45%). Rf O.20 (hexanes : ethyl acetate, 1:1);
IR (film) Vmax: 3383, 2974, 2930, 1693, 1672 , 1396, 1158, 988 em-I; IH NMR (300
MHz, CDCl3) 8: 5.43 (bs, 1H), 4.87 (bs, 1H), 3.96 (bs, 2H), 3.56 (bs, 1H), 2.99 (d, J
= 8.8 Hz, 1H), 2.91 (bs, 1H), 2.86 (s, 3H), 2.42 - 2.30 (m, 1H), 2.18 (d, J = 13.4 Hz,
1H), 2.03 (bs, 2H), 1.74 - 1.63 (m, 1H), 1.60 - 1.45 (m, 1H), 1.43 (s, 9H) ppm; 13C
NMR (150 MHz, CHCl3) 8: 157.0, 133.9, 128.8, 79.9, 70.0, 69.8, 48.3, 34.8, 34.0,
28.3, 25.4, 24.8 ppm; MS (EI) mlz (%): 144 (12), 110 (110), 57 (71), 44 (100).
HRMS (EI) (M+-57) calcd for CI4H2SN04: 271.1784, found 271.1787.
HO". ~MeBOC
TBSO"·O
6
(SS,6R)-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-6-hydroxy-cyclohex-l-enyl]-
ethyl}-methyl-carbamic acid tert-butyl ester (6).
To a solution ofdiol 336 (656 mg, 2.0 mmol) in DCM (8 mL) at -78°C was added
imidazole (272 mg, 4.0 mmol) followed by the addition of TBDMS-chloride (330
mg, 2.2 mmol). The reaction mixture was warmed to rt over 14 hrs and then
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quenched by the addition of a saturated aqueous solution of NH4Cl. The layers were
separated, and the aqueous layer was extracted twice with DCM. The organic layers
were combined and washed with cold 2% aqueous HCI, saturated aqueous solution of
NaHC03, then dried over anhydrous magnesium sulfate. Evaporation of the solvent
gave a crude oil, which was purified by flash column chromatography (hexanes :
ethyl acetate, 1: 1 to 0: 1) to give the mono-silyl derivative 6 as a clear and colorless
oil (678mg, 88%). Rf 0.47 (DCM : ethyl acetate, 96:4); [a]D24 -22.6 (c 0.5, CHCI3);
IR (film) Vrnax : 3556,3475,2953,2857, 1692, 1472, 1392, 1253, 1085 cm-I; IH NMR
(600 MHz, CDCI3) (mixture of rotamers) 8: 5.54 (s, 1H), 5.52 (s, 1H), 3.98 (s, 1H),
3.90 (s, 1H), 3.79 (s, 1H), 3.77 (s, 1H), 3.26 - 3.20 (m, 2H), 2.85 (s, 3H), 2.82 (s, 3H),
2.39 - 2.32 (m, 2H), 2.30 - 2.23 (m, 2H), 2.13 (bs, 2H), 1.98 (bs, 2H) 1.80 - 1.72 (m,
2H), 1.54 (s, 2H), 1.44 (s, 18H), 0.9 (s, 18H), 0.11 (s, 6H), 0.10 (s, 6H) ppm; I3C
NMR (150 MHz, CDCI3) 8: 155.7, 134.8, 126.6, 79.0 (br), 71.0, 68.8, 48.4, 47.2,
34.1,33.3,32.8, 28.4, 25.8, 25.4, 25.3, 24.3, 24.1, 18.1, - 4.4, - 4.8 ppm; MS (EI) m/z
(%): 228 (21), 197 (21), 136 (12), 74 (22), 73 (15), 57 (63), 44 (100); HRMS (EI)
(M+-57) calcd for CI2H30N04Si: 328.1944, found 328.1946; Anal calcd for
C2oH39N04Si: C 62.10% H 10.22%, found C 62.29% H 10.19%.
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N -[2-[(5S,6S)-6-(2-Bromo-3-formyl-6-methoxyphenoxy)-5-[[(1,I-dimethylethyl)
dimethylsilyl]oxy]-I-cyclohexen-l-yl]ethyl]-N-methyl carbamic acid 1,1-
dimethylethylester (337).
To a solution of DIAD (1.02 mL, 5.21 mmol) in THF (10 mL) at -10°C, was added
tributyl phosphine (1.69 mL, 5.21 mmol) dropwise. The solution was stirred at -10°C
for 10 min, then it was transferred dropwise to a solution of bromoisovanillin 174
(0.93 g, 4.01 mmol) and monoprotected diol 6 (1.39 g, 3.61 mmol) in THF (2 mL) at
-78°C. Once the addition was completed, the reaction vessel was warmed to rt and
stirred at ambient temperature for 48 hrs. The solvent was removed under reduced
pressure and the crude mixture was subjected to column chromatography (DCM :
ethyl acetate, 100:0 to 98:2). Compound 337 was isolated as colorless oil (1.19 g,
55%). Rf 0.81 (DCM:EtOAc, 96:4); [a]n22 +59.1 (c 0.35, CHC13); IR (film) Vmax:
3007,2952,2929,2857,1688,1578,1481,1275,1252, 1173, 1085, 1028,1005,836
em-I; IH NMR (600 MHz, CDC13) (two rotamers) 8: 10.30 (s, 1H), 7.75 (d, J =8.6
Hz, 1H), 7.00 (d, J =8.6 Hz, 1H), 5.79 - 5.90 (m, 1H), 4.57 (bs, 1H), 3.94 - 4.04 (m,
4H), 3.40 - 3.65 (m, 1H), 3.22 (bs, 1H), 2.85 (s, 3H), 2.37 - 2.57 (m, 2H), 2.17 - 2.28
(m, 2H), 2.02 - 2.10 (m, 1H), 1.65 - 1.74 (m, ~H), 1.46 (s, 9H), 0.76 (s, 9H), - 0.12 (s,
3H), -0.17 (s, 3H) ppm; 13C NMR (150 MHz, CDC13) 8: 191.3, 157.9, 155.8, 144.6,
130.9,130.3,127.7,125.9,123.5,110.9,80.3,79.1, 67.7, 56.1, 48.9, 48.3,41.5,35.0,
33.4,32.7, 28.5, 25.6, 25.4, 20.8, 18.0, -4.9, -5.1 ppm; MS (EI) m/z (%): 312 (28),
174
269 (10), 268 (45), 237 (24), 136 (31), 109 (14),75 (27),73 (33),57 (47),44 (100);
HRMS (EI) (M+-73) calcd for C24H3sNOsBrSi: 524.1468, found 524.1464; Anal
calcd for C28H44N06BrSi: C 56.18% H 7.41 %, found C 56.09% H 7.65%.
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(5S,6S,9aR)-{2-[6-(tert-Butyl-dimethyl-silanyloxy)-1-formyl-4-methoxy-6,7-
dihydro-SaH-dibenzofuran-9a-yl]-ethyl}-methyl-carbamic acid tert-butyl ester
(338).
To aryl bromide 337 (205 mg, 0.34 mmol) dissolved in degassed (N2) toluene (5 mL)
were added sequentially silver carbonate (283 mg, 1.03 mmol), diphenylphosphino
ferrocene (57 mg, 0.10 mmol), and Pd(OAc)2 (12 mg, 0.05 mmol). The reaction
mixture was heated to 110°C (preheated oil bath) in a Teflon-sealed Schlenk tube (10
mL) for 1 hour, before it was cooled to rt. The remaining black reaction mixture was
filtered through Celite and washed with several portions of CHCI3. The filtrate was
concentrated and adsorbed onto a mixture of silica gel and charcoal. Purification by
flash column chromatography (DCM : ethyl acetate, 4:1) gave 146 mg (82%) of the
title compound as colorless oil.Rf 0.80 (DCM : ethyl acetate, 96:4); [a]D24 +12.5 (c
0.6, CHCI3); IR (film) Vrnax: 3008, 2953, 2930, 2856, 2734, 1692, 1610, 1571, 1436,
1366, 1285, 1250, 1170, 1155, 1046, 837 em-I; IH NMR (600 MHz, CDCI3) (two
rotamers) 8: 9.90 (s, 1H), 9.89 (s, 1H), 7.38 (d, J = 8.2 Hz, 2H), 6.86 - 6.93 (m, 2H),
6.40 - 6.49 (m, 1H), 6.32 - 6.40 (m, 1H), 5.65 - 5.72 (m, 2H), 4.54 - 4.80 (m, 2H),
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3.95 (s, 6H), 3.91 (bs, 2H), 3.32 (bs, 1H), 3.16 - 3.25 (m, 1H), 2.93 - 3.03 (m, 2H),
2.78 (s, 6H), 2.01 - 2.29 (m, 8H), 1.43 (s, 18H), 0.91 (s, 18H), 0.14 (s, 6H), 0.04 (s,
6H) ppm; 13C NMR (150 MHz, CDCI3) (two rotamers) 8: 190.6, 155.5, 150.2, 147.5,
133.6, 130.4, 129.8, 129.2, 126.5, 124.1, 110.4, 90.9, 89.9, 79.5, 68.8, 68.4, 56.0,
55.9, 51.8,45.3,44.6, 36.4, 35.5, 34.7, 34.6, 34.1, 31.6, 30.5, 29.1, 28.4, 25.8, 25.7,
25.3,22.7,20.7, 18.1, 14.1, 11.4, -4.7, -5.2 ppm; MS (EI) m/z (%): 162 (12), 144
(17),136 (12),118 (13),117 (18),92 (32), 91 (38),88 (11), 75 (46),73 (38),57 (87),
44 (100); HRMS (EI) (M+-57) calcd for C24H34N06Si: 460.2155, found 460.2150;
Anal calcd for C2sH43N06Si: C 64.96% H 8.37%, found C 64.87% H 8.46%.
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(5R,6R,9aS)-{2-[6-(tert-Butyl-dimethyl-silanyloxy)-1-formyl-4-methoxy-6,7-
dihydro-SaH-dibenzofuran-9a-yl]-ethyl}-methyl-carbamic acid
tert-butyl ester (-)-(338).
Following the same procedure as for the preparation of compound 338, using
compound 364 (380 mg, 0.64 mmol), Pd(OAc)2 (22 mg, 0.10 mmol), dppf (105 mg,
0.19 mmol), and Ag2C03 (533 mg, 1.91 mmol) as starting materials, gave 301 mg
(91%) of compound (-)-338. Data for (-)-338 (lH NMR spectra, Rf value) are
identical to those of compound 338; [a]n22 -8.5 (c 0.6, CHCI3).
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(5S,6S,9aR)-{2-[6-(tert-Butyl-dimethyl-silanyloxy)-1-(2-bromovinyl)-4-methoxy-
6,7-dihydro-5aH-dibenzofuran-9a-yl]-ethyl}-methyl-carbamic acid tert-butyl
ester (339).
Potassium tert-butoxide (2.91 g, 26.0 mmol) was added to a solution of ylide
(prepared by refluxing a solution of triphenylphosphine (15 g, 57.0 mmol) and
methylene bromide (22.3 g, 115 mmol) in toluene (100 mL) for 24 hrs. The mixture
was cooled to 0 DC, the precipitate was collected by filtration, washed with toluene
and dried under reduced pressure) (12.2 g, 28.0 mmol) in THF (100 mL) at -30°C.
The solution was stirred for 5 min at - 30°C and then benzaldehyde 338 (4.05 g, 7.8
mmol) was added. The mixture was stirred at - 30°C until TLC analysis indicated full
conversion (20 min). The reaction mixture was quenched with brine (40 mL) and the
aqueous layer was extracted twice with ethyl acetate (50 ml). The organic layers were
combined, dried over anhydrous magnesium sulfate, and filtered. The concentrated
residue was purified by flash column chromatography (hexanes : ethyl acetate, 9: 1 to
4:1) to give the title compound as colorless oil (2.25. g, 49%). Rf 0.56 (hexanes :
ethyl acetate, 4:1); [a]D2I +46.6 (c 1.2, CHCI3); IR (film) Vrnax: 2952, 2929, 2855,
1691, 1620, 1502, 1366, 1282, 1156, 1122, 837 em-I; IH NMR (300 MHz, CDCI3)
(two isomers, ratio 2:1) 8: 7.10 (d, J =8.4 Hz, 1H), 6.70 - 6.86 (m, 3H), 6.56 (d, J =
13.9 Hz, 1H), 6.52 (d, J =7.9 Hz, 1H), 5.86 - 5.99 (m, 2H), 5.66 - 5.81 (m, 2H), 4.46
- 4.60 (m, 2H), 3.94 - 4.03 (m, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 3.18 - 3.48 (bs, 2H),
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2.89 - 3.04 (m, 2H), 2.80 (s, 3H), 2.76 (s, 3H), 2.31 (t, J = 4.5 Hz, 1H), 2.25 (t, J =
2.8 Hz, 1H), 2.03 - 2.18 (m, 2H), 1.80 - 2.03 (m,4H), 1.43 - 1.48 (m, 20H), 0.92 (s,
18H), 0.15 (s, 3H), 0.14 (s, 3H), 0.05 (s, 3H), 0.05 (s, 3H) ppm; 13C NMR (150 MHz,
CDCI3) (two isomers, ratio 2:1) 8: 155.5, 147.1, 145.3, 145.0, 130.2, 129.0, 128.6,
124.7, 122.5, 119.5, 111.7, 110.9, 108.6, 106.7,89.8,89.1,79.5,68.9,68.3,65.9,
55.9, 55.8, 55.7, 51.0, 50.9,45.2, 37.1, 34.2, 30.4, 30.3, 29.7, 28.5, 28.5, 25.8, 25.7,
25.7, 18.1, 15.3, -3.5, -4.7, -5.2 ppm; MS (EI) m/z (%): 536 (4),436 (7), 144 (8), 118
(6),88 (14), 86 (29),84 (44),75 (21),73 (38),59 (33),57 (61),47 (10),44 (100),41
(18), MS (ES- pos) m1z (%): 618 (100), 616 (92), 553 (20), 477 (14), 476 (52);
HRMS (EI) (M+-57) calcd for C2sH3sNOsBrSi: 536.1467, found 536.1461; Anal
calcd for C29H44NOsBrSi: C 58.57% H 7.46%, found C 59.48% H 7.87%.
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(5R,6R,9aS)-{2-[6-(tert-Butyl-dimethyl-silanyloxy)-1-(2-bromovinyl)-4-methoxy-
6,7-dihydro-5aH-dibenzofuran-9a-yl]-ethyl}-methyl-carbamic acid tert-butyl
ester (-)-(339).
Following the same procedure as for the preparation of compound 339, using
compound (-)-338 (0.75 g, 1.45 mmol), ylide (prepared by refluxing a solution of
triphenylphosphine (15 g, 57.0 mmol) and methylene bromide (22.3 g, 115 mmol) in
toluene (100 mL) for 24 hrs. The mixture was cooled to DoC, the precipitate was
collected by filtration, washed with toluene and dried under reduced pressure) (1.26
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g, 2.90 mmol), and potassium tert-butoxide (0.31 g, 2.76 mmol), gave 344 mg (40%)
of compound (-)-339. Data for (-)-339 (1H NMR spectra, Rf value) are identical to
those of compound 339; [a]n2I -37.1 (c 1.30, CHC13).
NMeBoc
340
(3aS,3S,9aR,9bR)..[2,[3..(tert..Butyl..dimethylsilanyloxy)..5..methoxy..3,8,9,9a..
tetrahydro..3aH..phenanthro[4,5..bed]furan..9b..yl]..ethyl]..methyl..carbamic acid
tert..butyl ester (340).
Vinyl bromide 339 (788 mg, 1.33 mmol) was dissolved in degassed (N2) toluene (20
mL) and transferred to a 50 mL Teflon-sealed Schlenk tube containing a magnetic
stirring bar. Silver carbonate (1.10 g, 4.0 mmol), diphenylphosphino propane (164
mg, 0.4 mmol), and Pd(OAc)2 (45 mg, 0.2 mmol) were added sequentially. The tube
was flushed with nitrogen, sealed, and placed in a pre-heated oil bath at 110°C for 3
hrs. The black reaction mixture was filtered through Celite and washed with several
portions of CHCI3. The filtrate was adsorbed onto a mixture of silica gel and charcoal
and loaded onto a silica gel column. Elution with DCM : ethyl acetate, 4: 1 gave
compound 340 as a yellow oil (300 mg, 44%). Rf O.55 (hexanes : ethyl acetate, 4:1);
IR (film) Vrnax : 2954, 2929, 2856, 1697, 1507, 1438, 1391, 1365, 1279, 1162, 1094,
865 cm-I; IH NMR (600 MHz, CDCI3) (two rotamers) D: 6.69 (d, J = 8.0 Hz, 1H ),
6.63 (d, J =8.0 Hz, 1H ),6.40 - 6.48 (m, 1H), 5.85 (dd, J =9.2, 5.8 Hz, 1H), 5.59 -
5.73 (m, 1H), 5.55 (d, J = 9.8 Hz, 1H ), 4.64 - 4.74 (m, 1H), 4.04 - 4.15 (m, 1H), 3.90
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(s, 3H), 3.16 - 3.28 (m, 1H), 3.05 - 3.14 (m, 2H), 2.68 - 2.80 (m, 3H), 1.92 - 2.01 (m,
1H), 1.80 - 1.91 (m, 1H), 1.38 - 1.46 (m, 10H), 0.92 (s, 9H), 0.16 (s, 3H), 0.07 (s, 3H)
ppm; 13C NMR (150 MHz, CDCI3) (two rotamers) 8: 155.5, 144.7, 141.7, 129.6,
128.2, 128.0, 127.7, 124.1, 117.8, 113.0, 102.1, 95.0, 85.7, 79.3, 68.8, 56.5,45.1,
38.8, 36.4, 34.7, 34.2, 28.4, 25.8, 25.3, 18.1, -4.7, -4.9 ppm; MS (EI) mlz (%): 440
(2), 370 (10, 356 (11), 355 (12), 299 (10), 281 (8), 238 (18), 225 (17), 224 983), 223
(14),158 (9) 117 (8),102 (54), 75 (41),73 (63),59 (38), 58 (59),57 (99),44 (100),
41 (22); HRMS (EI) (M+-73) calcd for C2sH34N04Si: 440.2257, found 440.2250.
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(3aR,3R,9aS,9bS)-[2,[3-(tert-Butyl-dimethylsilanyloxy)-5-methoxy-3,8,9,9a-
tetrahydro-3aH-phenanthro[4,5-bcd]furan-9b-yl]-ethyl]-methyl-carbamic acid
tert-butyl ester (-)-(340).
Following the same procedure as for the preparation of compound 340, using
compound (-)-339 (325 mg, 0.55 mmol), Pd(OAc)2-(31--mg,-0.14 mmol), dppp (111
mg, 0.27 mmol), and Ag2C03 (451 mg, 1.64 mmol) as starting materials, gave 127
mg (45%) of compound (-)-340. Data for (-)-340 (lH NMR spectra, Rf value) are
identical to those of compound 340; [a]n22 22.1 (c 0.3, CHCI3).
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(3aS,3S,9aR,9bR)-[2,[3-Hydroxy-5-methoxy-3,8,9,9a-tetrahydro-3aH-
phenanthro[4,5-bcd]furan-9b-yl]-ethyl]-methyl-carbamic acid tert-butyl ester
(341).
To compound 340 (278 mg, 0.54 mmol) dissolved in THF (3 mL) was added TBAF
(0.6 mL, 1M in THF) and the reaction mixture was stirred at ambient temperature for
one hour. The solvent was removed under reduced pressure and the residue was
purified by flash column chromatography (DCM : MeOH, 95:5) to give the title
compound as colorless oil (190 mg, 88%). Rf O.50 (DCM: MeOH, 95:5); [a]n21 -80.5
(c 1.2, CHCI3); IR (film) Vmax: 3417, 2974, 2933, 1675, 1633, 1507, 1438, 1366,
1280, 1162, 1051,878 cm-I; IH NMR (600 MHz, CDCI3) (two rotamers) 8: 6.68 (d, J
=9.1 Hz, IH), 6.64 (d, J =6.0 Hz, IH), 6.40 - 6.50 (m, IH), 5.83 (bs, IH), 5.75 (d, J
=9.91 Hz, IH), 5.61 (bs, 1H), 4.70 - 4.82 (m, IH), 4.14 (bs, IH), 3.89 (s, 3H), 3.21 -
3.42 em, 1H), 3.05 - 3.20 (m, 2H), 2.72 - 2.80 (m, 3H), 2.38 - 2.65 (m, IH), 1.90 -
2.08 (m, IH), 1.75 - 1.90 (m, 1H), 1.35 -1.50 (m, 9H) ppm; I3C NMR (150 MHz,
CDCI3) (two rotamers) 8: 155.5, 145.4, 144.1, 128.3, 128.0, 127.6, 127.2, 123.9,
123.3, 118.1, 117.9, 112.5,95.2,79.4,68.7,68.6,56.2,44.9,44.4,43.2, 43.0,39.3,
38.6, 36.1, 37.0, 34.2, 28.4 ppm; MS (EI) m/z (%): 399 (1), 256 (10), 242 (21), 241
(47),238 (21),225 (25),224 (89), 223 (23),213 (11),209 917), 181 (12), 152 (10),
102 (30), 88 (11), 85 (14), 83 (20), 59 (27), 58 (35), 57 (100), 44 (27); HRMS (EI)
calcd for C23H29N05: 399.2046, found 399.2043.
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(3aR,3R,9aS,9bS)-[2,[3-Hydroxy-5-methoxy-3,8,9,9a-tetrahydro-3aH-
phenanthro[4,5-bcd]furan-9b-yl]-ethyl]-methyl-carbamic acid tert-butyl ester
(-)-(341).
Following the same procedure as for the preparation of compound 341, using
compound (-)-340 (125 mg, 0.24 mmol) and TBAF (0.27 ml, 1M in THF) as starting
materials, gave 72 mg (72%) of compound (-)-341. Data for (-)-341 (lH NMR
spectra, Rf value) are identical to those of compound 341; [a]n21 68.5 (c 0.65,
NMeBoc
342
(3aS,-9aR;9bR)-[2,[3-on-5-Methoxy-3,8,9,9a-tetrahydro-3aH-phenanthro[4,5-
bcd]furan-9b-yl]-ethyl]-methyl-carbamic acid tert-butyl ester (342).
To compound 341 (157 mg, 0.39 mmol) dissolved in DMF (2 mL) was added IBX
(110 mg, 0.42 mmol) at room temperature. After completion consumption of starting
material (TLC) the reaction mixture was quenched with water (20 mL). The phases
were separated and the aqueous phase was extracted with DCM (3 x 20 mL). The
organic layers were combined, washed with a saturated aqueous solution of NaHC03,
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then dried over anhydrous sodium sulfate. Filtration and removal of the solvent under
reduced pressure gave the crude product, which was purified by flash column
chromatography (DCM : ethyl acetate, 4: 1) to afford the title product as colorless oil
(142 mg, 92%). Rf 0.68 (DCM : ethyl acetate, 90:10); [a]D21 +61.4 (c 1.4, CHCI3); IR
(film) Vrnax: 2928, 1683, 1508, 1438, 1393, 1366, 1281, 1153, 1050, 808 cm-I ; IH
NMR (600 MHz, CDCI3) (two rotamers) 8: 6.70 (bs, 1H), 6.58 - 6.66 (m, 1H),6.58
(dd, J=11.8, 1.3 Hz, 1H), 6.08 - 6.18 (m, 1H), 5.87 (t, J= 7.5 Hz, 1H), 4.90 (s, 1H),
3.91 (s, 3H), 3.68 - 3.74 (br s, 1H), 3.28 - 3.77 (m, 2H), 3.05 - 3.23 (m, 1H), 2.78 (s,
3H), 1.86 - 2.04 (m, 2H), 1.37 - 1.48 (m, 9H) ppm; 13C NMR (150 MHz, CDCI3) (two
rotamers) 8: 194.0, 155.4, 146.1, 145.7, 145.0, 144.7, 129.0, 128.6, 127.8, 126.3,
124.6, 124.2, 122.1, 119.2, 119.0, 113.9, 87.3, 79.6, 56.6, 45.0, 44.8, 44.4, 38.5, 37.6,
35.2, 34.2, 29.7, 28.4 ppm; MS (EI) mlz (%): 397 (1), 254 (23), 241 (14), 240 (77),
239 (38), 238 (12), 225 (17), 211 (14), 149 (12), 102 (21), 97 (13), 85 (27), 83 (35),
71 (20),70 (10), 69 (18), 59 (24), 58 (23),57 (100),56 (13), 55 (23),44 (31),43 (38),
41 (31); HRMS (EI) calcd for C23H27N05: 397.1889, found 397.1895.
NMeBoc
(-)-342
(3aR,9aS,9bS)-[2,[3-on-5-Methoxy-3,8,9,9a-tetrahydro-3aH-phenanthro[4,5-
bcd]furan-9b-yl]-ethyl]-methyl-carbamic acid tert-butyl ester (-)-(342).
To compound (-)-341 (70 mg, 0.18 mmol) dissolved in DMF (2 mL) was added IBX
(49 mg, 0.18 mmol) at room temperature. The reaction mixture was stirred at roonl
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temperature for 2 hours (TLC indicated unreacted starting material) and additional
IBX (15 mg, 0.05 mmol) was added. After completion consumption of starting
material (TLC) the reaction mixture was quenched with water (20 mL). The phases
were separated and the aqueous phase was extracted with DCM (3 x 20 mL). The
organic layers were combined, washed with a saturated aqueous solution of NaHC03,
then dried over anhydrous sodium sulfate. Filtration I and removal of the solvent under
reduced pressure gave the crude product, which was purified by flash column
chromatography (DCM : ethyl acetate, 9: 1 to 4: 1) to afford 60 mg of a mixture of two
compounds. Exhaustive purification by flash column chromatography gave 7 mg in
90% purity of compound (-)-342 and 50 mg of a 1:1 mixture of compounds «(-)-342
and a yet unidentified byproduct). Data for (-)-342 (lH NMR spectra, Rf value) are
nearly identical to those of compound 342; [a]n22 -59.2 (c 0.35, CHCI3).
NMeBoc
343
(3aS,3R,9aR,9bR)-[2,[3-Hydroxy-5-methoxy-3,8,9,9a-tetrahydro-3aH-
phenanthro[4,5-bcd]furan-9b-yl]-ethyl]-methyl-carbamic acid tert-butyl ester
(343).
To ketone 342 (123 mg, 0.31 mmol) dissolved in methanol (3 mL), was added
CeCl387H20 (182 mg, 0.62 mmol). The reaction mixture was stirred at ambient
temperature for 5 min and then cooled to 0 °C. NaBH4 (13 mg, 0.34 mmol) was added
portion-wise and the mixture was stirred at 0 °C for 20 min. The solvent was removed
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under reduced pressure and the residue was suspended in DCM (15 mL). The organic
layer was washed with a saturated aqueous solution of NH4CI (15 mL), dried over
anhydrous sodium sulfate, filtered and the volatiles were removed under reduced
pressure. The residue was purified by flash column chromatography (DCM : MeOH,
95:5) to give 110 mg (89%) of alcohol 343. Rf 0.48 (DCM : MeOH, 95:5); [a]n22 +98
(c 0.5, CHCI3); IR (film) Vrnax: 3449, 2973, 2932, 1690, 1637, 1507, 1457, 1393,
1366, 1269, 1160, 1089, 1051,798 em-I; IH NMR (300 MHz, CDCI3) 8: 6.63 (d, J =
8.0 Hz, 1H), 6.58 (d, J =8.0 Hz, 1H), 6.51 (d, J = 9.3 Hz, 1H), 6.00 (dd, J =9.3,6.2
Hz, 1H), 5.81 (d, J = 10.0 Hz, 1H), 5.28 (dd, J = 10.0, 2.3 Hz, 1H), 5.15 (bs, 1H),
4.17 - 4.28 (m, 1H), 3.85 (s, 3H), 3.22 - 3.45 (m, 1H), 2.80 - 2.99 (m, 2H), 2.76 (s,
3H), 2.05 - 2.22 (m, 1H), 1.76 - 1.99 (m, 1H), 1.42 (s, 9H) ppm; MS (EI) mlz (%):
399 (14), 343 (12), 246 (43), 242 (34), 241 (87), 240 (11), 252 (13), 224 (12), 223
(11), 213 (16), 209 (16), 181 (16), 88 (23), 86 (56), 84 (56), 59 (25), 58 (33), 57
(100),55 (12); HRMS (EI) calcd for C23H29N05: 399.2046, found 399.2044.
NHMe
(+)-184
(2aS,5R,5R,5aS)-2a,5,5,5a-tetrahydro-7-Methoxy-5-(2-(methylamino)ethyl)
phenanthro[4,5-bcd]furan-5-ol (+)-(184).
To compound 343 (105 mg, 0.26 mmol) dissolved in DCM (3 mL) was added
trifluoroacetic acid (0.5 mL) dropwise at 0 °C. The reaction mixture was stirred at 0
°c for 2 hrs and then the solvent was removed under reduced pressure. The residue
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was suspended in CHCl3 and washed with a saturated aqueous solution of Na2C03
and brine. The aqueous layers were combined and extracted with CHCI3. The organic
layers were combined, dried over anhydrous magnesium sulfate, filtered and then the
solvent was evaporated. The crude product was purified by flash column
chromatography (DCM : MeOH, 4:1) to give 69 mg (88%) of amine (+)-184. [a]D22
+112.5 (c 0.4, CHCI3); IR (film) Vmax: 3583, 3311~ 3032, 2931, 2851, 1635, 1573,
1506, 1457, 1381, 1270, 1194, 1161, 1050 cm-I; IH NMR (300 MHz, CDCI3) 6: 6.64
(d, J =7.9 Hz, 1H), 6.58 (d, J =7.9 Hz, 1H), 6.50 (d, J =9.0 Hz, 1H), 6.00 (dd, J =
9.3,6.4 Hz, 1H), 5.77 - 5.85 (m, 1H), 5.29 (dt, J =10.1,2.5 Hz, 1H), 5.16 (d, J =6.1
Hz, 1H), 4.19 - 4.26 (m, 1H), 3.85 (s, 3H), 2.78 - 2.86 (m, 1H), 2.71 (td, J =5.2,2.9
Hz, 1H), 2.31 - 2.49 (m, 2H), 2.36 (s, 3H), 2.06 - 2.19 (m, 2H), 1.78 - 1.92 (m, 1H)
ppm; I3C NMR (75 MHz, CDCI3) 6: 146.2, 143.8, 132.0, 129.2, 127.6, 125.1, 123.7,
117.8, 112.0,90.5,66.0,56.0,57.9,45.4,37.7,36.4,35.9, 25.8 ppm; MS (EI) m/z
(%): 299 (9), 242 (53), 240 (16), 225 (24), 197 (13), 152 (10), 59 (100), 44 (54);
HRMS (EI) calcd for CI8H2IN03: 299.1521, found 299.1517.
(+) -2
(+)-Codeine (2).
Amine (+)-184 (50 mg, 0.17 mmol) dissolved in THF (5 mL) was added to a mixture
of Hg(OAc)2 (80 mg, 0.25 mmol) and triethylamine (60 ilL, 0.40 mmol) in THF (2
mL). The mixture was stirred for 48 hrs and then a solution of LAH in THF (0.46 mL
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(1M THF), 0.46 mmol) was added dropwise. The reaction mixture was stirred for 2
hrs and then quenched with saturated aqueous solution of Na2C03 (2 mL). The
aqueous phase was extracted with CHCl3 (3 x 3 mL). The organic layers were
combined and dried over anhydrous sodium sulfate. The mixture was filtered and the
solvent was evaporated under reduced pressure. The concentrated product was
purified by flash column chromatography (DCM : MeOH : NH40H, 80:20: 1)
affording (+)-codeine (10 mg, 0.03 mmol, 17.6%). Rf 0.75 (DCM : MeOH, 4:1);
[a]D22 +130 (c 0.3, EtOH) (Lit. 173 +137.5 (c 0.16, EtOH). IR (film) Vrnax: 3402,2930,
2839, 1634, 1603, 1504, 1452, 1277, 1254, 1121, 1054, 942 cm-I; IH NMR (600
MHz, CDCI3) b: 6.69 (d, J = 8.2 Hz, 1H), 6.60 (d, J = 8.2 Hz, 1H), 5.74 (m, 1H), 5.31
(m, 1H), 4.93 (d, J = 6.5 Hz, 1H), 4.20 - 4.23 (m, 1H), 3.87 (s, 3H), 3.72 (m, 1H),
3.41 - 3.46 (m, 1H), 3.08 (d, J =18.5 Hz, 1H), 2.74 - 2.81 (m, 1H), 2.65 - 2.72 (m,
1H), 2.51 (s, 3H), 2.44 - 2.50 (m, 1H), 2.34 - 2.42 (m, 1H), 2.11 - 2.21 (m, 1H), 1.92
(d, J =12.4 Hz, 1H) ppm; I3C NMR (150 MHz, CDCI3) b: 146.3,142.3,133.7,130.8,
127.9, 119.7, 112.9,91.2,66.3,59.0,56.3,46.5,42.9,42.8,40.4, 35.4,29.9, 20.6
ppm; MS (EI) mlz (%): 300 (21), 299 (100), 298 (14), 229 (19), 188 (13), 162 (23),
124 (22), 115 (12), 59 914), 42 (13); HRMS (EI) calcd for CI8H2IN03: 299.1521,
found 299.1520.
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(-)-Codeine (2).
To a mixture of compounds (1: 1, (-)-342 and unidentified byproduct) (50 mg)
dissolved in methanol (1 mL), was added CeCl3·7H20 (70 mg, 0.19 mmol). The
reaction mixture was stirred at ambient temperature for 5 min and then cooled to 0
DC. NaBH4 (5 mg, 0.14 mmol) was added in one portion and the mixture was stirred
at 0 °c for 20 min. The solvent was removed under reduced pressure and the residue
was suspended in DCM (10 mL). The organic layer was washed with a saturated
aqueous solution of NH4Cl (10 mL), dried over anhydrous sodium sulfate, filtered
and the volatiles were removed under reduced pressure. The residue was purified by
flash column chromatography (DCM : MeOH, gradient and DCM : ethyl acetate,
gradient) to give 38 mg of a mixture of compounds (1.25: 1).
To this mixture of compounds (38 mg) dissolved in DCM (1 mL) was added
trifluoroacetic acid (0.25 mL) dropwise at 0 °C. The reaction mixture was stirred at 0
°c for 2 hrs and then the solvent was removed under reduced pressure. The residue
was suspended in CHCl3 and washed with a saturated aqueous solution of Na2C03
and brine. The aqueous layers were combined and extracted with CHCl3. The organic
layers were combined, dried over anhydrous magnesium sulfate, filtered and then the
solvent was evaporated. The crude product was purified by flash column
chromatography (DCM : MeOH, 4:1) to give 28 mg of a mixture of compounds
(1.25: 1).
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This mixture of compounds (28 mg) dissolved in THF (1 mL) was added to a mixture
of Hg(OAc)2 (45 mg, 0.14 mmol) and triethylamine (33 JlL, 0.23 mmol) in THF (1
mL). The mixture was stirred for 48 hrs and then a solution of LAH in THF (10 mg,
0.25 mmol in 1 mL of THF) was added dropwise. The reaction mixture was stirred
for 2 hrs and then quenched with saturated aqueous solution of Na2C03 (2 mL). The
aqueous phase was extracted with CHCl3 (3 x 3 mL). The organic layers were
combined and dried over anhydrous sodium sulfate. The mixture was filtered and the
solvent was evaporated under reduced pressure. The concentrated product (26 mg)
was purified by flash column chromatography (DCM : MeOH : NH40H, 100:0:0 to
90:10:1) affording (-)-codeine (4.2 mg, 0.014 mmol, 8% over four steps). Data for (-
)-codeine (2) (IIi NMR spectra, Rf value) are identical to those of (+)-codeine (2);
[ 20 6 0 0 (. 92 27a]D -124. (c .15, Et H), LIt. [a]D - 137 (c 1.15, EtOH».
NMeBoc
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{2-[5-(tert-Butyl-dimethyl-silanyloxy)-6-benoyloxy-cyclohex-l-enyll-ethyl}-
methyl-carbamic acid tert-butyl ester (345).
To a stirred solution of alcohol 6 (360 mg, 0.94 mmol) and benzoic acid (171 mg,
1.40 mmol) in THF (12 mL) at 0 °C, was added a solution of the Mitsunobu reagent
[previously prepared by addition of DIAD (568 mg, 2.81 mmol) to a stirred solution
of freshly distilled tributylphosphine (736 mg, 2.81 mmol) in THF (10 mL) at 0 °C],
and the mixture was warmed to rt After 16 hrs, silica gel was added to the reaction
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mixture and the solvent was removed under reduced pressure. The crude residue was
subjected to flash column chromatography (hexanes : ethyl acetate, 15:1 to 1:1) to
give compound 345 as a clear and colorless oil (380 mg, 83 %). Rf 0.55 (hexanes :
ethyl acetate, 1:1); [a]D23 -5.6 (c 0.8, CHCl3); IR (film) Vrnax : 3030,2956,2859, 1718,
1692, 1472, 1392, 1253, 1085 cm- I ; IH NMR (600 MHz, CDCl3) 8: 8.08 (d, J =7.8
Hz, 2H), 7.59 (t, J =7.8 Hz, 1H), 7.47 (t, J =7.8 Hz, 2H), 5.79 - 5.68 (m, 1H), 5.52
(bs, 1H), 4.03 (bs, 1H), 3.18 - 3.35 (m, 2H), 2.69 - 2.81 (m, 3H), 2.20 - 2.29 (m, 2H),
2.09 - 2.20 (m, 2H), 1.81 - 1.91 (m, 1H), 1.71 -1.80 (m, 1H), 1.45 (s, 9H), 0.89 (s,
9H), 0.07 (s, 3H), 0.02 (s, 3H) ppm; I3C NMR (150 MHz, CDCl3) 8: 166.2, 155.7,
133.0, 131.5, 130.3, 129.7, 129.1, 128.7, 128.4, 79.3, 74.6, 74.3, 69.9, 48.2, 47.7,
34.8, 34.4, 32.4, 31.6, 31.5, 28.5, 27.9, 25.7, 22.7, 22.5, 17.9, 14.2, - 4.76, - 4.82
ppm; HRMS (EI) (M+-57) calcd for C27H43NOsSi: 489.2911, found 428.2916.
346
{2-[5-(tert-Butyl-dimethyl-silanyloxy)-6-hydroxy-cyclohex-l-enyl]-ethyl}-methyl-
carbamic acid tert-butyl ester (346).
To a solution of compound 345 (370 mg, 0.76 mmol) in MeOH (5 mL) was added
1M NaOH (2.3 mL, 2.3 mmol) and the resulting reaction mixture was stirred at rt for
18 hrs. Brine was added and MeOH was removed on the rotary evaporator. The
aqueous layer was extracted five times with ethyl acetate and the organic layers were
combined and dried over anhydrous sodium sulfate. The solution was filtered and the
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solvent was removed under reduced pressure to yield a colorless oil, which was
purified by flash column chromatography (hexanes : ethyl acetate 8:1 to 5:1) to yield
compound 346 as a colorless oil (160 mg, 55%). Rf 0.62 (hexanes : ethyl acetate,
2:1); [a]D23 -12.6 (c 0.8, CHCI3); IR (film) Vmax: 3584, 2976, 2931, 1698, 1482, 1393,
1365,1162 cm-I; IH NMR (600 MHz, CDCI3) 8: 5.42 (bs, 1H), 3.87 - 4.11 (m, 1H),
3.69 - 3.87 (m, 2H), 2.88 (s, 3H), 2.25 - 2.45 (m, 1H), 2.08 - 2.22 (m, 2H), 1.85 - 2.01
(m, 1H), 1.65 - 1.79 (m, 1H), 1.58 - 1.62 (m, 2H), 1.44 (s, 9H), 0.89 (s, 9H), 0.09 (s,
3H), 0.08 (s, 3H) ppm; I3C NMR (150 MHz, CDCI3)8: 155.5, 129.3, 122.0, 80.1,
75.9,75.6,49.9,48.4,34.3,33.5,32.6,28.2,25.4, 25.2, 25.2, 24.3, 24.0, 17.9, -4.6, -
4.8 ppm; MS (EI) mlz (%): 367 (1), 272 (16), 228 (55), 197 (35), 185 (19), 153 (13),
144 (24), 136 (22), 127 (12), 88 (20), 75 (60), 73 (36), 57 (87), 45 (11), 44 (100);
HRMS (EI) (M+-18) calcd for C2oH37N03Si: 367.2543, found 367.2542.
348
{2-[5-Hydroxy-6-(4-nitro-benzoyloxy)-cyclohex-l-enyl]-ethyl}-methyl-carbamic
acid tert-butyl ester (348).
A magnetically stirred suspension of cis diol 336 (200 mg, 0.74 mmol) in toluene (5
mL) at 0 °C was treated with p-nitrobenzoic acid (369 mg, 2.21 mmol) and
triphenylphosphine (291 mg, 1.11 mmol). DIAD (209 mg, 1.04 mmol) was added
dropwise and the reaction mixture was warmed to rt and stirred for 18 hrs. The
reaction was quenched by the addition of a saturated aqueous solution of NaHC03.
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The layers were separated and the aqueous layer was extracted with ethyl acetate. The
organic layers were combined and washed with brine, dried over anhydrous sodium
sulfate, and filtered. The solvent was evaporated and the residue was purified by flash
column chromatography (hexanes : ethyl acetate, 12:1 to 1:1) to give the title
compound 348 as a colorless oil (220 mg, 71 %). Rf 0.38 (hexanes : ethyl acetate,
1:1); [a]n22 -41.6 (c 0.6, CHC13); IR (film) Vmax: 342LJ., 2977, 2931,1722,1692,1529,
1396, 1270, 1161, 1102 cm-1; IH NMR (600 MHz, acetone-d6) (two rotamers) 8: 8.39
(d, J = 8.4 Hz, 4H), 8.32 (d, J = 8.4 Hz, 4H), 5.64 - 5.81 (m, 4H), 4.38 (bs, 1H), 4.24
(bs, 1H), 4.02 (bs, 2H), 3.60 (bs, 1H), 3.41 (bs, 1H), 3.23 (bs, 1H), 3.08 (bs, 1H), 2.88
(bs, 1H), 2.82 (s, 3H), 2.76 (s, 3H), 2.12 - 2.39 (m, 8H), 1.88 - 1.99 (m, 2H), 1.71 -
1.82 (m, 2H), 1.46 (s, 18H) ppm; 13C NMR (150 MHz, aceton-d6) (two rotamers) 8:
164.6, 156.3, 150.7, 130.90, 130. 86, 129.1, 123.6,78.4,76.5,75.3,69.2,68.8,68.3,
47.7,46.6,33.6,33.4,31.6,31.4,27.6,27.5,22.7, 22.5, 21.9 ppm; MS (EI) m/z (%):
420 (1), 167 (14), 144 (35), 120 (14), 118 (11), 110 (29), 109 (13), 103 (43), 88 (10),
76 (51), 65 (15), 59 (17), 57 (83), 45 (13), 44 (100); HRMS (EI) calcd for
C21H28N207: 420.1897, found 420.1901; Anal calcd for C21H27N207: C 59.99% H
6.71 %, found C 60.02% H 7.24%.
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349
[2-(5, 6-Dihydroxy-cyclohex-l-enyl)-ethyl]-methyl-carbamic acid tert-butyl ester
(349).
To a solution of compound 348 (200 mg, 0.48 mmol) in MeOH (3 mL) was added
1M NaOH (1.43 mL, 1.43 mmol) and the resulting reaction mixture was stirred at rt
for 18 hrs. Brine was added and MeOH was removed on the rotary evaporator. The
aqueous layer was extracted five times with ethyl acetate and the organic layers were
combined and dried over anhydrous sodium sulfate. The solution was filtered .and the
solvent was removed under reduced pressure to yield a colorless oil, which was
purified by flash column chromatography (hexanes : ethyl acetate, 4: 1 to 1:3) to yield
compound 349 as a colorless oil (98 mg, 76%). Rf 0.10 (hexanes : ethyl acetate, 1:1);
[a]D23 +17.6 (c 1.0, CHCI3); IR (film) Vrnax: 3430, 2975, 2929, 1695, 1673, 1484,
1397, 1366, 1158, 1048 cm-I; IH NMR (300 MHz, CDCI3) 5: 5.34 (bs, 1H), 3.96 -
4.06 (m, 1H), 3.62 - 3.78 (m, 2H), 3.58 (bs, 2H), 2.98 - 3.18 (m, 1H), 2.82 (s, 3H),
2.31 - 2.43 (m, 1H), 2.20 - 2.31 (m, 1H), 1.95 - 2.20 (m, 2H), 1.82 - 1.95 (m, 1H),
1.55- 1.71 (m, 1H), 1.45 (s, 9H) ppm; I3C NMR (75 MHz, CDCI3) 5: 156.7, 134.6,
126.7,79.8,74.7,73.2,47.8,34.1,32.6,28.5,28.3, 27.2, 23.7 ppm; HRMS (EI) calcd
for CI4H25N04: 271.1784, found 271.1782.
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(+)-7
tert-Butyl-2-(7-oxa-bicyclo[4.1.0]hept-2-en-2-yl)ethylmethylcarbamate (7).
From trans-diol 349: (+)-(7).
A solution of trans diol 349 (80 mg, 0.30 mmol) in THF (1 mL) at 0 °C was treated
with bromoisovanillin (205 mg, 0.89 mmol) and triphenylphosphine (116 mg, 0.44
mmol). DIAD (89 mg, 0.44 mmol) was added dropwise and the reaction mixture was
warmed to rt and stirred for 18 hrs. The reaction was quenched by the addition of a
saturated aqueous solution of NaHC03. The layers were separated and the aqueous
layer was extracted with ethyl acetate. The organic layers were combined and washed
with brine, dried over anhydrous sodium sulfate, and filtered. The solvent was
evaporated and the residue was purified by flash column chromatography (hexanes :
ethyl acetate, 5:1 to 1:1) to give the title compound (+)-7 as a colorless oil (30 mg,
45%). Rf 0.40 (hexanes : ethyl acetate, 2:1); [a]D22 +20.6 (c 0.25,CHCI3); IR (film)
Vrnax : 2976,2931, 1692, 1482, 1393, 1365. 1134 cm-I; IH NMR (600 MHz, CDCI3) 8:
5.63 (d, J = 6.6 Hz, 1H), 3.54 (bs, 1H), 3.38 - 3.53 (m, 1H), 3.12 - 3.30 (m, 2H), 2.89
(bs, 3H), 2.32 - 2.48 (m, 2H), 2.16 - 2.28 (m, 1H), 1.88 - 2.04 (m, 2H), 1.52 - 1.60
(m, 1H), 1.48 (s, 9H) ppm; I3C NMR (150 MHz, CDCI3) 8: 155.7, 132.1, 127.3,79.7,
55.4, 50.2; 48.4, 47.8, 34.8, 34.5, 34.2, 28.5, 20.8, 20.2 ppm; MS (EI) m/z (%): 253
(1), 144 (34), 110 (24), 88 (10), 57 (94), 44 (100); HRMS (EI) calcd for C14H23N03:
253.1678, found 253.1680; Anal calcd for C14H23N03: C 66.37% H 9.15%, found C
66.37% H 9.09%.
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From compound 352: (-)-(7).
Compound 352 (1.70 g, 2.96 mmol) was dissolved in THF (30 mL) and 0.5 M
sodium methoxide solution in MeOH (7.1 mL) was added dropwise at 0 °C. The
reaction mixture was stirred at 0 °C for one hour, before it was quenched by the
addition of a saturated aqueous solution of NH4Cl (50 mL). The organic solvent was
removed under reduced pressure and the aqueous layer was extracted five times with
ethyl acetate. The organic extracts were combined and dried over anhydrous sodium
sulfate. The solution was filtered and the solvent was removed under reduced
pressure. The residue was purified by flash column chromatography (hexanes : ethyl
acetate, 9:1 to 3:1) to give the title compound (-)-7 as colorless oil (0.66 g, 88%).
[a]D22 -21.0 (c 0.25, CHCl3).
jM~:OC
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[2-[6-Hydroxy-5-(4-methylbenzenesulfonyl)-cyclohex-1-enyl]-ethy1]-methyl-
carbamic acid tert-butyl ester (351).
To a solution of diol 336 (2.0 g, 7.4 mmol) and tosylchloride (2.5 g, 13.3 mmol) in
DCM (20 mL) were added triethylamine (1.9 g, 18.5 mmol) and DMAP (catalytic
amount) at 0 °C. The reaction mixture was warmed to rt and was stirred until
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complete consumption of starting materials (TLC, 18 hrs). The solution was diluted
with DCM (20 mL) and washed three times with a saturated aqueous solution of
Na2C03, three times with a saturated aqueous solution of NH4CI, and brine. The
organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was
removed under reduced pressure. Purification of the crude residue by flash column
chromatography afforded the tile compound 351 as colorless oil (1.1 g, 35%) and 0.9
g (45%) of recovered starting material. Rf 0.48 (hexanes : ethyl acetate, 1:1); [a]D22
+107.1 (c 0.10, CHCI3); IR (film) Vmax: 3400, 2918, 2849, 1689, 1672, 1599, 1483,
1453, 1395, 1364, 1180, 1123, 1098 cm-I; IH NMR (600 MHz, CDCI3) (two
rotamers) 8: 7.78 - 7.92 (m, 2H), 7.31 - 7.39 (m, 2H), 5.38 - 5.59 (m, 1H), 4.56 - 4.69
(m, 1H), 4.00 - 4.23 (m, 2H), 3.58 - 3.70 (m, 1H), 3.18 - 3.39 (m, 1H), 3.00 - 3.13 (m,
1H), 2.82 (s, 3H), 2.45 (s, 3H), 2.26 - 2.37 (m, 1H), 2.08 - 2.19 (m, 2H), 1.95 - 2.07
(m, 2H), 1.41 (bs, 9H) ppm; I3C NMR (150 MHz, CDCI3) 8 (two rotamers): 156.4,
144.5, 134.3, 134.0, 129.8, 127.8, 127.4,81.4,79.6,68.1,47.6,34.0,33.8,28.3,24.3,
23.9,22.5, 21.7 ppm; HRMS (EI) (M+-73) calcd for CI7H22NOsS: 352.1219, found
352.1228; Anal calcd for C2IH3IN06S: C 59.27% H 7.34%, found C 59.34% H
7.18%.
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(5S,6S)-[2-[5-(4-Methylbenzenesulfonyl)-6-(4-nitro-benzoyloxy)-cyclohex-1-
enyl]-ethyl]-methyl-carbamic acid tert-butyl ester (352).
To a solution of nitrobenzoate 348 (2.3 g, 5.5 mmol) in DCM (30 mL) were added
tosylchloride (5.2 g, 27.4 mmol), triethylamine (7.6 mL, 54.8 mmol) and DMAP (60
mg) at 0 DC. The reaction mixture was warmed to rt and stirred for 22 hrs, before it
was quenched by the addition of water (20 mL). The layers were separated and the
aqueous layer was extracted three times with DCM (20 mL). The organic extracts
were combined, washed three times with a saturated aqueous solution of Na2C03,
three times with a saturated aqueous solution of NH4Cl, and brine. The organic layers
were dried over anhydrous sodium sulfate, filtered and the solvent was evaporated
under reduced pressure. Purification of the crude residue by flash column
chromatography (hexanes : ethyl acetate, 9: 1 to 1: 1) gave the title compound 352 as
colorless solid (2.5 g, 78%). mp 135 - 136°C (hexanes/ethyl acetate); Rf 0.48
(hexanes : ethyl acetate, 2:1); [a]D23 +81.6 (c 0.9, CHCl3); IR (film) Vmax: 3112,3054,
2976, 2931, 1730, 1691, 1599, 1529, 1454, 1350, 1266, 1190, 1101,914 cm-I; IH
NMR (600 MHz, CDCl3) (two rotamers) 8: 8.28 (d, J = 7.9 Hz, 2H), 8.10 (d, J = 8.8
Hz, 2H), 7.71 (d, J = 7.9 Hz, 2H), 7.11 - 7.18 (m, 2H), 5.80 - 5.88 (m, 1H), 5.73 -
5.76 (m, IH), 4.88 - 4.93 (m, IH), 3.28 - 3.45 (m, IH), 3.08 - 3.16 (m, IH), 2.70 -
2.78 (m, 3H), 2.30 (s, 3H), 2.22 - 2.28 (m, 2H), 2.09 - 2.19 (m, 2H), 1.95 - 2.09 (m,
2H), 1.43 (s, 9H) ppm; I3C NMR (150 MHz, CDCl3) (two rotamers) 8: 164.0, 155.6,
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150.6, 144.7, 134.0, 131.0, 130.9, 129.2, 129.7, 128.6, 127.6, 123.4, 79.9, 79.6, 79.2,
72.8,72.4,47.6,47.0,34.2,31.3,30.7,28.5,26.7, 23.2, 23.0, 21.6 ppm; HRMS (EI)
(M+-73) calcd for C24H25N20gS: 501.1326, found 501.1330; Anal calcd for
C2gH34N209S: C 58.52% H 5.96%, found C 58.78% H 6.02%.
NMeBoc
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tert-Butyl-2-((5R,6R)-5-hydroxy-6-phenoxycyclohex-1-
enyl)ethylmethylcarbamate (358).
To a solution of epoxide (-)-7 (50 mg, 0.20 mmol) in DME (0.5 mL) was added
potassium phenoxide (52 mg, 0.40 mmol) followed by the addition of 18-crown-6-
ether (catalytic amount). The reaction mixture was heated at reflux for 16 hrs, before
it was cooled to rt and quenched by the addition of water (2 mL). The layers were
separated and the aqueous layer was extracted three times with ethyl acetate. The
organic layers were combined, washed three times with a saturated aqueous solution
of Na2C03 and brine. The organic layer was dried over anhydrous sodium sulfate,
filtered, and the solvent was removed under reduced pressure. The crude residue was
purified by flash column chromatography (hexanes : ethyl acetate, 5: 1 to 1: 1) and the
title compound 358 was isolated as colorless oil (54 mg, 78%). Rf 0.35 (hexanes :
ethyl acetate, 2:1); [a]D23 -33.2 (c 0.59, CHCI3); IR (film) Vrnax: 3429, 2975, 2928,
1694, 1670, 1596, 1492, 1454, 1396, 1366, 1228, 1164, 1078 em-I; IH NMR (600
MHz, CDCI3) 8: 7.31 (t, J =7.4 Hz, 2H), 7.07 (d, J =7.4 Hz, 2H), 6.98 (t, J =7.4 Hz,
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1H), 5.70 - 5.73 (m, 1H), 4.69 - 4.72 (m, 1H), 4.15 - 4.19 (m,lH), 3.85 - 3.93 (m,
1H), 3.63 (d, J = 6.4 Hz, 1H), 2.86 (s, 3H), 2.73- 2.80 (m, 1H), 2.13 -2.32 (m, 3H),
2.04 - 2.11 (m, 1H), 1.77 - 1.85 (m, 2H), 1.46 (s, 9H) ppm; 13C NMR (150 MHz,
CDCI3) 8: 158.6, 157.0, 130.6, 129.7, 121.1, 115.6, 79.9, 73.6, 66.0, 46.3, 34.0, 32.7,
28.5,24.4, 20.7 ppm; HRMS (EI) calcd for C2oH29N04: 347.2097, found 347.2084;
Anal calcd for C2oH29N04: C 69.14% H 8.41 %, found C 68.85% H 8.49%.
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N -[2-[(5R,6R)-6-(2-bromo-3-formyl-6-methoxyphenoxy)-5-hydroxy-1-
cyclohexen-l-yl]ethyl]-N-methyl carbamic acid 1,1-dimethylethylester (350).
To a solution of epoxide (-)-7 (90 mg, 0.375 mmol) in DME (0.5 mL) and DMF (0.5
mL) was added potassium phenoxide derivative 362 (260 mg, 1.126 mmol), followed
by the addition of 18-crown-6-ether (catalytic amount). The reaction mixture was
heated at 90°C for 24 hrs, before it was cooled to rt and diluted with diethyl ether (20
mL). The organic layer was extracted three times with a saturated aqueous solution of
Na2C03 (10 mL), ten times with water (0.5 mL) and brine. The organic layer was
dried over anhydrous sodium sulfate, filtered, and the solvent was removed under
reduced pressure. Purification by flash column chromatography (hexanes : ethyl
acetate, 4:1 to 1:1) gave the title compound 350 (130 mg, 75%) and compound 363 (8
mg, 5%). Compound 350: colorless oil; Rf 0.35 (hexanes : ethyl acetate, 3:2); [a]n23 -
93.0 (c 0.2, CHCI3); IR (film) Vmax: 3428,3088,2975,2931,2869,2741, 1678, 1579,
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1482, 1440, 1367, 1276, 1253, 1164, 1029,938 em-I; IH NMR (600 MHz, CDCl3) 8:
10.27 (s, 1H), 7.73 (d, J =8.6 Hz, 1H), 6.97 (d, J =8.6 Hz, 1H), 5.71 - 5.75 (m, 1H),
4.78 - 4.82 (m, 1H), 3.98 - 4.06 (m, 2H), 3.95 (s, 3H), 3.53 (bs, 1H), 2.89 (s, 3H),
2.80 - 2.87 (m, 1H), 2.65 - 2.79 (m, 1H), 2.22 - 2.37 (m, 2H), 2.03 - 2.21 (m, 2H),
1.80 - 1.89 (m, 1H), 1.42 (s, 9H) ppm; I3C NMR (150 MHz, CDCl3) 8: 191.3, 158.1,
157.1, 144.7, 130.9, 130.4, 127.6, 126.1, 123.4, 111.0,80.0,76.9,66.4,56.1,46.3,
34.0, 32.8, 28.5, 28.5, 24.3, 20.7 ppm; HRMS (EI) (M+-73) ealed for CIsH2INOs:
410.0603, found 410.0601; Anal ealed for C22H30BrN06: C 54.55% H 6.24%, found
C 54.68% H 6.41 %.
363
tert-Butyl-2-((4aR,1OaR)-6-bromo-7-formyl-l,2,4a,1Oa-tetrahydrodibenzo
[b,e][1,4] dioxin-4-yl)ethylmethylcarbamate (363).
Colorless oil; Rf 0.42 (hexanes : ethyl acetate, 3:1); [a]D22 +168.3 (c 0.5, CHCl3); IR
(film)vrnn: 2975,2931,287~ 1686, 1591, 1561, 1477, 1392, 128~ 116~ 105~969
em-I; IH NMR (600 MHz, DMSO-d6) (two rotamers) 8: 10.14 (s, 1H), 7.46 (d, J =8.7
Hz, 1H), 7.12 (d, J =8.7 Hz, 1H), 5.58 - 5.66 (m, 1H), 4.60 - 4.79 (m, 1H), 4.10 -
4.25 (m, 1H), 3.47 - 3.78 (m, 1H), 2.74 - 2.88 (m, 3H), 2.52 - 2.64 (m, 1H), 2.13 -
2.47 (m, 4H), 1.63 - 1.87 (m, 2H), 1.28 - 1.44 (s, 9H) ppm; I3C NMR (600 MHz
based on HSQC, DMSO-d6) (two rotamers) 8: 190.7,127.9,123.9,117.2,76.5,75.5,
40.3,34.1,30.1,28.3,25.7,23.9 ppm; HRMS (EI) ealed for C2IH26BrNOs: 451.0994,
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found 451.0995; Anal calcd for C21H26BrNOs: C 55.76% H 5.79%, found C 56.51 %
H5.96%.
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N -[2-[(5R,6R)-6-(2-Bromo-3-formyl-6-methoxyphenoxy)-5-[[(1,1-
dimethylethyl)dimethylsilyl]oxy]-I-cyclohexen-l-yl]ethyl]-N-methyl carbamic
acid 1,I-dimethylethylester (364).
To a solution of compound 350 (15 mg, 0.03 mmol) in diethyl ether (0.5 mL) were
added imidazole (8.2 mg, 0.12 mmol) and TBDMSCI (9.1 mg, 0.06 mmol) at -60°C.
The reaction mixture was warmed to rt and stirred at ambient temperature for 18 hrs.
The reaction mixture was diluted with DCM (5 mL) and extracted three times with a
saturated aqueous solution of NH4Cl. The organic layer was washed with brine, dried
over anhydrous sodium sulfate and filtered. Evaporation of the solvent and
purification of the crude residue by flash column chromatography gave the title
compound 364 as colorless oil (11 mg, 61 %). Data for 364 is identical to data of 337
except [a]D21 -55.8 (c 0.325, CHCI3); 337 [a]D22 +59.1 (c 0.35, CHCI3).
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8,14-Dihydrothebaine (237).
Thebaine (4) (30 mg, 0.10 mmol) was dissolved in MeOH (1 mL) and nitrogen was
bubbled through the reaction mixture for five min. Crabtree's catalyst 368 (4 mg,
0.005 mmol) was added and the reaction vessel was evacuated and flushed with
hydrogen. This cycle was repeated two more times. The reaction mixture was
hydrogenated (55 psi H2 pressure) for 12 days. Crabtree's catalyst (4 mg, 0.005
mmol) was added every fourth day. After each addition of catalyst the reaction vessel
was evacuated and flushed with hydrogen as written before. The progress of the
reaction was monitored by HPLC.
The reaction mixture was filtered through a plug of Celite and the filtrate was
concentrated under reduced pressure. The crude reaction mixture was purified by
flash column chromatography (DCM : MeOH : NH40H, 100:0:0 to 94:6:1) and a
mixture of 8,14-dihydrothebaine (237) and tetrahydrothebaine (367) in aratio of 5 :3
(72% combined yield) was recovered. Analyses are based on comparison of the data
obtained on the mixture with analytical data of purified standards. 8,14-
Dihydrothebaine (237) was prepared according to a procedure by Weller and
RapoportI74 to give compound 237 as colorless crystals. mp 163 - 165°C
(CHC13/MeOH) (lit. mpI74 158 - 160°C); Rf 0.60 (DCM : MeOH : NH40H, 92:8:1);
IR (film) Vmax: 3030, 3005, 2923, 2848, 2793, 2771, 1658, 1633, 1605, 1501, 1446,
1374, 1215, 1150, 1057 cm-I; IH NMR (CDC13, 600MHz) b: 6.69 (d, J = 7.9 Hz, 1H),
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6.60 (d, J =7.9 Hz, 1H), 4.84 (s, 1H), 4.72 (d, J =5.3 Hz, 1H), 3.83 (s, 3H), 3.48 (s,
3H), 3.11 - 3.14 (m, 1H), 3.01 (d, J =18.5 Hz, 1H), 2.52 (dd, J = 12.1,4.5 Hz, 1H),
2.41 (s, 3H), 2.35 - 2.40 (m, 1H), 2.29 - 2.34 (m, 1H), 2.25 (dt, J = 12.4,4.0 Hz, 1H),
1.89 - 2.00 (m, 2H), 1.79 - 1.84 (m, 1H), 1.52 - 1.60 (m, 1H) ppm; 13C NMR (CDCI3,
150MHz) 8: 152.3, 145.2, 143.1, 129.3, 127.0, 118.6, 113.5, 98.1, 88.6, 59.0, 56.5,
54.4,46.5,43.1, 42.5, 39.9, 35.8, 23.6, 20.2 ppm; HRMS (EI) calcd for C19H23N03:
313.1678, found 313.1664.
8,14-Dihydrothebaine (237) from codeine methyl ether (327).
Codeine methyl ether (327) (10 mg, 0.03 mmol) was dissolved in dry EtOH (0.1 mL)
and Wilkinson's catalyst (0.1 mg) was added. The reaction mixture was heated at
reflux for 14 hrs, before it was cooled to rt and filtered through a plug of silica.
Evaporation of the solvent and analysis by NMR and HPLC showed a 20%
conversion to 8,14-dihydrothebaine (237), besides unreacted starting material.
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Tetrahydrothebaine (367).
A standard of tetrahydrothebaine (367) was prepared by following procedure.
Thebaine (30 mg, 0.100 mmol) was dissolved in DCM (0.3 mL) and catalyst 369 (3.5
mg, 0.005 mmol) was added. The reaction vessel was evacuated and flushed with
hydrogen. This cycle was repeated two more times. The reaction mixture was
203
hydrogenated (14 psi H2pressure) for 18 hrs, before it was filtered through a plug of
silica. The solvent was removed under reduced pressure to yield the title compound
after purification by flash column chromatography ((DCM : MeOH : NH40H,
100:0:0 to 94:6:1) as colorless oil (27 mg, 90%). Data for 367 are identical to those
published in the literature. 175 Rf 0.60 (DCM : MeOH : NH40H, 96:4: 1); IR (film)
Vm~: 3429,2933,2835,1635,1609,1504,1440,1337,1277, 1258, 1152, 1105, 1057
cm-1; I H NMR (CDCI3, 600 MHz) b: 6.71 (d, J = 8.2 Hz, IH), 6.58 (d, J = 8.2 Hz,
IH), 4.68 (d, J =5.0 Hz, IH), 3.85 (s, 3H), 3.50 - 3.54 (m, 2H), 3.68 (s, 3H); 3.09 -
3.12 (m, IH), 2.98 (d, J = 18.5 Hz, IH), 2.51 - 2.57 (m, IH), 2.39 - 2.45 (m,4H),
2.21 - 2.32 (m, 2H), 1.89 (dt, J = 12.5,4.9 Hz, IH), 1.72 (dd, J = 11.3,1.1 Hz, IH),
1.37 - 1.54 (m, 3H) ppm; 13C NMR (CDCI3, 150 MHz) 8: 147.1, 141.8, 129.9, 126.4,
118.4, 113.5,89.3,76.9,59.9,58.2,56.5,46.9,42.9,42.3, 39.9, 37.1,24.3,20.1, 19.4
ppm; MS (EI) m/z (%): 316 (18.3),315 (87.3), 300 (42.5), 178 (15.0), 86 (68.8),85
(75.8), 84 (97.1), 83 (100), 70 (18.3), 49 (30.5), 47 (53.5), 42 (19.9); HRMS (EI)
calcd for C19H25N03: 315.1834, found 315.1831.
327
Codeine methyl ether (327).
To a solution of thebaine (30 mg, 0.10 mmol) in MeOH (0.5 mL) was added catalyst
369 (3.5 mg, 0.005 mmol). The reaction vessel was evacuated and flushed with
hydrogen. This cycle was repeated twice. The reaction mixture was hydrogenated (14
204
psi H2pressure) for 18 hrs. The reaction mixture was filtered through a plug of silica
and the filtrate was concentrated under reduced pressure. The crude reaction mixture
was purified by flash column chromatography (DCM : MeOH : NH40H, 100:0:0 to
94:6: 1) and a mixture of codeine methyl ether (327) and thebaine (4) in a ratio of 2 :3
(98% combined yield) was recovered. Analyses are based on comparison of the data
obtained on the mixture with analytical data of purified standards. Codeine methyl
ether was prepared according to a procedure by Barber and Rapoport176 to give
compound 327 as colorless crystals. mp 135 - 136 °C (EtOH) (lit. mp176 138 - 139
°C); Rf 0.60 (DCM : MeOH : NH40H, 92:8:1); IR (film) Vmax: 2930, 2837, 1635,
1603, 1504, 1443, 1389, 1351, 1278, 1254, 1121, 1104, 1053 em-I; IH NMR (CDC13,
600 MHz) 8: 6.63 (d, J = 8.1 Hz, 1H), 6.51 (d, J = 8.1 Hz, 1H), 5.73 (d, J = 9.8 Hz,
1H), 5.30 - 5.34 (m, 1H), 4.99 (d, J = 5.8 Hz, 1H), 3.82 (s, 3H), 3.76 - 3.80 (m, 1H),
3.53 (s, 3H); 3.35 - 3.38 (m, 1H), 3.04 (d, J =18.5 Hz, 1H), 2.65 - 2.68 (m, 1H), 2.56
- 2.61 (m, 1H), 2.44 (s, 3H), 2.39 - 2.43 (m, 1H), 2.31 (dd, J =18.5,6.0 Hz, 1H), 2.05
(dt, J = 11.4, 3.5 Hz, 1H), 1.88 - 1.93 (m, 1H) ppm; 13C NMR (CDC13, 150MHz) 8:
147.6, 142.1, 130.8, 130.6, 128.8, 126.9, 118.8, 89.4, 76.9, 76.2, 58.9, 57.2, 56.4,
46.5,43.5,43.2,41.3,36.1,20.5 ppm; HRMS calcd for C19H23N03: 313.1678, found
313.1678.
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Hydrocodone (12).
A solution of 8,14-dihydrothebaine (237) (20 mg, 0.06 mmol) in 2N HCI (0.2 mL)
was heated at reflux for 30 min (according to a published procedure). 155g The reaction
mixture was cooled to rt and poured into 15% aqueous solution of NaOH (1 mL). The
aqueous layer was extracted three times with CHCl3 (3 mL). The organic layers were
combined, washed with brine, dried over anhydrous sodium sulfate and filtered.
Evaporation of the solvent and purification by flash column chromatography (DCM :
MeOH: NH40H, 100:0:0 to 94:6:1) yielded 16 mg (82%) of the title compound 12.
Analytical data generated for hydrocodone synthesized in this manner is identical
with that of an authentic sample of hydrocodone (12).
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Dihydro-O-methyl-thebainol A (370).
Thebaine 8 (60 mg, 0.19 mmol) was dissolved in MeOH (4 mL) and PdCl2 (67 mg,
0.38 mmol) was added. The suspension was cooled to 0 °C and NaBH4 (72 mg, 1.93
mmol) was added portionwise. The reaction mixture was allowed to stir at rt for 4
hrs, before it was filtered through a plug of silica. The filtrate was quenched by the
addition of 15% NaOH (4 mL). MeOH was carefully removed under reduced
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pressure and the aqueous solution was extracted three times with CHCI3. The organic
layer were combined and washed with brine, dried over anhydrous magnesium
sulfate, filtered, and the solvent was evaporated. The residue was purified by flash
column chromatography (CHCI3 : MeOH : NH40H, 100:0:0 to 85:15:1) to give 24
mg (40 %) of compound 370 as colorless oil. Rf 0.33 (DCM : MeOH : NH40H,
92:8:1); IR (film) Vrnax : 3517,2997,2933,2850, 1606, 1581, 1277, 1234, 1099 cm-I;
IH NMR (CDCI3, 600MHz): 6.69 (d, J =8.2 Hz, 1H), 6.60 (d, J =8.2 Hz, 1H), 6.02
(bs, 1H), 3.90 (dt, J = 14.9, 2.6 Hz, 1H), 3.87 (s, 3H), 3.51 - 3.55 (m, 1H), 3.19 (s,
3H), 2.85 - 2.95 (m, 2H), 2.76 (dd, J = 17.7,5.3 Hz, 1H), 2.46 - 2.52 (m, 1H), 2.40 (s,
3H), 2.05 (td, J = 11.7, 2.0 Hz, 1H), 1.86 - 1.93 (m, 2H), 1.74 - 1.82 (m, 1H), 1.52 -
1.67 (m, 3H), 1.26 - 1.31 (m, 1H), 1.21 (dd, J = 14.7, 2.4 Hz, 1H) ppm; I3C NMR
(CDCI3, 150 MHz): 144.6, 130.2, 127.3, 118.6, 108.2, 108..0,76.6,58.1,56.7,56.3,
47.8,46.5,42.6,38.7,37.0,35.8,31.3,24.2,22.5 ppm; HRMS calcd for C19H27N03:
317.1991, found 317.1986.
14
(Sa)-Cyclic-l,2-ethanediyl acetal-8,14-didehydro-4,S-epoxy-3-methoxy-17-
methyl-morphinan-6-one (14).
Thebaine (0.5 g, 1.6 mmol) was dissolved in CHCl3 (0.9 mL) and freshly distilled
ethylene glycol (1.0 g, 16.1 mmol) was added. To this biphasic mixture was added
TsOH-H20 (1.0 g, 5.3 mmol) under vigorous stirring. The reaction mixture was
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heated at reflux for 45 min, cooled to 0 °C and the pH was adjusted to 11, using a
saturated aqueous solution of K2C03. The reaction solution was extracted three times
with CHCl3 (5 mL) and the organic layers were combined. Drying over anhydrous
sodium sulfate, filtration and evaporation of the solvent provided a dark yellow
residue, which was purified by flash column chromatography (CHCI3 : MeOH :
NH40H, 98:2: 1) to give the title compound 14 as a' pale yellow oil in 38% yield. Rf
0.55 (DCM : MeOH : NH40H, 96:4:1); IR (film) Vrnax: 3407,3031,2924,2903,2833,
2791, 1634, 1603, 1504, 1448, 1325, 1277, 1258, 1165, 1050, 1035, 825 em-I; IH
NMR (CDCI3, 600 MHz) b: 6.74 (d, J =8.2 Hz, IH), 6.64 (d, J = 8.2 Hz, IH), 5.56
(d, J = 5.6 Hz, IH), 4.70 (s, IH), 4.28 (q, J = 6.2 Hz, IH), 3.93 (q, J = 6.8 Hz, IH),
3.86 - 3.90 (m, 4H), 3.81 (q, J = 6.2 Hz, IH), 3.64 (d, J = 3.64 Hz, IH), 3.26 (d, J =
18.1 Hz, IH), 2.67 - 2.78 (m, 2H), 2.61 (dd, J = 12.6,4.6 Hz, IH), 2.50 (d, J = 1.1
Hz, IH), 2.47 (s, 3H), 2.14 (dd, J =16.2, 6.4 Hz, IH), 2.06 (td, J =12.5, 5.0 Hz, IH),
1.85 (dd, J = 12.3, 1.9 Hz, IH) ppm; I3C NMR (CDCI3, 150 MHz) 8: 145.6, 142.1,
138.4, 131.8, 127.2, 119.4, 113.8, 113.2, 108.1, 93.1, 66.7, 65.4, 61.2, 56.8, 45.9,
45.8,42.2,36.2,32.7,26.8 ppm; MS (EI) mlz (%): 342 (23),341 (100),326 (10), 269
(11), 268 (21), 255 (18), 254 (52), 240 (10), 226 (15), 212 (11), 85 (22), 83 (34), 42
(18); HRMS (EI) calcd for C2oH23N04: 341.1627, found 341.1621.
208
Meo~.
,M
o =O~NMe
~o
380
(Sa)-Cyclic-l,2-ethanediyl acetal-4,S-epoxy-3-methoxy-17-methyl-morphinan-6-
one (380).
A solution of 14 (100 mg, 0.3 mmol) in CHCl3(1 mL) was treated with Pt/C (10%)
under 1 atm of H2 for 16 hrs. Filtration through a plug of silica and elution with
CHCl3 : MeOH : NH40H, 92:8: 1 gave the title compound 380 in quantitative yield.
Data for 380 are identical to those published in the literature. I?? Rf 0.55 (DCM :
MeOH: NH40H, 96:4:1); IR (film) Vmax: 2941,2926,2889,1636,1611,1502,1441,
1325, 1275, 1258, 1190, 1155, 1060, 922 cm-I; IH NMR (CDCI3, 600 MHz) 8: 6.67
(d, J =8.2 Hz, 1H), 6.55 (d, J =8.2 Hz, 1H), 4.42 (s, 1H), 4.12 (q, J =6.5 Hz, 1H),
3.97 (q, J =5.0 Hz, 1H), 3.78 - 3.85 (m, 5H), 3.72 (q, J =6.3 Hz, 1H), 3.01 - 3.05 (m,
1H), 2.93 (d, J = 18.3 Hz, 1H), 2.44 (dd, J = 12.1,4.3 Hz, 1H), 2.33 (s, 3H), 2.27 (dd,
J =18.2,5.4 Hz, 1H), 2.09 - 2.17 (m, 2H), 1.79 (dt, J =12.3,4.9 Hz, 1H), 1.56 - 1.66
(m, 1H), 1.41 - 1.50 (m, 2H), 1.08 (td, J =12.7,2.2 Hz, 1H) ppm; I3C NMR (CDCI3,
150 MHz) 8: 146.6, 142.1, 129.2, 126.5, 118.6, 113.4, 108.6, 94.4, 66.4, 64.9, 59.5,
56.5,47.1,43.6,42.9,42.6,36.5,33.4,22.3,20.1 ppm; MS (EI) mlz (%): 344 (23),
343 (100), 342 (13), 329 (14), 256 (11), 244 (17), 198 (11), 99 (87), 59 (17), 55 (12);
HRMS (EI) calcd for C20H2SN04: 343.1784, found 343.1777.
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Hydrocodone (12) (One pot procedure from 14)
A solution of 14 (45 mg, 0.13 mmol) in MeOH (90 JlL) was treated with Pt/C (10%)
(1 mg) under 1 atm of H2 for 12 hrs. 25% v/v H2S04/MeOH (0.5 mL) was added to
the reaction solution, which was stirred for 3 hrs. The pH of the solution was adjusted
to >11 with saturated aqueous K2C03and extracted three times with CHCl3(5 mL).
The combined organic extracts were dried over anhydrous sodium sulfate, filtered,
concentrated and the crude material was purified by flash column chromatography
(CHCI3: MeOH : NH40H, 98:2:1) to yield hydrocodone 12 in 75% yield. Analytical
data generated for hydrocodone synthesized in this manner was identical with those
of an authentic sample of hydrocodone (12).
Hydrocdone (12) (One pot procedure from 4)
Thebaine (4) (100 mg, 0.32 mmol) was dissolved in THF (1 mL) and water (1 mL)
added. To this solution Pd(OAc)2 (72 mg, 0.32 mmol) was added. After two hrs at rt
the orange/red reaction solution contains no thebaine as evidenced by TLC. H2 was
added to the reaction vessel by use of a balloon on the reaction stirred for a further 4
hrs. Removal of the balloon and filtration of the reaction mixture through a plug of
silica (CHCI3: MeOH : NH40H, 92:8: 1) gave the crude products 12 and 20 in a ratio
of 3:4. Purification of the crude material was achieved by column chromatography
(CHCI3 : MeOH : NH40H, 98:2: 1) to yield 12 in 43% and 382 in 52% yield. All
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analytical data generated for hydrocodone synthesized in this manner was identical
with those of an authentic sample of hydrocodone. Data for 382 are identical to those
published in the literature. 178
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4-Hydroxy-3-methoxy-17-methyl-morphinan-6-one (382).
Rf 0.35 (DCM : MeOH : NH40H, 96:4:1); IR (film) Vmax: 3401, 2935, 2839, 2243,
1710, 1604, 1583, 1483, 1439, 1277, 1228, 1062,922 cm-1; IH NMR (CDCI3, 600
MHz) 5: 6.68 (d, J =8.3 Hz, 1H), 6.60 (d, J =8.3 Hz, 1H), 4.25 (dd, J =13.3,2.5 Hz,
1H), 3.82 (s, 3H), 3.13 - 3.16 (m, 1H), 2.98 (d, J = 18.5 Hz, 1H), 2.76 (dd, J = 18.5,
6.0 Hz, 1H), 2.60 - 2.64 (m, 1H), 2.46 (s, 3H), 2.41 - 2.45 (m, 1H), 2.31 (dt, J = 12.8,
3.2 Hz, 1H), 2.23 - 2.28 (m, 2H), 2.12 (td, J = 12.0,4.1 Hz, 1H) 2.05 (s, 1H), 1.84 -
1.93 (m, 3H), 1.68 (qd, J =13.2, 5.0 Hz, 1H) ppm; 13C NMR (CDCI3, 150 MHz) 8:
210.7, 145.1, 144.8, 129.7, 122.6, 118.5, 109.0,57.0,56.1,50.4,46.4,44.3,42.1,
41.0,40.9,38.0,27.0,23.8 ppm; MS (EI) m/z (%): 302 (12), 301 (56),300 (18), 242
(10),164 (53),88 (11),86 (64),84 (100),60 (19), 59 (17),49 (20),47 (24), 45 (25),
44 (13), 43 (35), 42 (18); HRMS (EI) calcd for C18H23N03: 301.1678, found
301.1671.
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(Sa)-1,7,10-Tribromo-cyclic-l,2-ethanediyl acetal-8,14-didehydro-4,S-epoxy-3-
methoxy-17-methyl-morphinan-6-one (381).
Thebaine (4) (50 mg, 0.16 mmol) was dissolved in THF (1 mL) and freshly distilled
ethylene glycol (100 mg, 1.61 mmol) was added. Br2 (103 mg, 0.64 mmol) was added
in a single portion and the reaction stirred for 10 hrs. A saturated aqueous solution of
Na2S03 was add~d to remove excess bromine. The reaction was cooled to 0 °C and
the pH was adjusted to 11 using a saturated aqueous solution of K2C03. The reaction
solution was extracted five times with CHCl3 (5 mL) and the organic extracts were
combined, dried over anhydrous sodium sulfate. Filtration and evaporation of the
solvent gave a crude mixture, which was further purified by flash column
chromatography (CHCl3 : MeOH, 200:1) to provide the title compound 381 in 27%
yield. Rf 0.60 (DCM : MeOH : NH40H, 96:4:1); IR (film) Vrnax : 2391, 2937, 2891,
1654, 1632, 1611, 1487, 1435, 1287, 1203, 1160, 1125, 1089, 1051, 909 cm-I; IH
NMR (CDCI3, 600 MHz) B: 6.92 (s, IH), 5.88 (d, J = 6.4 Hz, IH), 5.25 (s, IH), 4.61
(d, J = 6.4 Hz, IH), 3.94 - 3.99 (m, IH), 3.88 (s, 3H), 3.81 - 3.87 (m, IH), 3.61 - 3.64
(m, IH), 3.11 (d, J = 18.6 Hz, IH), 3.04 (s, 3H), 2.70 - 2.79 (m, IH), 2.56 - 2.68 (m,
2H), 2.50 (s, 3H), 2.37 - 2.43 (m, IH), 1.76 (dd, J = 12.8,2.3 Hz, IH) ppm; I3C NMR
(CDCI3, 150 MHz) 8: 145.2, 143.1, 132.3, 126.5, 117.0, 116.3, 112.0, 98.4, 92.0,
77.2,64.4,62.0,60.1,57.0,49.5,46.4,45.3,41.9, 35.1, 30.3 ppm; MS (EI) m/z (%):
531 (M+-CH2CH20), 451 (1),435 (1),420 (1), 407 (1), 301 (1),217 (16), 216 (81),
212
188 (54), 187 (100), 171 (22), 145 (13), 118 (11), 117 (22), 90 (13), 86 (20), 84 (24),
78 (16), 71 (11), 57 (12), 55 (14), 47 (12), 44 (28), 43 (41), 42 (12), 41 (33).
Pd/C hydrogenation of thebaine (4).
Thebaine (4) (100 mg, 0.32 mmol) was dissolved in 20% HCI (0.5 mL) and Pd/C
(10%,5 mg) was added. The reaction mixture was stirred under 1 atm of H2 at rt for
12 hrs, after which time the reaction mixture was basified with NH40H and extracted
three times with DCM (2 mL). The organic layers were combined, dried over
anhydrous sodium sulfate and filtered. Evaporation of the solvent gave a mixture of
compounds, which was purified by flash column chromatography (CHCI3 : MeOH :
NH40H, 98:2:1) to give hydrocodone (12) (63%), ~-dihydro-thebainone (382) (20%),
and tetrahydrothebaine (367) (8%).
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Metathebainone (385).
Thebaine (4) (100 mg, 0.32 mmol) was dissolved in an aqueous solution of 20% HCI
(0.5 mL) and Pt/C (1 %), vanadium doped (16 mg) was added. The reaction mixture
was stirred under 1 atm of H2 at rt for 12 hrs, after which time the reaction mixture
was basified with NH40H and extracted three times with DCM (2 mL). The organic
layers were combined, dried over anhydrous sodium sulfate and filtered. Evaporation
of the solvent gave a mixture of compounds, which was purified by flash column
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chromatography (DCM : MeOH, 200:1 to 200:4) to give 14 mg (15%) of
hydrocodone (12) and 72 mg (75%, 90% purity) ofmetathebainone (385). Data for
385 are identical to those published in the literature. I79 Rf 0.50 (DCM : MeOH :
NH40H, 96:4:1); IR (film) Vmax: 3306, 2927, 2851, 2782, 1727, 1650, 1601, 1479,
1441, 1349, 1266, 1183, 1092, 1002 cm-I; IH NMR (CDC13, 600 MHz) 8: 6.83 (d, J =
8.0 Hz, 1H), 6.69 (d, J = 8.0 Hz, 1H), 6.50 (s, 1H), 3.90 (s, 3H), 2.94 - 2.99 (m, 1H),
2.69 - 2.82 (m, 2H), 2.57 (dd, J =14.9, 3.6 Hz, 1H), 2.50 - 2.55 (m, 1H), 2.33 (s, 3H),
2.22 - 2.29 (m, 2H), 2.05 - 2.15 (m, 2H), 2.00 (ddd, J =13.3,5.4,2.1 Hz, 1H), 1.51 -
1.58 (m, 1H) ppm; I3C NMR (CDC13, 150 MHz) 8: 199.6, 158.4, 145.5, 131.4, 126.2,
120.4, 118.7, 113.9, 111.7,73.1,56.2,55.3,46.6,40.4,35.0,33.9,33.8, 30.6 ppm;
HRMS (EI) calcd for CIsH2IN03: 299.1678, found 299.1521.
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N-AcetyI-norhydrocodone 386.
The title compound was isolated following the general procedure for N-demethylation
acylation reaction as a mixture of two isomers in a ratio of 3: 1 in 80% yield. mp 99 -
100°C (DCM); Rf 0.3 (DCM : MeOH, 96:4); IR (film) Vmax: 2929, 1727, 1628, 1505,
1436, 1325, 1274, 1241, 1121, 1061, 1026 cm-I; (major isomer) IH NMR (CDC13,
600 MHz) 8: 6.77 (d, J =8.2 Hz, 1H), 6.68 (d, J =8.2 Hz, 1H), 5.25 - 5.28 (m, 1H),
4.69 (s, 1H), 3.94 (s, 3H), 3.67 (dd, J = 13.8,4.8 Hz, 1H), 3.09 (dt, J = 13.2,4.0 Hz,
1H), 2.91 (dd, J = 18.6,6.1 Hz, 1H), 2.67 (d, J = 18.5 Hz, 1H), 2.32 - 2.51 (m,3H),
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2.14 (s, 3H), 1.91 - 2.02 (m, 3H), 1.20 - 1.32 (m, 1H) ppm; 13C NMR (CDCI3, 150
MHz) 8: 206.8, 169.0, 145.6,143.2, 126.0, 124.9, 120.4, 115.1,91.0, 56.8,47.6,47.3,
41.2, 40.5, 39.9, 35.5, 28.4, 25.3, 22.1 ppm; (minor isomer) I H NMR (CDCI3, 600
MHz) 8: 6.77 (d, J = 8.2 Hz, 1H), 6.67 (d, J = 8.2 Hz, 1H), 4.70 (s, 1H), 4.56 (dt, J =
14.2,3.1 Hz, 1H), 4.27 - 4.31 (m, 1H), 3.94 (s, 3H), 3.67 (dd, J =13.8,4.8 Hz, 1H),
3.09 (dt, J = 13.2,4.0 Hz, 1H), 2.97 (dd, J = 18.2,5.8 Hz, IH), 2.76 (d, J = 18.1 Hz,
1H), 2.53 - 2.61 (m, 1H) 2.32 - 2.51 (m, 2H), 2.14 (s, 3H), 1.91 - 2.02 (m, 2H), 1.20-
1.32 (m, 1H) ppm; 13C NMR (CDCI3, 125 MHz) 8: 206.7, 168.7, 145.6, 143.6, 126.0,
123.9, 120.3, 115.3, 91.0, 56.8, 53.8, 47.2, 42.1, 39.7, 35.4, 34.7, 29.2, 25.5, 21.9
ppm; MS (EI) m/z (%) 327 (24), 241 (23),117 (10), 87 (68),86 (21),85 (72),84 (31),
83 (100), 57 (12), 49 (13), 48 (12), 47 (28), 43 (23), 41 (10); HRMS (EI) calcd for
6.47%, found C 69.38% H 6.47%.
N-Formyl-norhydrocodone 387.
Hydrocodone (50 mg, 0.17 mmol) was dissolved in MeOH (1 mL) and Pd on
charcoal (89 mg, 0.08 mmol) was added at 0 °C. The reaction mixture was stirred
open to air at rt for three days. The reaction mixture was filtered through a plug of
Celite. The solvent was evaporated and the residue was purified by flash column
chromatography (CHCI3 : MeOH : NH40H, 100:0:0 to 85:15:1) to give 10 mg (17 %)
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of the title compound 387 as a mixture of 2 isomers in a ratio of 4:3 as colorless oil.
Rf 0.53 (DCM : MeOH, 92:8); IR (film) Vrnax: 3007,2932, 1728, 1660, 1609, 1505,
1438, 1276, 1108 em-I; IH NMR (CDCI3, 600 MHz) (two isomers) 8: 8.23 (s, 1H),
8.06 (s, 1H), 6.78 (d, J = 8.3 Hz, 2H), 6.67 - 6.72 (m, 2 H), 5.01 - 5.05 (m, 1H), 4.71
(s, 1H), 4.70 (s, 1H), 4.35 (dd, J = 14.1, 5.1 Hz, 1H), 4.07 - 4.10 (m, 1H), 3.94 (s,
6H), 3.87 - 3.99 (m, 2 H), 3.45 - 3.50 (m, 1H), 3.10 - 3.17 (m, IH), 2.91 - 3.04 (m,
2H), 2.77 (d, J = 18.1 Hz, 1H), 2.71 (d, J = 19.3 Hz, 1H), 2.63 (td, J = 13.1,4.3 Hz,
1H), 2.45 - 2.52 (m, 2H), 2.33 - 2.44 (m, 3H), 1.90 - 2.02 (m, 5H), 1.22 - 1.35 (m,
2H) ppm; I3C NMR (CDCI3, 150 MHz) (two isomers) 0: 206.5, 206.4, 160.7, 160.5,
145.7, 143.5, 143.4, 126.0, 125.9, 124.5, 123.9, 120.5, 120.3, 115.4, 115.2, 91.1,
56.80, 56.77, 54.3, 48.1, 48.0, 46.8, 42.6, 41.3, 40.7, 39.7, 39.6, 35.5, 34.5, 34.3,
29.8, 28.2, 25.2, 25.1 ppm; HRMS (EI) calcd for CI8HI9N04: 313.1314, found
313.1308.
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N-Cyclopropylmethyl-norhydrocodone 388.
The title compound 388 was isolated following the general procedure for N-
demethylation acylation reaction as a mixture of two isomers in a ratio of 3: 1 in 76%
yield. Rf 0.28 (DCM : MeOH, 96:4); IR (film) Vrnax : 3448,3007,2929, 1728, 1631,
1505, 1438, 1327, 1275, 1115,960, 753 em-I; (major isomer) IH NMR (CDCI3, 600
MHz) 8: 6.76 (d, J =8.2 Hz, 1H), 6.64 - 6.70 (m, 1H), 5.22 - 5.26 (m, 1H), 4.69 (s,
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IH), 4.09 (dd, J = 13.7, 4.6 Hz, IH), 3.92 (s, 3H), 3.12 (dt, J = 13.2, 3.7 Hz, IH),
2.89 (dd, J=18.3, 6.2 Hz, IH), 2.65 (d, J = 18.5 Hz, IH), 2.31 - 2.63 (m, 5H), 2.04
(dt, J =12.5, 5.1 Hz, IH), 1.89 - 2.00 (m, IH), 1.70 - 1.78 (m, IH), 1.18 - 1.36 (m,
IH), 0.96 - 1.09 (m, IH), 0.74 - 0.92 (m, 2H) ppm; 13C NMR (CDCI3, 150 MHz) 8:
207.1,172.0, 145.6, 143.3, 126.2, 125.1, 120.4, 115.1,91.1,67.1,56.7,48.3,47.4,
42.1,39.9,36.2,29.7,28.4, 11.5,8.8,7.6 ppm; (minor isomer) I H NMR (CDCI3, 600
MHz) 8: 6.76 (d, J = 8.2 Hz, IH), 6.64 - 6.70 (m, IH), 4.73 - 4.77 (m, IH), 4.70 (s,
IH), 4.50 (dd, J = 13.9, 3.6 Hz, IH), 3.92 (s, 3H), 2.99 (dd, J = 18.0,5.7 Hz, IH),
2.80 (d, J =18.1 Hz, IH), 2.31 - 2.63 (m, 5H), 2.04 (dt, J =12.5,5.1 Hz, IH), 1.89 -
2.00 (m, IH), 1.81 - 1.83 (m, IH), 1.57 - 1.65 (m, IH), 1.18 - 1.36 (m, IH), 0.96 -
1.09 (m, IH), 0.74 - 0.92 (m, 2H) ppm; 13C NMR (CDCI3, 150 MHz) 8: 206.9,171.9,
145.5, 143.1, 126.2, 125.1, 120.2, 114.9,91.0,67.1,56.7,48.3,47.4,41.2,39.7,35.7,
29.4,25.3, 11.5,7.5,7.3 ppm; MS (EI) m/z (%): 354 (17), 353 (66),301 (28),300
(11), 242 (30), 241 (57), 240 (14), 213 (11), 199 (11), 185 (19), 164 (30), 141 (10),
129 (16), 128 (12), 127 (10), 115 (15), 114 (11), 113 (61), 112 (82), 111 (28), 109
(11), 99 (11), 98 (73), 97 (11), 88 (23), 87 (19), 86 (48), 85 (89), 84 (80), 83 (100), 82
(18),72 (13), 71 (21),70 (25),69 (81), 68 (14),60 (12),59 (18),58 (22), 57 (37),56
(13), 55 (31), 49 (21), 48 (13), 47 (36), 45 (22), 44 (28), 43 (40), 42 (32), 41 (77)
HRMS (EI) calcd for C21H23N04: 353.1627, found 353.1612.
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N-iso-Butyricacetyl-norhydrocodone 389.
The title compound was isolated following the general procedure for N-demethylation
/ acylation reaction as a mixture of two isomers in a ratio of 13:4 in 13% yield. Rf
0.32 (DCM : MeOH, 96:4); IR (film) Vrnax: 3444, 2970, 2933, 1728, 1643, 1634,
1505, 1435, 1327, 1276, 1260, 1177, 1156, 1032,958,754 cm-I; IH NMR (CDC13,
300 MHz) (major isomer) 8: 6.77 (d, J =8.2 Hz , 1H), 6.68 (d, J =8.6 Hz, 1H), 5.26 -
5.33 (m, 1H), 4.68 (s, 1H), 3.94 (s, 3H), 3.74 - 3.84 (m, 1H), 2.73 - 3.12 (m, 3H),
2.62 (d, J = 18.5 Hz, 1H), 2.28 - 2.51 (m, 3H), 1.87 - 2.06 (m, 3H), 1.20 - 1.30 (m,
1H), 1.19 (d, J =6.8 Hz, 3H), 1.12 (d, J =7.0 Hz , 3H) ppm; I3C NMR (CDC13, 75
MHz) 8: 206.9,175.4,145.6,143.2,126.2,125.1,120.4,115.1, 91.0, 56.8,47.6,47.4,
41.4, 39.9, 39.4, 35.9, 30.5, 28.5, 25.4, 19.6, 19.1 ppm; MS (EI) m/z (%): 355 (35),
242 (13), 241 (34), 115 (99), 100 (13), 88 (13), 87 (16), 86 (66), 84 (100), 72 (24), 55
(11), 49 (20), 47 (24), 43 (53), 41 (15); HRMS (EI) calcd for C2IH25N04: 355.1784,
found 355.1777.
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N-n-Propylacetyl-norhydrocodone 390.
The title compound 390 was isolated following the general procedure for N-
demethylation / acylation reaction as a mixture of two isomers in a ratio of 3: 1 in
53% yield. Rf 0.32 (DCM : MeOH, 96:4); IR (film) Vrnax: 3436, 2918, 2849, 1727,
1634, 1505, 1437, 1276, 1118, 1031, 971 cm-I; IH NMR (CDCI3, 600 MHz) (major
isomer) 8: 6.68 (d,J =8.2 Hz, IH), 6.59 (d, J =8.3 Hz, IH), 5.17 - 5.22 (m, IH), 4.60
(s, IH), 3.85 (s, 3H), 3.62 (dd, J =13.4,5.0 Hz, IH), 2.96 (dt, J =13.0,3.8 Hz, IH),
2.83 (dd, J = 18.6, 6.0 Hz, IH), 2.56 (d, J=8.5 Hz, IH), 2.20 - 2.47 (m, 6H), 1.81 -
1.93 (m, 3H), 1.10 (t, J = 7.7 Hz, 3H) ppm; I3C NMR (CDCI3, 150 MHz) 8: 206.9,
172.3, 145.6, 143.3, 126.2, 125.2, 120.5, 115.2, 91.1, 56.8,47.9,47.3,41.4,40.1,
39.5,35.9,28.5,27.2,25.4,9.7 ppm; MS (EI) mlz (%): 341 (33),242 (12), 241(31),
188 (11), 185 (11), 167 (11), 149 (28), 129 (13), 113 (10), 102 (11), 101 (100), 72
(18), 71 (14), 70 (14), 57 (85), 56 (11), 55 (19), 43 (18), 41 (14); HRMS (EI) calcd
219
391
N-n-Decanylacetyl-norhydrocodone 391.
The title compound 391 was isolated following the general procedure for N-
demethylation / acylation reaction as a mixture of two isomers in a ratio of 3: 1 in
36% yield. Rf 0.35 (DCM : MeOH, 96:4); IR (film) Vrnax: 3435, 2926, 2850, 1726,
1626, 1505, 1436, 1155, 1030, 892, 753 cm-1; IH NMR (CDCI3, 600 MHz) (major
isomer) 8: 6.68 (d, J =8.2 Hz, IH), 6.59 (d, J =8.0 Hz, IH), 5.18 - 5.21 (m, IH), 4.60
(s, IH), 3.84 (s, 3H), 3.62 (dd, J =13.5,4.6 Hz, IH), 3.38 (m, IH), 2.96 (dt, J =13.1,
3.8 Hz, IH), 2.83 (dd, J = 18.6, 6.1 Hz, IH), 2.55 (d, J = 18.4 Hz, IH), 2.34 - 2.40
(m, IH), 2.20 - 2.33 (m,3H), 1.81 - 1.93 (m, 2H), 1.59 - 1.65 (m, 2H), 1.49 - 1.58 (m.
2H), 1.13 - 1.33 (m, 12H), 0.81 (t, J = 6.8 Hz, 3H) ppm; 13C NMR (CDCI3, 150 MHz)
8: 207.3, 171.9, 145.6, 143.4, 126.2, 124.9, 120.7, 115.1,91.3,56.7,47.4,41.3,39.9,
39.7,35.7,34.0,33.8,31.9,31.7,29.5,29.4,28.4, 25.6, 25.4, 25.0, 22.7, 14.1 ppm;
MS (EI) m/z (%): 439 (1), 224 (42),172 (10), 143 (36), 100 (16), 99 (57), 98 (37), 83
(18), 82 (11), 70 (21), 67 (10), 61 (52), 57 (19), 56 (100), 55 (43), 44 (14), 43 (46), 41
(43); HRMS (EI) calcd for C27H37N04: 439.2723, found 439.2719.
220
Ny (CH2)10CHS
o
392
N-n-Dodecanylacetyl-norhydrocodone 392.
The title compound 392 was isolated as a mixture of two isomers in a ratio of 7:2 in
43% yield. Rf 0.35 (DCM : MeOH, 96:4); IR (film) Vmax: 3334, 2926, 2852, 1729,
1627, 1575, 1505, 1438, 1275, 1031, 965 cm-I; IH NMR (CDCI3, 300 MHz) (major
isomer) 3: 6.77 (d, J =8.2 Hz, 1H), 6.67 (d, J =8.5 Hz, 1H), 5.24 - 5.32 (m, 1H), 4.69
(s, 1H), 3.93 (s, 3H), 3.66 - 3.76 (m, 1H), 3.42 - 3.58 (m, 1H), 2.98 - 3.11 (m. 1H),
2.91 (dd, J =18.6,6.1 Hz, 1H), 2.63 (d, J =18.5 Hz, 1H), 2.23 - 2.52 (m, 3H), 1.87 -
2.04 (m, 4H), 1.54 - 1.79 (m, 4H), 1.20 - 1.47 (m, 12H), 1.01 .. 1.20 (m, 3H), 0.89 (t,
J = 6.5 Hz, 3H); I3C NMR (CDCI3, 75 MHz) 3: 207.2, 171.8, 145.9, 143.3, 126.2,
125.2, 120.5, 115.2, 91.1, 56.8, 49.4, 47.6, 47.4, 41.4, 39.8, 35.9, 35.7, 34.2, 34.0,
32.1, 32.0, 29.7, 29.6, 29.5, 25.8, 25.4, 25.0, 22.8, 14.3; MS (EI) mlz (%): 467 (3),
224 (21),143 (18), 100 (10), 99 (27), 98 (17),61 (23),56 (100),55 (20),43 (21),41
(19); HRMS (EI) calcd for C29H4IN04: 467.3036, found 467.3037.
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Sa-4,S-Epoxy-3-methoxy-6-oxo-morphinan-17-carboxylic acid methyl ester
(393).
Hydrocodone bitartrate (100 mg, 0.22 mmol) was suspended in a mixture of benzene
(1 mL) and dimethyldicarbonate (1 mL), and Pd(OAc)2 (2 mg, 0.01 mmol) were
added. The reaction mixture was heated at 80 °C for 18 hrs, before it was cooled to rt
and filtered through a plug of Celite. The solvent was evaporated and the residue was
taken up in CHCl3 and the organic layer was washed with IN HCI. The organic layer
was dried over anhydrous magnesium sulfate, filtered and the solvent was evaporated.
The residue was purified by flash column chromatography (CHCI3 : MeOH, 100:0 to
90:10) to give 25 mg (33%) of compound 393 as mixture of two isomers in a ratio of
3:2 as colorless oil. Analytical data for the m-ajor isomer are identical to those
published in the literature. I80 Rf 0.55 (DCM : MeOH, 92:8); IR (film) Vrnax: 3019,
2955, 2934, 2842, 2806, 1744, 1637, 1610, 1506, 1441, 1325, 1263, 1164, 1040 em-I;
IH NMR (CDCI3, 600 MHz) (two isomers) 8: 6.75 (d, J =8.2 Hz, 2H), 6.63 - 6.68
(m, 2H), 4.77 - 4.81 (m, 1H), 4.67 - 4.70 (m, 2H), 4.60 - 4.64 (m, 1H), 4.10 (dd, J =
13.5, 5.0 Hz, 1H), 3.93 - 3.98 (m, 1H), 3.92 (s, 6H), 3.80 - 3.88 (m, 2H), 3.76 (s, 3H),
3.73 (s, 3H), 2.83 - 2.91 (m, 2H), 2.75 - 2.82 (m, 2H), 2.68 - 2.74 (m, 2H), 2.42 - 2.48
(m, 4H), 2.34 - 2.41 (m, 2H), 1.82 - 2.00 (m, 4H), 1.18 - 1.28 (m, 2H)ppm; I3C NMR
(CDCI3, 150 MHz) 8: 207.2, 155.9, 155.5, 145.5, 143.1, 126.1, 124.9, 124.7, 120.4,
120.3,114.9,114.8,91.2,56.7,52.9,52.8,50.9, 50.6,47.24,47.17,41.5,41.4,40.7,
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39.9,39.8,38.01,37.97,35.0,34.8,28.9,28.5,25.4, 25.3 ppm; HRMS (EI) calcd for
69.07% H 6.51 %, found C 69.07% H 6.41 %.
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5a-4,5-Epoxy-3-methoxy-6-oxo-morphinan-17-carboxylic acid tert-butyl ester
(394).
Hydrocodone bitartrate (100 mg, 0.22 mmol) was suspended in a mixture of benzene
(1 mL) and di-tert-butyl dicarbonate (1 mL), followed by the addition of Pd(OAc)2 (2
mg, 0.01 mmol). The reaction mixture was heated at 80°C for 18 hrs, before it was
cooled to rt and filtered through a plug of Celite. The solvent was evaporated and the
residue was taken up in CHCI3. The organic layer was washed with IN HCI, dried
over anhydrous magnesium sulfate, filtered and the solvent was evaporated. The
residue was purified by flash column chromatography (CHCl3 : MeOH, 100:0 to
90:10) to give 19 mg (15 %) of compound 394 as mixture of two isomers in a ratio of
3:2 as colorless oil. Rf 0.60 (DCM : MeOH, 92:8;); IR (film) Vrnax: 3366, 2975, 2932,
1728, 1683, 1505, 1366, 1259, 1165, 1126 em-I; IH NMR (CDCI3, 600 MHz) (major
isomer) 8: 6.74 (d, J =8.1 Hz, 1H), 6.65 (d, J =8.0 Hz, 1H), 4.67 (s, 1H), 4.48 (bs,
1H), 3.91 (s, 3H), 2.73 - 2.89 (m, 2H), 2.69 (d, J = 17.8 Hz, 1H), 2.32 - 2.48 (m, 3H),
1.78 - 1.99 (m, 3H), 1.47 - 1.54 (m, 10H), 1.13 - 1.16 (m, 1H) ppm; I3C NMR
(CDCI3, 150 MHz) 8: 207.3, 156.3, 154.8, 145.5, 143.1, 126.2, 120.3, 114.8, 114.8,
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91.2, 80.0,56.7,51.2,49.9,41.4,39.9,38.3,35.1,28.6, 25.4, 24.3 ppm; HRMS (EI)
calcd for C22H27N05: 385.1892, found 385.1879.
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8-Acetyl-8-aza-bicyclo[3.2.1]octan-3-one (396).
Tropane (100 mg, 0.72 mmol) was dissolved in neat acetic anhydride (2 mL) and
Pd(OAc)2 (32 mg, 0.14 mmol) was added. The reaction mixture was heated at 80°C
for 14 hrs. The reaction mixture was filtered through a plug of Celite and the solvent
was removed under reduced pressure. The pH of the residue was adjusted to 9 using a
50% aqueous solution of NaOH. The aqueous layer was extracted three times with
CHCl3 (5 mL). The organic layers were combined, washed three times with IN HCI
and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and
the solvent was evaporated under reduced pressure. The crude product was purified
by flash column chromatography (DCM : MeOH, 98:2) to yield 86 mg (72%) of the
title compound 396 as colorless oil. Data for 396 are identical to those published in
the literature. 181 Rf 0.65 (DCM : MeOH, 96:4); IH NMR (CDCI3, 300 MHz) 8: 4.90-
4.99 (m, 1H), 4.39 - 4.47 (m, 1H), 2.67 - 2.82 (m, 1H), 2.33 - 2.64 (m, 3H), 2.19 (s,
3H), 2.00 - 2.21 (m, 2H), 1.65 - 1.87 (m, 2H); 13C NMR (CDCI3, 75 MHz) 8: 207.2,
167.0,54.4,50.8,49.7,48.8, 29.9, 28.0, 21.6 ppm; HRMS (EI) calcd for C9H13N02:
167.0946, found 167.0942.
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1-(8-Aza-bicyclo[3.2.1]octan-8-yl)ethanone (398).
Compound 398 was prepared by following the procedure for the preparation of
compound 396 using tropane (200 mg, 1.60 mmol), Pd(OAc)2 (72 mg, 0.32 mmol)
and acetic anhydride (2 mL) as starting materials. The crude product was purified by
flash column chromatography (DCM : MeOH, 98:2) to yield 172 mg (70%) of the
title compound 398 as colorless oil. Data for 398 are identical to those published in
the literature. 182 Rf 0.70 (DCM : MeOH, 96:4); IH NMR (CDCI3, 300 MHz) 8: 4.48 -
4.59 (m, 1H), 3.93 - 4.04 (m, 1H), 1.96 (s, 3H), 1.32 - 1.94 (m, 10H); 13C NMR
(CDCI3, 75 MHz) 8: 165.9,55.7,51.7,32.3,30.6,28.5,27.0,21.5, 16.6 ppm; HRMS
(EI) calcd for C9HlSN02: 153.1154, found 153.1153.
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8-Acetyl-8-aza-bicyclo[3.2.1]octan-3-yl acetate (400) and 8-methyl-8-aza-
bicyclo[3.2.1]octan-3-yl acetate (401).
Tropine (200 mg, 1.42 mmol) was dissolved in acetic anhydride (2 mL) and
Pd(OAc)2 (64 mg, 0.28 mmol) was added. The reaction mixture was heated at 80°C
for 14 hrs. The reaction mixture was cooled to rt, water (5 mL) was added and the pH
was adjusted to 9, using a 50% aqueous solution of NaOH. The aqueous layer was
extracted three times with CHCl3 (5 mL). The organic layers were combined, washed
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three times with IN HCI and brine. The organic layer was dried over anhydrous
sodium sulfate, filtered and the solvent was evaporated to yield 129 mg (43%) of
compound 400. Data for 400 are identical to those published in the literature. 183 Rf
0.56 (DCM : MeOH, 96:4); IH NMR (CDCI3, 300 MHz) 8: 5.04 (t, J = 5.8 Hz, 1H),
4.57 - 4.66 (m, 1H), 4.03 - 4.13 (m, 1H), 2.04 - 2.18 (m, 3H), 2.03 (s, 3H), 2.02 (s,
3H), 1.70 - 2.00 (m, 5H); 13C NMR (CDCI3, 75 MHz) 8: 170.1, 166.1,67.5, 54.2,
50.1, 37.2, 35.5, 28.7, 27.0, 21.5, 21.4 ppm; HRMS (EI) calcd for CIIH17N03:
211.1208, found 211.1205.
In addition, the acidic extracts were combined and basified to pH 9 (50% aqueous
solution of sodium hydroxide). The aqueous layer was extracted three times with
CHCl3 (5 mL). The organic layers were combined, washed with brine, and dried over
anhydrous sodium sulfate, filtered and the solvent was evaporated. The crude product
was purified by flash column chromatography (DCM : MeOH : NH40H, 98:2) to
yield 91 mg (35%) of compound 401 as colorless oil. Data for 401 are identical to
those published in the literature. 184 Rf 0.32 (DCM : MeOH, 96:4;); IH NMR (CDCI3,
300 MHz) 8: 4.97 (t, J = 5.3 Hz, 1H), 3.08 - 3.17 (m, 1H), 2.30 (s, 3H), 2.16 (td, J =
15.2,4.2 Hz, 2H), 1.90 - 2.07 (m, 7H), 1.71 (d, J =15.2 Hz, 2H); 13C NMR (CDCI3,
75 MHz) 8: 170.3,67.3,59.9,40.3,36.4,25.5,21.6 ppm.
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403
8-Acetyl-8-aza-bicyclo[3.2.1]octan-3-yl 2-phenylacrylate (403).
Atropine (100 mg, 0.35 mmol) was dissolved in benzene (1 mL) and acetic anhydride
(1 mL) followed by the addition of Pd(OAc)2 (16 mg, 0.07 mmol). The reaction
mixture was heated at 80 °C for 16 hrs, before it was cooled to rt and filtered through
a plug of Celite. The solvent was evaporated and the residue was taken up in CHC13
and the organic layer was washed with IN HCI. The organic layer was dried over
anhydrous magnesium sulfate and filtered. The solvent was evaporated under reduced
pressure and the residue was purified by flash column chromatography (CHCI3 :
MeOH, 100:0 to 90:10) to give 85 mg (82%) of compound 403 as colorless solid. Rf
0.45 (DCM : MeOH, 96:4); mp 104 - 107 °C (DCM / hexanes); IR (film) Vmax: 2953,
2922, 1714, 1635, 1495, 1445, 1424, 1327, 1196, 1167, 1076, 1034 em-I; IH NMR
(CDCI3, 300 MHz) 8: 7.29 - 7.42 (m, 5H), 6.37 (s, 1H), 5.89 (s, 1H), 5.25 (t, J = 4.8
Hz, 1H), 4.59 - 4.68 (m, 1H), 4.04 - 4.13 (m, 1H), 2.22 (dt, J = 15.3,4.3 Hz, 1H),
2.05 (s, 3H), 1.78 - 2.15 (m, 7H) ppm; I3C NMR (CDCI3, 75 MHz) 8: 166.1, 165.8,
141.8, 136.7, 123.3, 128.2, 128.1, 127.0,68.3,54.2,50.1,37.3,35.6,28.6,26.9,21.5
ppm; MS (EI) mlz (%) 299 (18), 257 (16), 168 (15), 152 (28), 151 (32), 136 (18), 126
(10),111 (14), 110 (100),109 (38), 108 (17),103 (38),97 (10),86 (27),84 (44),83
(15), 82 (19), 81 (25), 80 (29), 77 (22), 71 (11), 69 (33), 68 (35) 67 (28), 57 (19), 55
(18), 47 (10), 43 (68), 41 (26); HRMS (EI) calcd for CIsH2IN03: 299.1521, found
227
299.1518; Anal calcd for CI8H2IN0381/3 H20: C 70.80 % H 7.15%, found C 70.84%
H 7.18%.
Me:Mo~NH
16
Norhydrocodone (16).
The title compound 16 was isolated following the general procedure for Cu(OAc)2
mediated demethylation in 64% yield as colorless solid. In addition the compound
was isolated following the general procedure for Pd(OAc)2mediated demethylation in
40% yield along with 55% recovered starting material. Data for 16 are identical to
those published in the literature. I85 mp 149 - 151 °C (MeOHldiethyl ether); Rf 0.25
(DCM : MeOH : NH40H, 98:2:1); IR (film) Vmax: 3369, 2928, 1725, 1636, 1609,
1504, 1439, 1274, 1061 cm-I; IH NMR (CDCI3, 600 MHz) 8: 6.74 (d, J = 8.2 Hz,
1H), 6.67 (d, J = 8.2 Hz, 1H), 4.66 (s, 1H), 3.93 (s, 3H), 3.48 - 3.52 (m, 1H), 2.85 -
2.95 (m, 2H), 2.79 (d, J =18.5 Hz, 1H), 2.71 - 2.77 (m, 1H), 2.55 (dt, J =12.6, 3.2
Hz, 1H), 2.45 (dt, J = 13.8,4.6 Hz, 1H), 2.40 (td, J =13.8,4.6 Hz, 1H), 1.97 (td, J =
12.3, 4.8 Hz, 1H), 1.82 - 1.91 (m, 2H), 1.22 (qd, J = 13.3, 3.2 Hz, IH); ppm; I3C
NMR (CDCI3, 150 MHz) 8: 207.6, 145.5, 142.9, 127.3, 126.3, 119.9, 114.7, 91.6,
56.8,52.4,47.7,43.0,40.3,39.0,36.0,30.8,25.8 ppm; MS (EI) m/z (%) 285 (9), 87
(11), 86 (21), 85 (65), 84 (35), 83 (100), 49 (14), 48 (13), 47 (33); HRMS (EI) calcd
for CI7HI9N03: 285.1365, found 285.1364.
228
405
Norcodeine (405).
The title compound 405 was isolated following the general procedure for CU(OAC)2
mediated demethylation in 64% yield as colorless solid. Data for 405 are identical to
those published in the literature. 167 mp 182 - 183 °C (MeOH/diethyl ether); Rf 0.22
(DCM : MeOH : NH40H, 98:2:1); IR (film) Vrnax : 3309, 3000, 2935, 2837, 1635,
1603, 1504, 1453, 1282, 1127,943 cm- l ; IH NMR (CDCI3, 600 MHz) 8: 6.70 (d, J =
8.2 Hz, 1H), 6.60 (d, J = 8.2 Hz, 1H), 5.72 - 5.76 (m, 1H), 5.28 (dt, J = 9.9,2.5 Hz,
1H), 4.89 (d, J = 6.4 Hz, 1H), 4.17 - 4.22 (m, 1H), 3.87 (s, 3H), 3.65 - 3.69 (m, 2H),
2.98 (td, J = 12.1,4.4 Hz, 1H), 2.86 - 2.93 (m, 2H), 2.83 (d, J =18.7 Hz, 1H), 2.59 -
2.63 (m, 1H), 1.88 - 1.98 (m, 2H) ppm; 13C NMR (CDCI3, 150 MHz) 8: 146.4, 142.2,
133.7, 131.1, 128.2, 127.4, 119.6, 112.8,91.9,66.3,56.3,52.0,43.9,41.3,38.5,36.6,
31.4 ppm; MS (EI) m/z (%) 285 (39),87 (13), 86 (17),85 (70),84 (25),83 (100),82
(10), 59 (34), 49 (11), 47 (25), 45 (13), 44 (29), 43 (19), 42 (12) HRMS (EI) calcd for
CI7HI9N03: 285.1365, found 285.1368.
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